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Abstract
Breast cancer is the most commonly diagnosed malignancy in women and is the leading cause of cancerrelated death in the female population worldwide. In these women, breast cancer recurrence--local,
regional, or distant--represents the principal cause of death from this disease. The mechanisms
underlying tumor recurrence remain largely unknown. To dissect those mechanisms, our laboratory has
developed inducible transgenic mouse models that accurately recapitulate key features of the natural
history of human breast cancer progression: primary tumor development, tumor dormancy and
recurrence. Dysregulated metabolism has long been known to be a key feature in tumorigenesis. Yet, very
little is known about the connection, if any, between cellular metabolic changes and breast cancer
recurrence. In this work, I design and implement a systems engineering-based approach, magnetic
resonance-based integrative metabolomics, to better understand the metabolic and genetic regulation of
breast cancer recurrence. Through a combination of 1H and 13C magnetic resonance spectroscopy
(MRS), mass spectrometry (MS) as well as gene expression profiling and functional metabolic and
genetic studies, I aim to identify the metabolic profile of mammary tumors during breast cancer
progression, identify the molecular basis and role of differential glutamine uptake and metabolism in
breast cancer recurrence and finally, investigate the molecular basis and role of differential lactate
production in breast cancer recurrence. The findings suggest an evolving metabolic phenotype of tumors
during breast cancer progression as well as metabolic dysregulation in some of the key regulatory nodes
that control that evolution. Identifying the metabolic changes associated with tumor recurrence can pave
the way for identifying novel diagnostic strategies and therapeutic targets that can contribute to improved
clinical management and outcome for breast cancer patients.
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ABSTRACT
UNDERSTANDING THE METABOLIC AND GENETIC REGULATION OF BREAST
CANCER RECURRENCE USING MAGNETIC RESONANCE-BASED
INTEGRATIVE METABOLOMICS
Dania Daye
Lewis A. Chodosh, M.D., Ph.D.
Mitchell D. Schnall, M.D., Ph.D.

Breast cancer is the most commonly diagnosed malignancy in women and is the leading
cause of cancer-related death in the female population worldwide. In these women,
breast cancer recurrence—local, regional, or distant—represents the principal cause of
death from this disease. The mechanisms underlying tumor recurrence remain largely
unknown.

To dissect those mechanisms, our laboratory has developed inducible

transgenic mouse models that accurately recapitulate key features of the natural history
of human breast cancer progression: primary tumor development, tumor dormancy and
recurrence.

Dysregulated metabolism has long been known to be a key feature in

tumorigenesis. Yet, very little is known about the connection, if any, between cellular
metabolic changes and breast cancer recurrence. In this work, I design and implement
a systems engineering-based approach, magnetic resonance-based integrative
metabolomics, to better understand the metabolic and genetic regulation of breast
cancer recurrence.

Through a combination of

1

H and

13

C magnetic resonance

spectroscopy (MRS), mass spectrometry (MS) as well as gene expression profiling and
functional metabolic and genetic studies,

I aim to identify the metabolic profile of

mammary tumors during breast cancer progression, identify the molecular basis and role
of differential glutamine uptake and metabolism in breast cancer recurrence and finally,
v

investigate the molecular basis and role of differential lactate production in breast cancer
recurrence. Our findings suggest an evolving metabolic phenotype of tumors during
breast cancer progression as well as metabolic dysregulation in some of the key
regulatory nodes that control that evolution.

Identifying the metabolic changes

associated with tumor recurrence can pave the way for identifying novel diagnostic
strategies and therapeutic targets that can contribute to improved clinical management
and outcome for breast cancer patients.
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CHAPTER 1

Breast Cancer Recurrence and Metabolism

1.1 Breast Cancer Recurrence
Epidemiology
Breast cancer is the most commonly diagnosed malignancy in women and the leading
cause of cancer-related death in the female population worldwide1. In the United States,
breast cancer is the second leading cause of death in women and the leading cause of
death in females aged 40 to 592.

This year, approximately 230,000 women are

projected to be diagnosed with invasive breast cancer and approximately 40,000 will die
from this disease3. Since 1975, breast cancer mortality rates have declined with the
wide adoption of screening mammography and improvements in available treatment
options.

However, this trend is largely due to improvements in the diagnosis and

treatment of primary breast cancer, as recurrent breast cancer remains a fatal disease4.
A number of risk factors are associated with the development of breast cancer.
These include older age and female gender, which are among the strongest risk factors.
Women are 100 times more likely to develop breast cancer than men, with 207,000
breast cancers diagnosed among women, as compared to 2,000 diagnosed in men in
20105. Breast cancer incidence rates also increase with age2. Other risk factors include
race/ethnicity, reproductive and hormonal factors, environmental factors and exposure to
ionizing radiation.
1

In the US, breast cancer is the most commonly diagnosed malignancy in women
of all major ethnic groups4.

However, the highest incidence rates are reported in

Caucasians (124 per 100,000) and the lowest in Asian Americans (82 per 100,000) with
African Americans, Hispanics and Native Americans having intermediate incidence rates
(113 per 100,000, 90 per 100,000 and 92 per 100,000 respectively)6. Reproductive and
endocrine factors have also been reported to strongly contribute to breast cancer risk.
For instance, younger age at menarche and later age at menopause are associated with
increased risk for breast cancer7. Furthermore, nulliparity and older age at first birth are
associated with increased risk of breast cancer7, 8. Other risk factors for breast cancer
include exposure to ionizing radiation at a young age, especially in patients who have
undergone treatment for Hodgkin’s lymphoma9.
A number of studies have reported an association between breast cancer risk
and lifestyle and dietary factors. Substantial evidence suggests an association between
high body mass index (BMI), low physical activity, smoking, high alcohol intake and high
fat intake and an increased risk of breast cancer10-13. Finally, a positive family history of
breast cancer in a first-degree relative is also an important risk factor. Although family
history is reported in only about 15 to 20% of women with breast cancer, familial
inheritance of certain gene mutations (such as in BRCA1, BRCA2, p53, ATM and PTEN)
is an established risk factor that predisposes to a high susceptibility of developing this
disease14.

In addition, having a personal history of invasive breast cancer also

increases the risk of developing cancer in the contralateral breast by approximately 1
percent per year15.
With declining mortality rates resulting from widespread adoption of screening
mammography and improvements in adjuvant therapy, more women are surviving their
2

primary breast cancers with earlier detection and better treatment regimens16. In this
regard, breast cancer patients are at risk for developing a recurrent tumor in the
ipsilateral breast. Breast cancer recurrence describes the return of breast cancer after
primary treatment. There are three types of recurrent breast cancer: local, regional and
distant. In local recurrence, breast cancer appears at the original tumor site. In regional
recurrence, cancer occurs in the chest wall or regional lymph nodes.

In distant

recurrence, breast cancer can reappear in other sites including the lungs, liver, bone,
brain and other organs. Most breast cancer recurrences appear in the first decade
following primary treatment, with the majority occurring in years 2 to 517. Recurrences
can also occur much later, especially for ER-positive tumors with up to one half of those
recurrences happening more than five years after diagnosis18.
Recurrence rates of primary breast cancers are associated with the mode of
therapy used to treat the primary tumors, as well as a number of important prognostic
markers that include lymph node involvement at diagnosis and primary tumor size19. In
patients treated with surgery but not adjuvant therapy, recurrence rates can approach
50% in lymph node-positive patients and 32% in node-negative patients in the 10-year
period following diagnosis20. Current treatment guidelines recommend adjuvant therapy
for qualifying patients, combined with either surgical breast conservation therapy with
radiation therapy (BCT + RT) or mastectomy for most breast cancer patients.
Recurrence rates post-mastectomy generally range between 8 and 10%21,

22

.

Recurrence rates in the treated breast following BCT with radiation therapy have been
reported to range between 10 and 15%23. However, women who only receive BCT,
without radiation therapy, have rates of local recurrence as high as 34%21, 24.

3

With breast conservation therapy, recurrences tend to appear later compared to
patients treated with mastectomy, with a median time of three to four years with the
former versus two to three years with the latter25. For patients treated for invasive breast
cancer, more than 80% of locoregional recurrences following BCT are also invasive and
75% are isolated to the ipsilateral breast26, 27. Following mastectomy, recurrences tend
to occur in the chest wall (50 to 70%) or regional nodes (40%) with the latter being
associated with poorer survival28. Five-year survival rates for women with breast cancer
recurrences range from 7 to 50% with combined chest wall and supraclavicular node
recurrences carrying the worst prognosis28.
According to the American Cancer Society, the current 5-year survival rate of
women afflicted with primary breast cancer ranges between 67-93% for women
diagnosed with stages 0-III disease29. However, this mortality rate is disproportionately
being observed in the cohort of breast cancer patients diagnosed with primary tumors.
Recurrent disease is almost uniformly fatal.

Our understanding of breast cancer

recurrence remains relatively limited. More research is needed in this area in an effort to
achieve better survival and improved quality-of-life in patients afflicted with recurrent
disease.

Recurrence Risk Assessment
In breast cancer management, it is important to have access to prognostic markers
capable of providing information on the clinical outcome of patients. To date, pathologic
evaluation of tumor tissue remains the gold standard for this purpose. In particular,
clinicians often rely on lymph node status, tumor size, histologic grade, histologic tumor
4

type and the presence or absence of lymphatic and vascular invasion as the key factors
for predicting clinical outcome in breast cancer patients30, 31. Each of these factors has
been associated with increased likelihood of cancer recurrence.

Lymph node

involvement remains one of the strongest factors associated with increased recurrence:
the higher the number of involved lymph nodes, the worse the patient’s prognosis.
Conversely, negative lymph node status has been consistently associated with a
favorable outcome31. Histologically, positive excision margin, larger tumor size, higher
histological grade, vascular invasion and higher proliferation rate predict increased
likelihood of recurrence31, 32. High proliferation rate is associated with shorter diseasefree and overall survival33. Hormone receptor status is also an important predictor of
prognosis, whereby ER and PR receptor positivity are each associated with favorable
outcomes23. In contrast, the presence of HER2/neu amplification and overexpression is
associated with high rates of relapse and poor overall prognosis34.
In 2005, the St. Gallen expert consensus meeting defined three risk categories of
breast cancer recurrence in patients with operable breast cancer based on the above
prognostic factors35. According to their classification criteria, patients can be divided into
those with low, intermediate or high recurrence risks.

Their report concluded that

patients had a low risk for recurrence if they had node-negative breast cancer of size
less than 2 cm, histologic grade of 1, negative HER2/neu receptor status, no peritumoral
vascular invasion and the patient is older than 35 at the time of diagnosis. Patients are
at intermediate risk of recurrence if their disease is node-negative and at least one of the
following is present: tumor size greater than 2 cm, histologic grade of 2 or 3, presence of
peritumoral vascular invasion, HER2/neu overexpression or amplification, or the patient
is younger than 35. Patients can also have an intermediate risk of recurrence if they
5

have node-positive disease, but no HER2/neu overexpression. Finally, patients have a
high risk for breast cancer recurrence if they have node-positive disease with HER2/neu
amplification or overexpression.

Based on these risk categories, treatment

recommendations were established that highlight the importance of personalizing
treatment options based on patient prognosis.
More recently, commercial genetic assays have been introduced to aid in
assessing patient prognosis and predicting recurrence risk. One of these is Oncotype
DX, a 21-gene assay that is used to generate a prognostic score predicting recurrence
risk in patients with newly diagnosed node-negative ER-positive disease36. The use of
this multigene assay to aid in patient prognostication and treatment decisions is now
recommended in treatment guidelines promulgated by the American Society of Clinical
Oncology (ASCO). The wide implementation of this test highlights the importance of
prognostic molecular profiling research in breast cancer management.

Diagnosis of Tumor Recurrence
With more women surviving their primary breast cancers as a result of advances in
detection and treatment options, post-treatment surveillance strategies to detect
recurrent disease are taking center stage. The primary goal of these strategies is the
early detection and treatment of potentially curable recurrent disease. With the majority
of breast cancer recurrences reported in the first 5 years following diagnosis, the
greatest emphasis of surveillance is during that time period. However, lifelong follow-up
remains warranted as recurrent tumors may arise as late as 20 years following primary
tumor development18. According to published guidelines by ASCO and the National
6

Comprehensive Cancer Network (NCCN), routine history and physical exam as well as
regularly scheduled mammograms are the standard of care for the surveillance of breast
cancer survivors37.
According to the published guidelines, breast cancer survivors should be seen
every three to six months during the first three years post primary therapy, every six to
twelve months for the next two years, and then annually18.

Mammograms are

recommended starting six months after definitive treatment, then obtained every 6 to 12
months thereafter. Local recurrences are detected by mammography alone in 40 to
75% of cases, by physical exam alone in 10 to 30% of the cases, and by combination of
the two in 10 to 15% of the cases38, 39. With a large number of recurrences diagnosed by
routine screening mammography, most published guidelines recommend long-term
follow-up with screening mammography even in older patients. Potentially curable local
recurrences have been reported up to 10-years post treatment38. Notably, however,
breast conservation therapy can lead to marked architectural distortion of the breast,
which thereby limits the sensitivity of both clinical exam and mammography. These facts
warrant the exploration of other imaging modalities for the early detection of recurrent
disease.
The detection of clinically or radiographically suspicious lesions triggers further
work-up, including biopsy.

Core needle biopsy or excisional biopsy are typically

performed to confirm or rule out the diagnosis of local recurrence. If confirmed, the
biopsied tissue is assayed for receptor status and HER2/neu overexpression for
prognostic information and to aid in treatment decisions.

7

Role of Imaging in Breast Cancer Recurrence
Mammography is currently considered the gold standard for post-treatment surveillance
of breast cancer survivors. However, with both radiation therapy and surgery being the
mainstay of treatment, the breast frequently undergoes architectural distortion and local
mass-like fibrosis that renders the detection of local recurrence more challenging. In
those patients, up to one half of local recurrences are mammographically occult. With
reduced mammographic sensitivity in this context, MRI is being explored as a potential
technique to complement mammographic surveillance.

Accumulating evidence

suggests that MRI is able to detect mammographically occult lesions in architecturally
distorted breasts40, 41. However, while MRI provides increased sensitivity, this technique
is far less specific and has a high rate of false-positives. As a result, the widespread
clinical implementation for surveillance remains controversial. Current clinical guidelines
recommend that MRI be used in women at high risk for recurrence with the decision
being made based on the complexity of the clinical scenario.
Additional evidence exists suggesting a benefit of adding ultrasound to screening
mammography to complement the surveillance of breast cancer survivors.

A large

randomized clinical trial conducted to address this question revealed an increased
diagnostic yield with 4.2 additional recurrences detected due to the addition of
ultrasound for every 1,000 women screened42. However, similar to MRI, the addition of
ultrasound to mammography also resulted in a substantial increase in false-positives,
making its widespread clinical implementation also controversial.
At present, PET imaging is primarily used for the staging of women in whom
breast cancer has been detected. However, its role in surveillance remains less clear.
8

To our knowledge, no trials are currently available that have considered this question.
Some retrospective cohort studies have reported a high sensitivity of PET for the early
detection of recurrent lesions43,

44

.

It is not clear, however, whether PET will have

specificity drawbacks similar to MRI and ultrasound. It is possible that the use of PET
for surveillance might be a promising approach. Further studies are needed to assess
its role.
At present, mammography remains the mainstay for the surveillance of breast
cancer patients as indicated by the guidelines of the American Society of Clinical
Oncology (ASCO). Other imaging modalities might hold additional promise for improved
sensitivity. However, larger clinical trials are needed to validate their potential role in the
surveillance of breast cancer survivors.

Treatment of Breast Cancer Recurrence
Treatment decisions for breast cancer recurrence are made following biopsying the
detected lesion as part of the staging process. During that process, hormone receptor
status as well as HER2/neu overexpression is determined. This information aids the
clinician to better tailor treatment choices to complement standard therapeutic
approaches. Treatment decisions are also primarily dictated by the initial therapy that
was employed to eradicate the primary tumor, typically consisting of either breast
conservation therapy (BCT) with radiation therapy or mastectomy.

Of note, some

recurrent lesions are not amenable to biopsy such as in the case of bone metastasis. In
these instances and although not an ideal approach, treatment decisions are based on
the features of the original primary tumor.
9

For patients who originally underwent BCT for their primary cancers, the most
established predictor of prognosis following surgical excision has been reported to be
the duration of time between BCT and recurrence detection. Recurrences occurring less
than 2 years from diagnosis tend to have worse prognosis than those that are detected
more than 2 years after diagnosis23. Mastectomy is the principal treatment for local
recurrence following BCT. After mastectomy, the risk of a subsequent recurrence has
been reported to be less than 10%45. Addition of radiation therapy to the treatment
regimen is often not possible, as most patients undergo whole breast irradiation during
initial treatment of their primary tumor, making it less likely to improve survival rates.
For patients who underwent mastectomy as part of the treatment for their primary
breast cancer, recommended treatment options for locoregional recurrence consist of
wide local excision of all gross disease combined with radiation therapy28, 46. However,
with a post-mastectomy recurrence, the likelihood of a subsequent recurrence following
treatment can be as high as 70%47. Similar to BCT, the likelihood of local control of
disease is greatest when recurrence happens more than 2 years following initial therapy
and when recurrent disease is focal rather than multifocal48, 49.
For locoregional recurrences occurring after BCT or mastectomy, established
treatment guidelines recommend the addition of systemic therapy to surgery and
radiation therapy. Chemotherapy is recommended for women with hormone receptornegative disease, as is hormonal therapy for those with hormone receptor-positive
disease.

Addition of trastuzumab is indicated in women with HER2/neu-positive

disease. Although recommended, the clear benefit of systemic therapy following local
disease control (i.e. surgery and radiation therapy) has not been fully established.
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Randomized clinical trials are warranted to further validate the effect of this treatment
approach.

HER2/neu Amplification and Breast Cancer Recurrence
HER2/neu is amplified and overexpressed in 18 to 20% of human breast cancers50, 51.
The HER2/neu oncogene encodes a 185 KD transmembrane glycoprotein with an
intrinsic intracellular tyrosine kinase activity52. It activation is critical for the activation of
intracellular signaling pathways responsible for epithelial cell growth and differentiation53.
Assessing HER2/neu status in diagnosed breast cancers is an essential part of standard
clinical management, as HER2/neu overexpression carries both predictive and
prognostic value. HER2/neu positivity identifies women likely to benefit from treatments
targeted against HER2/neu such as trastuzumab and lapatinib. In addition, HER2/neu
status may identify women who are more likely to be sensitive or resistant to certain
systemic treatment regimens. Women with HER2/neu-positive breast cancers tend to
be more sensitive to anthracyclines, but display relative resistance to endocrine
therapies, mainly selective estrogen modulator therapy (SERM)54, 55.
In addition to its predictive value in the clinical management of breast cancer
patients, HER2/neu status also provides prognostic information. In particular, HER2/neu
overexpression is associated with high rates of disease recurrence and acquired
resistance to therapy. HER2/neu overexpression is also correlated with other pathologic
factors previously shown to predict poor prognosis such as tumor grade, tumor size and
lymph node status51,

55,

56

.

HER2/neu amplification and overexpression is an
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independent predictor of decreased 10-year relapse free survival in both node-positive
and node-negative breast cancer patients57.
In 2005, assessing HER2/neu overexpression took center stage when the St.
Gallen International expert consensus added HER2/neu status as a feature defining
recurrence risk category.

According to their published report published, "HER2/neu

status should be regarded as useful for patient care, with overexpression indicating
worse prognosis."35 Today, HER2/neu-status is also part of a 21-gene recurrence score
assay that is widely used clinically, Oncotype DX. This test is recommended by ASCO
for the assessment of recurrence risk in women with ER-positive, node-negative disease
to guide treatment decisions36.
Although trastuzumab is the mainstay therapy for women with HER2/neu-positive
disease, resistance to therapy develops commonly, especially in the context of recurrent
disease. Studies suggest that a number of recurrent cancers downregulate HER2/neu,
upregulate other genes or activate alternative pathways to escape therapy, particularly
PI3K, IGF-1 and MYC58-60. A subset of tumors also express p95HER2 , a truncated form
of HER2 that has intrinsic kinase activity but lacks the extracellular trastuzumab binding
domain61.

These cancers tend to have worse prognosis.

Acquiring a better

understanding of the mechanisms contributing to the resistance to therapy and worse
prognosis typically associated with HER2/neu overexpression is vital to achieve better
survival rates in patients diagnosed with HER2/neu-positive disease.

12

Mouse Model of HER2/neu Breast Cancer Recurrence
As was summarized above, despite significant improvements in five-year survival rates
in recent years, breast cancer recurrence still constitutes the principal cause of morbidity
and mortality in this disease. At present, the mechanisms underlying tumor recurrence
remain largely unknown. As such, identifying critical drivers of breast cancer recurrence
is essential for improving the long-term survival of breast cancer patients. To dissect the
mechanisms responsible for breast cancer recurrence, our laboratory has developed a
number of inducible transgenic mouse models that accurately recapitulate key features
of the natural history of human breast cancers, including primary tumor development,
minimal residual disease, tumor dormancy and tumor recurrence62-66.

One of those

models, the MMTV-rtTa;TetO-HER2/neu model, is a mammary-specific inducible
transgenic model designed to investigate the molecular underpinnings of HER2/neuinduced tumorigenesis as well as the treatment and recurrence of mammary tumors
induced by this oncogene66.
The MMTV-rtTa;TetO-HER2/neu model is a doxycycline-inducible bitransgenic
mouse model, in which the reverse tetracycline-inducible transactivator (rtTA) is
specifically expressed in the epithelial compartment of the mammary gland under the
control of the mouse mammary tumor virus (MMTV) promoter.

Following the

administration of doxycycline, rtTA binds to the TetO operator and induces the
expression of the neu oncogene, leading to the eventual development of a primary
mammary tumor.

Upon doxycycline withdrawal, HER2/neu expression is acutely

downregulated and tumors regress to a non-palpable state.

Here, genetic

downregulation of HER2/neu mimics the effect of targeted phamacologic inhibition
against this receptor. However, as observed in patients, the tumors subsequently recur
13

in a stochastic manner following a latent period that reflects tumor dormancy.
Accordingly, we believe that assessing the molecular and phenotypic differences
between primary and recurrent mammary tumors in this model will shed light on
mechanisms of tumor recurrence that may contribute to the reported association
between

HER2/neu-positive

breast

cancers

and

poor

prognosis.

Moreover,

understanding the molecular pathways responsible for recurrence will be essential for
enabling improvements in the detection and treatment of recurrent disease.

1.2 HER2/neu Overexpression and Cancer Metabolism
HER2/neu over-expression in breast cancer results in activation of the (PI3K)-AKT
signaling pathway67, 68. Persistent activation of the (PI3K)-AKT pathway, independent of
HER2/neu activation, is associated with poorer response and resistance to trastuzumab
in humans59, 69 as well as an increased risk of local tumor recurrence70. The (PI3K)-AKT
pathway plays a central role in the regulation of cellular metabolism and is thought to
underlie the increased dependence of cancer cells on glycolysis71,

72

.

Accordingly,

understanding the metabolic dependencies of cancer cells during breast cancer
progression might further our understanding of recurrence and permit the identification of
novel prognostic markers and therapeutic targets.
Dysregulated cellular metabolism is a key feature of tumorigenesis73-75. Among
the numerous metabolic pathways altered in cancer cells, aerobic glycolysis (the
Warburg effect), glutamine metabolism and fatty acid/lipid synthesis are among the most
established of these and have been found to be required for tumor growth within
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different contexts73. In what follows, we briefly summarize the key features of each of
these three pathways.

Role of Aerobic Glycolysis (Warburg Effect) in Tumorigenesis
The Warburg effect, which consists of high glucose utilization and increased lactate
production in tumors despite the presence of oxygen, is among the most fundamental
alterations observed in tumor metabolism76. AKT induction can increase glycolysis and
lactate production and is sufficient to induce the Warburg effect in nontransformed cells
as well as cancer cells77-79.

Given the established association of the (PI3K)-AKT

pathway with breast cancer recurrence70 and the role of AKT in inducing the Warburg
effect, studying alterations in glycolysis and lactate production during breast cancer
progression could help elucidate key metabolic control points that might contribute to
carcinogenesis.
Increased lactate production has been directly implicated in established
hallmarks of cancer.

For example, high lactate levels have been correlated with

avoidance of immunosurveillance within the tumor microenvironment80. Patients with
high lactate levels in their sera tend to exhibit higher tumor burden and worse overall
prognosis81. Similarly, high lactate levels have also been associated with increased
tumor invasion and metastasis82. At the molecular level, a number of enzymes directly
implicated in modulating lactate levels have been shown to be required for tumor growth.
Particularly, inhibition of the expression of the A subunit of lactate dehydrogenase (Ldha)
as well as the expression of the M2 isoform of pyruvate kinase (Pkm2) have been shown
to reduce the growth rate of primary tumors in vivo83,
15

84

. Ldha is the enzyme directly

responsible for lactate production. Pkm2 is the embryonic isoform of pyruvate kinase,
the isoform that is preferentially expressed in cancer cells and that has been shown to
be associated with increased lactate levels.
In

the

glycolytic

pathway,

lactate

dehydrogenase

catalyzes

the

interconversion of pyruvate and lactate with concomitant interconversion of NADH and
NAD+.

Functional lactate dehydrogenases, considered to be key mediators of

glycolysis, are homo- and hetero-tetramers of M and H proteins encoded by the Ldha
and Ldhb genes respectively85. Five iso-enzymes, with different activity levels, have
been described in the literature: LDH-1 (4H), LDH-2 (3H1M), LDH-3 (2H2M), LDH-4
(1H3M) and LDH-5 (4M)85.

High LDH-5 levels have been associated with worse

prognosis and have been shown to play a direct functional role in promoting cancer
growth84, 86. On the other hand, while some reports suggest a possible contribution of
Ldhb in cancer progression87, its role remains less well understood.

Glutamine Metabolism in Cancer
Another metabolic pathway required for the growth of certain tumor types is
mitochondrial glutamine metabolism. Since the 1950s, glutamine has been recognized
as an important tumor nutrient that contributes to key metabolic processes in
proliferating cancer cells88,

89

.

Glutamine participates in bioenergetics, supports cell

defenses against oxidative stress, complements glucose metabolism and is an obligate
nitrogen donor for nucleotide and amino acid synthesis73, 75, 90-93.
The metabolism of glutamine can be divided into reactions that use its α-nitrogen,
γ-nitrogen or carbon skeleton.

The γ-nitrogen from glutamine’s amide group is a
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required nitrogen source for de novo nucleotide synthesis. This nitrogen is needed in
three independent enzymatic steps in purine synthesis, as well as in two independent
steps in pyrimidine synthesis92.

The γ-nitrogen is also required for hexosamine

biosynthesis, a precursor for glycosylation reactions.
hexosamine

production is

catalyzed

by

The rate-limiting step of

glutamine:fructose-6-phosphate

amido-

transferase. This reaction uses glutamine’s amido nitrogen to produce glucoasamine-6phosphate, a precursor for O-linked and N-linked glycosylation in cells90.
Glutamine’s γ-nitrogen is released following glutamine’s conversion into
glutamate by glutaminase (Gls).

The glutaminase-catalyzed reaction leads to the

formation of glutamate and ammonia. The latter is a potentially toxic metabolite, mostly
secreted from the cell and shown to play a role in inducing autophagy94, 95. Glutamate
carries glutamine’s remaining nitrogen and is a major nitrogen source for nonessential
amino acid production in cells. Alanine transaminase and aspartate aminotransferase
catalyze the transfer of glutamate’s amino group directly into alanine and aspartate,
respectively.

Furthermore, transfer of the amino group from glutamate to alpha-

ketoacids is also used to generate serine, glycine, cysteine, arginine, asparagine and
proline. In addition to its role in nonessential amino acid synthesis, glutamate is also an
important component of the synthesis of glutathione, an endogenous antioxidant that
protects cells against various forms of oxidative stress.
The final major fate of glutamine is the oxidation of its carbon backbone in
mitochondria. Entry of glutamine’s carbon into the TCA cycle requires conversion of
glutamine into glutamate by glutaminase, followed by conversion of glutamate into
alpha-ketoglutarate by glutamate dehydrogenase, alanine transaminase or aspartate
transaminase.

The complete oxidation of glutamine’s carbon backbone in the TCA
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cycle, through a process termed glutaminolysis, contributes to lipid synthesis and results
in the production of lactate through the malic enzyme, conversion to pyruvate and,
finally, re-introduction into the TCA cycle as acetyl-coA. This process allows glutamine
to participate in lipid synthesis and to support anaplerosis, the replenishment of TCA
cycle intermediates. It also leads to the production of ATP and NADPH. The latter is an
important reducing equivalent required for lipid and nucleotide synthesis as well as for
maintaining GSH in the reduced state.
Glutamine itself also influences a number of signaling pathways that contribute to
tumor growth, in part through maintaining activation of the mTOR kinase, a major
component of the (PI3K)-AKT pathway. Myc activation has also recently been found to
induce glutamine addiction in certain cancer cell lines96, 97. Specifically, Myc can render
tumor cells dependent on glutamine uptake to sustain their viability by directly regulating
the levels of the glutamine transporter slc1a5 and indirectly regulating gls1 (glutaminase)
expression through miR-23a/b92,

96, 98, 99

. Glutaminase is a key glutaminolytic enzyme

that converts glutamine to glutamate and whose expression is required for tumor
growth100, 101. While MYC amplification is linked to aggressive tumor behavior and poor
prognosis102-111, to date no association has been established between increased
glutamine metabolism and breast cancer recurrence. Establishing such a connection
could suggest new avenues for diagnostic and targeted therapeutic strategies in breast
cancer recurrence.
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Lipid Biosynthesis is Tumorigenesis
Another characteristic feature of cancer cells is increased lipogenesis, the process by
which acetyl-coA is converted to lipids.

Increased lipid biosynthesis is of particular

importance with its key contribution to membrane synthesis in rapidly proliferating cancer
cells, as well as its role in forming the backbone for lipid-based signaling molecules112.
In lipogenesis, glucose-derived pyruvate enters the TCA cycle through it conversion to
acetyl-coA, a reaction catalyzed by pyruvate dehydrogenase (PDH). This, in turn, is
condensed with oxaloacetate to produce citrate by citrate synthase.

Citrate is then

exported into the cytoplasm where it is converted back to acetyl-coA by ATP citrate
lyase (ACL), the entry point to lipogenesis.
Emerging evidence also suggests a contribution of glutamine-derived carbon to
citrate production under hypoxic conditions113. This occurs through a process termed
reductive carboxylation where glutamine carbon is consumed while proceeding in the
“reverse” direction in the TCA cycle to act as a major contributor to citrate production
and lipid synthesis in glutamine-dependent cancer cells subjected to hypoxic conditions.
A number of oncogenic signaling pathways are involved in regulating lipid
metabolism. In Particular, the PI3K-(AKT) pathway as well as the MAPK pathway have
each been found to play a role in lipid biosynthesis, through regulation of SREBPdependent transcription of several key lipogenic enzymes, primarily ATP citrate lyase
(ACL) and fatty acid synthase (FAS)114,

115

. Due to its importance in the synthesis of

cholesterol and fatty acid synthesis, ACL is an especially promising therapeutic target in
cancer cells. FAS catalyzes the reaction in lipogenesis that leads to the production of
fatty acids. Both ACL and FAS have been shown to be required for cancer growth within
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the context of AKT-driven tumors. ACL knockdown reduces the rate of tumor growth in
vivo116,

117

. Similarly, FAS inhibition results in the reduced proliferation of tumor cells

both in vitro and in vivo118.
While modulation of lipid metabolism is increasingly seen as a promising
approach to cancer treatment, the role of lipogenesis in cancer progression remains less
understood.

Further research in this area is warranted to explore changes in the

lipogenic phenotype, if any, that accompany cancer progression.

Identifying such

changes could help elucidate novel therapeutic targets in cancer progression and
recurrence.

1.3 Thesis Objectives
The goal of this work was to identify the metabolic changes that occur during breast
cancer progression.

Specifically, we proposed to use

Spectroscopy (MRS) and

1

H Magnetic Resonance

13

C MRS for the in vivo study of alterations in cellular

metabolism that occur during breast cancer progression. Magnetic resonance-based
results were subsequently used to guide the implementation of an integrative
metabolomics approach, where we further characterized the observed metabolic
phenotypes using mass spectrometry, gene expression profiling, biochemical assays
and functional genetic experiments to better understand the metabolic and genetic
regulation of breast cancer recurrence. These studies were pursued through three aims:
SA1: Identify the evolving metabolic profile of mammary tumors during breast cancer
progression using 1H MRS.
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SA2: Identify the molecular basis and role of differential glutamine uptake and
metabolism during breast cancer recurrence.
SA3: Investigate the molecular basis and role of differential lactate production during
breast cancer recurrence.
Understanding the metabolic dependencies of cancer cells during breast cancer
recurrence will further our understanding of cancer progression. This has the potential
to pave the way for the identification of early diagnostic markers of recurrence as well
as prognostic markers and therapeutic targets that could be used to improve the care
and outcome of women with breast cancer.

21

CHAPTER 2

Magnetic Resonance-based Integrative Metabolomics: Design and
Implementation of a Systems Engineering-based Approach

2.1 Introduction
In this chapter, we aim to design and implement a process-based system to establish a
structured and optimizable framework that allows for better understanding of the
metabolic and genetic regulation of breast cancer recurrence. In an effort to achieve this
end, we use a systems engineering-based approach as a guiding strategy. Systems
engineering is an interdisciplinary engineering field that focuses on solving complex
technical problems. It often involves working on projects residing at the intersection of
different technical fields and typically necessitates the coordination of teams with diverse
scientific backgrounds. In systems engineering, the basic principles of addressing a
given problem consist of a 3-step approach: 1) define the problem and its components;
2) develop and deploy a system aimed to solve the problem at hand; and 3) assess,
validate and optimize the performance of the proposed system.

Among those, the

development of a system is the most crucial step of this process. A system consists of a
group of components that work together to achieve a specific purpose.

Proposed

systems can be process-oriented, product-oriented or service-oriented.

Here, we

attempt to design a process-oriented system to define a structured framework for
understanding the metabolic and genetic regulation of breast cancer recurrence.
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The first step in a systems engineering development approach involves
decomposing the problem at hand into smaller measurable components.

For our

purposes, those can consist of:
1. Identifying the metabolic differences between primary and recurrent tumors in a
mouse model of breast cancer recurrence
2. Investigating the precise dysregulated steps in the identified metabolic pathways
3. Identifying the underlying molecular/genetic determinants of the observed
metabolic changes
4. Assessing the functional effect of the identified changes on tumorigenesis
5. Investigating the translational potential and relevance of our findings to human
breast cancer
The second step of the systems engineering approach consists of analyzing and
proposing individual solutions to each of the identified components. Here, we propose
the following solutions to each of the steps identified above:
1. Unsupervised metabolic profiling using 1H Magnetic Resonance Spectroscopy to
identify metabolic differences between primary and recurrent tumors
2. Pathway-focused characterization of key dysregulated steps and fluxes using
13

C-labeling experiments followed by Mass Spectrometry and/or

13

C-Magnetic

Resonance Spectroscopy
3. Genetic expression profiling at the mRNA and protein level and enzyme activity
assessment of potential underlying molecular/genetic determinants of observed
changes
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4. Genetic engineering of cells to modulate expression levels of identified genetic
changes in order to assess their role in tumor growth and progression
5. Computational biology and statistical modeling using microarray and outcome
data in human cancers to assess the clinical translational potential of a given
metabolic observation
In this approach, we rely on established metabolic engineering strategies to derive
insights about breast cancer progression. By detecting dysregulated metabolites using
1

H-MRS, we first identify, on a macroscopic level, metabolic alterations that accompany

tumor

recurrence

across

multiple

pathways.

Subsequently,

characterization is performed using isotopic tracers.

pathway-specific

Metabolism of these tracers

generates a pool of labeled metabolites with various levels of enrichment that reflect the
metabolic state of the pathway catabolizing the labeled substrate.

Analysis of the

enrichment distribution enables identification of kinetic limiting steps in a given pathway
and sheds light on genetic modifications that might underlie the observed metabolic
changes. The identified genetic underpinning is further interrogated using biochemical
and molecular biology techniques to assess its functional role in tumor growth and
progression as well as its translational potential.
Combined, the above two steps enable development of the functional architecture of
the proposed process-based system. Lastly, the final step of the systems engineering
approach involves aggregation of the proposed solutions to ensure that the combined
product of the system provides an adequate and measurable solution to the problem at
hand. Using the system proposed above, the final outcome for a metabolic observation
that successfully fulfills each of the components of this process-based system, will result
in a well-characterized metabolic dysregulation that exerts a functional effect on
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tumorigenesis, as well as evidence for potential clinical relevance. In aggregate, this
should result in a better understanding of the metabolic and genetic regulation of breast
cancer recurrence.
The interdisciplinary approach articulated above, which we will term magnetic
resonance-based integrative metabolomics,

will combine molecular

biology,

biochemistry, computational biology, imaging, statistical modeling, clinical science and
engineering principles and is envisioned to allow for rigorous assessment of the
diagnostic, prognostic and predictive potential of a given metabolic observation.
Ultimately, a measurable outcome of this system could include the clinical translation of
a metabolic finding identified and characterized using this approach.
In this chapter, we expand on the individual steps of this approach and present a
technical overview of some of the underlying technical concepts necessary for the
adoption of this system. A schematic of the proposed system is shown is Figure 1 and
each step is discussed in further detail in what follows.

2.2 Proposed Approach
I. Unsupervised Magnetic Resonance-based Metabolic Profiling
Magnetic resonance spectroscopy (MRS) is a widely used technique to monitor total
metabolite concentrations in vivo and in tissue samples119,
magnetic properties of NMR active nuclei.
number ½ (such as 1H and

120

.

MRS exploits the

For instance, nuclei with spin quantum

13

C) can orient themselves either parallel (‘‘spin up’’) or anti-

parallel (‘‘spin down’’) to an externally-applied magnetic field. The net magnetization
and the available NMR signal are proportional to the population difference between the
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two states. By convention, an external magnetic field is assigned to act along the z-axis
of a 3-dimensional frame of reference. Thus, at thermal equilibrium, the spins of NMRactive nuclei exhibit a net magnetization along the z-direction. In magnetic resonance
spectroscopy, a 90-degree radio frequency (RF) pulse is typically applied to a sample
placed in a magnetic field. This rotates the net magnetization from the z-direction to the
y-direction.

The spins subsequently precess about the z-axis while simultaneously

relaxing to align back along the original direction of the externally-applied magnetic field.
The behavior of spins placed in a magnetic field and subjected to RF excitation can be
described using the Bloch equations:

where gamma corresponds to the gyromagnetic ratio; Mx, My and Mz correspond to the
magnetization along the x,y and z directions, respectively; Bo is the externally-applied
magnetic field; T1 is the spin-lattice relaxation and T2 is the spin-spin relaxation.
Following RF excitations, as the spins relax to align along the externally-applied
magnetic field, they generate RF pulses that are collectively detected by the NMR
system as a free induction decay (FID) signal.

This signal, which represents the

behavior of spins as a function of time, is a convolution of the RF pulses being emitted
by the decaying spins. Applying a Fourier transform operation to the resulting FID leads
to the generation of the 1D NMR spectrum that represents each of the component
resonance frequencies of the molecules present in a sample. Each peak (or collection
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of peaks) in a spectrum represents the resonance frequency of one specific nucleus in a
particular species of molecule.
When 1H MRS is applied to study the metabolism of a tissue sample, the
spectrum typically consists of multiple frequency components due to the many
detectable molecular constituents of the tissue.

Of note, different components can

possess molecular groups with similar chemical shifts allowing their peaks to overlap,
which can limit the utility of these spectra for the detection and quantification of certain
compounds within tissues.
1

H MRS permits the identification and quantification of a relatively large number

of metabolites that are present in tumor samples.

The area under each peak is

proportional to the molar concentration of the molecule identified at a specific chemical
shift on the spectrum.

This approach provides an unsupervised metabolic profiling

technique, where we are able to broadly screen and identify metabolic differences
between primary and recurrent tumors in a mouse model of breast cancer recurrence.
Those differences can then be further assessed using pathway-specific characterization.
Other unsupervised metabolic profiling techniques are also available, such as
mass spectrometry. These can also be alternatively pursued for this step of the process
for yet broader metabolic screening.

II. Pathway-focused Metabolic Characterization Using 13C-Labeling Experiments
In order to better characterize pathway-specific metabolic dysregulation in primary and
recurrent tumors, we propose the implementation of
experiments, a

13

C-labeling experiments. In these

13

C-labeled tracer is infused into mice bearing primary or recurrent

tumors. Tumors can then be dissected and 13C isotopic enrichment as well as positional
labeling assessed. This technique allows for the construction of a metabolic flux map for
27

a specific compound and provides information about the amount and distribution of each
labeled metabolite in a given pathway. The two most-widely used techniques for this
purpose are mass spectrometry and

13

C-MRS. MRS is the preferred technique when

determination of positional labeling in a compound is desired. Mass spectrometry (MS),
on the other hand, provides information about the amount of 13C-enrichment of individual
metabolite isotopomers with no information on which carbon is labeled within a
molecule.

The information provided by MS and

13

C-MRS studies can be highly

complementary in metabolic studies.
The basis of

13

C-MRS is similar to that described above.

In mass

spectrometry, samples are typically first derivatized and fractionated by liquid or gas
chromatography. Following fractionation, samples are ionized by electron impact. The
resulting ions are subsequently characterized based on their mass to charge ratio (m/z).
With ions typically carrying a single charge, the fragments are separated based on their
molecular weight. The typical MS spectrum contains a number of peaks corresponding
to different fragments of a given compound. Mass isotopomers are molecules that have
incorporated the same number of labeled atoms. They are usually denoted by M0 (no
label incorporation beyond natural abundance), M+1 (molecule has incorporated 1
labeled carbon), M+2 (molecule has incorporated 2 labeled carbons) etc...

13

C-

enrichment is typically reported in molar percent enrichment (MPE), reflecting the mol
fraction (%) of analytes containing 13C atoms in excess of natural abundance, where:

MPE (M+i) = % AM+i/[AM + Σ AM+i]
AM and AM+I represent the peak area from MS ions corrected for natural abundance and
corresponding to the unlabeled (M0) and

13

C-labeled (M+i) mass isotopomers,

respectively. The number of labeled carbons in a molecule can sometimes provide
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information about the direction in which a pathway is proceeding, such as in the case of
reductive carboxylation in the TCA cycle. The extent of labeling can provide information
about the flux in a specific pathway as well as help identify any potential dysregulated
enzymatic steps.
In this work, we use

13

C-MRS when looking for compounds with relatively high

concentration in tumors, allowing for their easy detection by MRS.

In these cases,

compounds labeled at only one or two carbons are used and positional labeling and
concentration are assessed by following the label on the NMR spectrum through some
of the successive steps of the given pathway.
On the other hand, when attempting to investigate metabolic flux and trying to
characterize individual enzymatic steps known to yield low-concentration products, MS is
used. In those cases, we use uniformly labeled compounds to assess the amount of
labeling and the isotopomers present for each metabolic step in a given pathway. The
combination of

13

C-MRS and MS following tracer infusion allows for a focused approach

to identify key steps within a pathway where metabolism might be dysregulated in
primary and recurrent tumors.
Another emerging technique that could further aid in this step of our approach is
hyperpolarized magnetic resonance spectroscopy.

This technique allows the

characterization of single enzyme-characterized reactions in real-time following the
injection of a hyperpolarized

13

C-tracer.

Future studies will seek to incorporate this

technique to further refine our proposed approach.
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III. Genetic Profiling of Potential Underlying Determinants of Observed Metabolic
Changes
Once a key dysregulated metabolic step is identified in a metabolic pathway, assessing
its underlying molecular determinants constitutes the next step in our proposed
approach. To achieve this end, we perform expression profiling of the genes expressing
the key enzymes known to catalyze the identified dysregulated metabolic reactions.
Expression profiling is done at both the mRNA as well as the protein level to account for
any post-translational modifications that might underly the observed metabolic changes.
mRNA levels are assessed by qRT-PCR and protein levels are assessed by
immunoblotting.
Changes in metabolite levels can also result solely from changes in enzymatic
activity, rather than gene expression.

To address this possibility, we also perform

enzymatic activity assays and zymography experiments.

Enzymatic activity assays

allows the user to measure the rate of conversion of a given metabolite into a product
while measuring a surrogate of the reaction rate constant. Zymography, on the other
hand, provides for a mean to isolate different isozymes of a given enzyme and to assess
their individual activity.

These techniques can be complementary depending on the

enzyme being investigated.
Finally, in order to establish a direct association between a given metabolic
change and an identified change in gene expression, we genetically engineer primary
and recurrent tumor cells to downregulate or overexpress the gene in question. This is
followed by assessment of the levels of the associated metabolite relative to its levels in
control cells. A change in the metabolite levels in the expected direction in the context of
gene expression level modulation establishes the identified genetic change as the most
likely molecular determinant of the changing metabolite level.
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IV. Assessment of the Functional Effect of the Identified Metabolic and Genetic
Change
Once a genetic change is identified and characterized, the next step consists of
assessing the functional role of this change in tumorigenesis. This can be achieved
through orthotopic tumor experiments where genetically-engineered cells, in which the
expression level of the metabolic gene of interest has been modulated, are injected into
the mammary fat pads of immunocompromised mice. The effect of gene modulation on
tumor growth can then be followed and assessed. Differences in the growth rates of
tumors with gene downregulation (or overexpression) relative to controls indicates a
functional role for the identified metabolic and genetic alteration in tumorigenesis.
Furthermore, we also perform a tumor recurrence assay to assess the effect of
metabolic gene modulation on the complex phenotype of tumor regression and
recurrence. The details of this assay are detailed in Chapter 6.
If a functional effect is demonstrated, we proceed to identify the mechanism that
might underlie the observed metabolic and genetic change as well as to characterize the
molecular pathway by which the observed metabolic and genetic changes might
contribute to tumorigenesis and/or recurrence.

This can enable the identification of

upstream metabolic regulators that could serve as useful therapeutic targets.

V. Assessment of the Translational Potential of a Functional Metabolic and
Genetic Finding
In an effort to assess the translational potential of an identified functional metabolic and
genetic finding, we conduct human association analysis where we assess the effect of
the expression of the identified metabolic gene on prognosis in human breast cancer
datasets.

In this work, we investigate the correlation between metabolic gene
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expression from microarray data and recurrence-free survival in breast cancer patients.
This is done following the stratification of patients into cancer subtype-specific subsets to
reduce the contribution of confounding variables. Most of this analysis is conducted in
node-negative patients and patients not treated with chemotherapy in order to evaluate
the effect of each gene on outcome data, independent of those variables. In the context
of this analysis, identifying a correlation between metabolic gene expression level and
outcome using Cox proportional hazards modeling indicates a potential prognostic role
for a metabolic change in breast cancer patients.

Eventual clinical translational,

however, will require proving that a newly-identified marker can add to existing
clinicopathological prognostic markers. In this work, we show a proof-of-concept of such
an approach at the end of chapter 7.
Further clinical translational can also be assessed by investigating whether the
identified metabolic gene can act as a predictive marker for response to therapy. Such
an analysis will necessitate access to datasets of treated patients with available outcome
data of partial versus complete pathologic response post-treatment. Finally, one can
also assess the translational potential of a metabolic finding where imaging techniques
can be developed and assessed for a potential role either in the early detection of
tumors upregulating a specific metabolic pathway or monitoring response to therapies
targeted against that pathway.

2.3 System Impact and Validation
In summary, our proposed systems-based approach, magnetic resonance-based
integrative metabolomics, involves combining multi-disciplinary techniques to address
the problem of understanding the metabolic and genetic regulation of breast cancer
recurrence.

By combining molecular biology, biochemistry, computational biology,
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imaging, statistical modeling, clinical science and engineering principles, our system
provides a top-down framework for the assessment of the clinical and functional
relevance of specific pre-clinical metabolic observations.

It is our hope that this

approach will lead to better avenues for clinical translation of newly identified functional
metabolic and genetic findings and better aid in the management and treatment of
cancer patients.
In what follows, we attempt to validate and optimize our proposed system. In
chapter 3, we present results of the unsupervised metabolic profiling of primary and
recurrent tumors conducted in our mouse model using 1H-MRS. In chapters 5 and 6, we
validate the remaining steps of our approach by studying the roles of glutaminolysis and
lactate metabolism in breast cancer recurrence. This is followed by an assessment of
the translational potential of findings from those studies.
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2.4 Figure Legend

Figure 1. Magnetic resonance-based integrative metabolomics: functional
architecture of the proposed process-based system to better understand the
metabolic and genetic regulation of breast cancer recurrence. Presented is the
proposed multi-step algorithm aimed to address the problem at hand.

Following

systems engineering conceptual frameworks, the algorithm consists of 3 key steps: 1)
problem formulation; 2) the proposed multi-step process-based system; and 3) system
assessment, optimization and validation.
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2.5 Figures

Figure 1
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CHAPTER 3

Metabolic and Genetic Profiling of Mammary Tumor Recurrence using1H
Magnetic Resonance Spectroscopy

ABSTRACT
Tumor recurrence represents the principal cause of mortality in human breast cancer,
yet little is known about its underlying molecular mechanisms.

In particular, while

alterations in cellular metabolism have long been recognized as a key feature of the
development of primary cancers, the metabolic changes that accompany cancer
recurrence are poorly understood, if at all. To address this gap, we have used 1H
magnetic resonance spectroscopy (MRS) in combination with expression analysis of key
metabolic enzymes to identify changes in metabolism that occur during mammary tumor
recurrence in genetically engineered mice. The resulting metabolic and genetic profile
revealed highly reproducible alterations in recurrent mammary tumors, which displayed
higher levels of lactate and glycine, lower levels of succinate and phosphocholine (PC),
and a higher glutamate to glutamine ratio (glu/gln) compared to primary tumors. These
characteristic changes in metabolites were accompanied by concordant changes in
expression of the corresponding enzymes that control their production and consumption.
Accordingly, observed changes in the levels of succinate, glu/gln, phosophocholine,
glycine and lactate, were significantly correlated with higher expression levels of Sdhb
and Gls, as well as lower levels of Chka, Gldc and Ldhb, respectively. A composite
metabolic gene expression activity score based upon observed metabolic and genetic
changes in recurrent mouse mammary tumors was associated with decreased relapse36

free survival in women with HER2/neu-positive breast cancer. In aggregate, our findings
demonstrate that tumor recurrence is accompanied by pronounced and reproducible
alterations in tumor metabolism. This, in turn, suggests that increased understanding of
the molecular determinants underlying these metabolic alterations will provide insights
into the molecular pathways that drive breast cancer recurrence, as well as aid in the
identification of novel biological markers and therapeutic targets that could improve
clinical outcomes in breast cancer patients.

3.1 Introduction
Breast cancer is the most commonly diagnosed malignancy as well as the leading cause
of cancer mortality among women worldwide1, 121. While improvements in detection and
treatment in recent decades have led to increases in overall survival, breast cancer
recurrence remains the principal cause of death from this disease66. In fact, up to 20%
of women with breast cancer will be diagnosed with recurrent breast cancer within 10
years of completing adjuvant treatment122. Nevertheless, despite the unrivaled clinical
importance of breast cancer recurrence, little is known about the molecular mechanisms
underlying it development.
The HER2/neu proto-oncogene is amplified and overexpressed in up to 25% of
primary human breast cancers and its amplification is associated with aggressive tumor
behavior and poor prognosis, in part due to high rates of relapse51,

123

.

Notably,

HER2/neu amplification results in downstream activation of the PI3K-AKT signaling
pathway, which plays a central role in the regulation of cellular metabolism67,

68, 71, 72

.

However, while the role of dysregulated cellular metabolism in primary cancer
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development has been a focus of intense investigation, the metabolic changes that
accompany breast cancer recurrence are poorly understood73-75, 124. While some studies
have examined the association between metabolism and histopathologically-based
prognostic features of primary breast cancers125-127, or have explored predictive models
for the early detection of recurrent breast cancer based on metabolic profiles in patient
sera128-131, to date no direct comparisons of the metabolic features of primary and
recurrent human breast cancers have been reported.
To address this question, we have employed a mammary-specific, doxycyclineinducible bitransgenic mouse model for HER2/neu-induced breast cancer that accurately
recapitulates key features of human breast cancer progression, including primary tumor
development, tumor dormancy and tumor recurrence

63, 66, 132

. In this study, we have

used 1H Magnetic resonance spectroscopy (MRS) to identify metabolic changes that
accompany mammary tumor recurrence in mice bearing HER2/neu-induced mammary
tumors, elucidated some of the molecular determinants that might underlie those
changes, and examined the association between the observed metabolic changes and
relapse-free survival in women with HER2/neu-positive breast cancer. These studies
provide new insights into the metabolic alterations that accompany breast cancer
progression.

3.2 Methods
Mouse model
Primary and recurrent mouse mammary tumors were generated in MMTV-rtTA;TetOHER2/neu

(MTB/TAN)

doxycycline-inducible
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bitransgenic

mice

as

previously

described63, 66, 132. HER2/neu expression was induced in MTB/TAN mice by the addition
of 2 mg/mL doxycycline. Tumors that reached a size of approximately 1 cm x 1cm were
dissected and immediately clamp-frozen in liquid nitrogen.

Nine primary mammary

tumors and nine recurrent mammary tumors were harvested from a cohort of 18
MTB/TAN mice, along with normal mammary tissue from three un-induced MTB/TAN
mice. All animal experiments were performed in accordance with protocols approved by
the University of Pennsylvania institutional animal care and use committee (IACUC).

Sample preparation
Frozen tissue samples weighing 200±50 mg were homogenized in ice-cold 12%
perchloric acid. Care was taken to avoid including visibly necrotic areas of tumors. After
homogenization, samples were centrifuged at 15,000 g for 10 min. The supernatant was
collected and neutralized with KOH. Samples were then centrifuged at 15,000 g for 10
min and supernatants were collected and lyophilized.

Lyophilized samples were

dissolved in 0.6 ml D2O before introduction into a 5-mm NMR tube for spectroscopic
analysis.

1

H NMR spectroscopy

NMR spectroscopy was performed at 400MHz on a Bruker Avance DMX 400 wide-bore
spectrometer. Fully relaxed proton spectra were acquired with a 5 mm inverse probe
using the following conditions: PW 45º, TR 8s, water saturation during the relaxation
delay, 6775 Hz SW, TD 64k and 64 scans.

An external standard made of

trimethylsilylpropionic acid (TSP) was introduced into the NMR tube and used as a
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chemical shift reference and as a quantification standard.

Metabolite resonance

assignments were estimated based on previously published spectra in breast cancer
tissue133. The resonance assignments used in this study are listed in Table 1. Analysis
of collected NMR spectra was performed using NUTS (Acorn NMR Inc). Peak integrals
were computed for each metabolite and normalized to the number of contributing
protons per molecule, to tissue weight, and to the known concentration of the TSP
external standard to allow for inter-sample comparison. Metabolite concentrations are
provided as µmol/gram of wet weight of tissue.

RNA isolation and qRT-PCR
Snap-frozen primary and recurrent mammary tumor tissue samples were homogenized
to prepare for RNA extraction. RNA isolation was performed using the RNeasy RNA
isolation kit (Qiagen) according to the manufacturer’s protocol. The cDNA High Capacity
Reverse Transcriptase Kit (Applied Biosystems) was used for reverse transcription
according to the manufacturer’s protocol starting from 2 µg of RNA. qRT-PCR was
performed using the resulting cDNA. qRT-PCR analysis was carried out on the Applied
Biosystems 7900 HT Fast Real-Time PCR system using 6-carboxyfluorescein–labeled
Taqman probes (Applied Biosystems).

qRT-PCR analysis was performed on the 9

recurrent tumors profiled in this study and 8 primary tumors. Sufficient tissue was not
available for one of the primary tumors.
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Principal component analysis
Principal component analysis was performed using Matlab (Mathworks Inc.). Briefly, the
loadings and scores were computed from a matrix that included metabolite levels for the
14 metabolites analyzed for each of the 21 samples included in this study.

The

outputted scores represent the principal components. For the analyzed dataset, a scree
plot revealed that the first 3 components explained 94% of the observed variance.
Accordingly, a plot of the first three principal components is presented.

Statistical analysis
Statistical significance was determined using a two-tailed Student's t-test. Univariate
linear regression to assess the correlation between gene expression levels and
metabolite levels was performed using Matlab (Mathworks Inc.). Pearson analysis was
used to assess the extent of correlation.

The significance of the t-test and of the

Pearson correlation analysis was determined at p<0.05.

Metabolic gene expresion signature generation and human association analysis
A tumor metabolism gene expression signature was generated from the qRT-PCR data
of the six profiled metabolic enzymes whose mRNA expression levels exhibited
differences between primary and recurrent breast tumors in the MTB/TAN mouse model.
The six metabolic enzymes whose expression was included in the signature were Ldhb,
Gldc, Phgdh, Gls1, Sdhb, Chka. The metabolic gene expression signature was used to
assess the combined activities of these enzymes in microarray data of mouse and
human breast tumors using a previously described scoring system134. The signature
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was validated using a set of 10 primary and recurrent MTB/TAN mammary tumors from
another study.

Prognostic value of this six-gene signature was subsequently

assessed in 943 lymph node-negative patients who did not receive any systemic
adjuvant treatment.
In the human association analysis, five human breast cancer microarray data
sets135-139 profiled using the Affymetrix HG-U133A platform were downloaded from Gene
Expression Omnibus and RMA-normalized individually.

943 lymph node-negative

patients who did not receive any systemic adjuvant therapy were identified from these
five data sets according to available clinical information.

Microarray data for these

patients were mean-centered by gene within each data set and combined into one data
set. HER2-positive status was approximated by visual inspection of the rank plot of
HER2 mRNA level, and defined as samples having mean-centered log2 expression
greater than 1. Patients were assigned to either a high scoring or a low scoring class
based on their metabolism signature scores. The cutoff between high- and low-scoring
classes was determined by an outcome-oriented approach140.

Differences in 5-year

relapse-free survival between the two classes was assessed by p-value from the logrank test and hazard ratio from Cox proportional hazards regression. To guard against a
high false-positive rate resulting from multiple testing, a corrected p-value was also
calculated as part of the cut-point determination step140.

These analyses were

performed specifically for the HER2-positive subset of patients. All data analyses were
performed in the R environment141.
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3.3 Results
To identify metabolic differences between primary and recurrent mammary tumors in a
genetically defined model system, we made use of a previously described doxycyclinedependent genetically engineered mouse model for HER2/neu-induced mammary
tumorigenesis63,

66

.

In this model, the reverse tetracycline-dependent transcriptional

activator, rtTA, is specifically expressed in the mammary epithelial compartment of
MMTV-rtTA (MTB) transgenic mice under the control of the mouse mammary tumor
virus promoter/enhancer132.

When interbred with TetO-HER2/neu (TAN) transgenic

mice, in which expression of an activated allele of the rat HER2/neu proto-oncogene is
controlled by the tet operator, administration of doxycycline to MTB/TAN bitransgenic
mice results in binding of activated rtTA to the tet operator, and expression of the
HER2/neu transgene in mammary epithelial cells63.
Activation of HER2/neu in MTB/TAN mice results in mammary epithelial
hyperplasia and the eventual development of primary mammary tumors that are
addicted to HER2/neu expression63. Consequently, when doxycycline is withdrawn, the
resulting acute downregulation of HER2/neu pathway activity results in the regression of
mammary tumors to a non-palpable state, akin to the treatment of women with
HER2/neu-amplified breast cancers with a targeted agent that blocks HER2/neu
activity63. Also akin to human breast cancer patients, primary mammary tumors that
regress to a non-palpable state following doxycycline withdrawal subsequently recur with
stochastic kinetics following a variable latent period that mimics human tumor dormancy
(Figure 1A)66.

Recurrent mammary tumors in this system do not re-activate the

HER2/neu transgene, but rather escape their dependence on HER2/neu signaling by
activating alternate growth and survival pathways66.
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Primary and recurrent mammary tumors exhibit different metabolic profiles
We compared the metabolic profiles of primary mammary tumors arising in doxycyclineinduced MTB/TAN mice with recurrent mammary tumors that had arisen in MTB/TAN
mice harboring primary tumors that had regressed to a clinically undetectable state
following doxycycline withdrawal, and had then recurred in the absence of doxycycline.
Tumors that reached a size of approximately 1 cm were dissected, clamp-frozen
and homogenized in ice-cold perchloric acid. Following centrifugation and neutralization
of supernatants with KOH, lyophilized samples were dissolved in D2O.

1

H NMR

spectroscopy was performed at 400MHz on a Bruker Avance DMX 400 wide-bore
spectrometer and fully relaxed proton spectra were acquired with a 5 mm inverse probe.
Trimethylsilylpropionic acid (TSP) was introduced as an external standard and used as a
chemical shift reference and quantification standard.
Metabolite resonance assignments were estimated based on published spectra
in breast cancer tissue133 and are listed in Table 1. Analysis of collected NMR spectra
was performed using NUTS (Acorn NMR Inc). Peak integrals were computed for each
metabolite and normalized to the number of contributing protons per molecule and to
tissue weight, as well as to the known concentration of the TSP external standard to
enable inter-sample comparison.

Metabolite concentrations were calculated as

µmol/gram of wet weight of tissue.
1

H MRS metabolic profiling of 9 primary and 9 recurrent mammary tumors from a

cohort of 18 MTB/TAN mice revealed clear differences in spectroscopic features
between primary and recurrent mammary tumors (Figure 1B).

The spectroscopic

profiles of tumors were also distinct from those of un-induced mammary glands in which
the HER2/neu oncogene had not been activated. Quantification of fourteen metabolites
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in the 1H spectra of each tumor yielded eight metabolites that exhibited statistically
different levels (p<0.05) between primary and recurrent tumors (Table 2). Specifically,
when compared to primary mammary tumors, recurrent tumors displayed higher levels
of lactate, glutamate, taurine and glycine, and lower levels of succinate, glutamine,
phosphocholine

and

myo-Inositol.

Alanine,

acetate,

glycerophosphocholine and formate levels were unchanged.

creatine,

choline,

Further analysis also

revealed a higher glutamate to glutamine ratio (glu/gln) and a higher glycine to creatine
ratio (Gly/Cr) in recurrent tumors compared to primary tumors.

No changes were

observed in the ratio of alanine to creatine (Ala/Cr) or the ratio of total choline (the sum
of the choline, phosphocholine (PC) and glycerophosphocholine (GPC) integrals) to
creatine (tCho/Cr).
Principal component analysis performed on the fourteen quantified metabolites in
each spectrum revealed distinct metabolic signatures of primary tumors, recurrent
tumors and un-induced mammary glands (Figure 1C).

Unsupervised dimensionality

reduction of the metabolic data into three orthogonal components led to consistent
clustering of the twenty-one analyzed tissue samples by tumor/gland type in principal
component space.

Lactate levels increase during mammary tumor recurrence
Recurrent mammary tumors exhibited higher lactate levels than primary tumors.
Therefore, we sought to determine the potential underlying molecular determinant of
these observed changes.

A number of steps in the glycolytic pathways have been

previously implicated in dictating cellular lactate levels.

These include reactions

catalyzed by pyruvate kinase isoform M2 (Pkm2), lactate dehydrogenase A subunit
(Ldha) and lactate dehydrogenase B subunit (Ldhb). Pkm2 expression is associated
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with increased lactate production. Ldha catalyzes the conversion of pyruvate to lactate
and Ldhb is thought to be responsible for catalyzing the reverse reaction of lactate to
pyruvate conversion. Quantification of the expression levels of each of the above genes
by qRT-PCR revealed similar expression levels of Ldha and Pkm2 in primary and
recurrent tumors (p>0.05). Ldhb expression, however, was downregulated in recurrent
tumors compared to primary tumors (p<0.05) (Figure 2B).
Univariate linear regression to examine the correlation between lactate levels
and the expression of each of the above genes in the analyzed tissue samples revealed
a statistically significant correlation between lactate levels and Ldhb expression
(r=0.556, p=0.017) as well as between lactate levels and Pkm2 expression levels
(r=0.496, p=0.036) (Figure 2C). However, whereas Pkm2 expression was unchanged
during the process of recurrence, Ldhb expression was downregulated approximately
10-fold in recurrent tumors.

As expected from the fact that Ldhb catalyzes the

conversion of lactate to pyruvate, the correlation between lactate levels and Ldhb
expression was negative (Figure 2C). Taken together, these data suggest that recurrent
tumors may have higher lactate levels as a consequence of Ldhb downregulation.

Glycine levels increase during mammary tumor recurrence
Recurrent mammary tumors exhibit higher levels of glycine.

To investigate the

underlying molecular determinants of the change in glycine levels during mammary
tumor

progression,

we

examined

the

expression

levels

of

phosphoglycerate

dehydrogenase (Phgdh) and glycine decarboxylase (Gldc) in primary and recurrent
tumors. Each of these genes has been previously implicated in regulating glycine levels
during tumorigenesis.

Phgdh catalyzes the conversion of the 3-phosophoglycerate

glycolytic intermediate into 3-phophohydroxypuruvate contributing glycolytic carbon to
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the serine biosynthesis pathway where glycine is produced (Figure 3A).

Gldc is a

component of the glycine cleavage system and catalyzes the breakdown of glycine into
carbon dioxide and ammonia (Figure 3A). qRT-PCR revealed higher levels of Phgdh
and lower levels of Gldc in recurrent tumors compared to primary tumors (p<0.05)
(Figure 3B).

Specifically, recurrent tumors exhibited an approximately 10-fold

downregulation in Gldc expression and an approximately two-fold increase in Phgdh
levels compared to primary tumors.
To assess the correlation between glycine levels and the expression of each of
these genes, univariate linear regression was performed. Regression analysis revealed
a statistically significant correlation between glycine levels and Gldc levels when
considering all analyzed tumors (r=0.546 and p=0.028) (Figure 3C). As predicted based
on the fact that Gldc catalyzes the breakdown of glycine, the correlation between Gldc
expression and glycine levels was negative.

In contrast, Phgdh levels were not

significantly correlated with glycine levels in the analyzed tumors. Together, these data
indicate that the observed upregulation in glycine levels in recurrent tumors may be due
to Gldc downregulation.

Glutamine, choline and succinate metabolism exhibit marked changes during
mammary tumor recurrence
Spectroscopic results revealed higher glutamate levels and lower glutamine levels in
recurrent tumors compared to primary tumors. Since the inter-conversion of glutamine
and glutamate is catalyzed by glutaminase (Gls), we sought to identify changes in
glutaminase expression levels that might occur during the process of recurrence. qRTPCR quantification of glutaminase expression revealed a modest increase in Gls1
(referred to as Gls in this study) expression levels in recurrent tumors compared to
47

primary tumors (p<0.05) (Figure 4B). Univariate linear regression analysis revealed a
statistically significant correlation between the ratio of glutamate to glutamine (Glu/Gln)
and Gls1 expression levels across all the tumors analyzed (r=0.53, p=0.024). Since
Gls1 catalyzes the conversion of glutamine to glutamate, higher Gls1 levels are thought
to be associated with: a) decreased glutamine levels reflecting increased consumption;
b) increased glutamate levels reflecting increased production; and, by extension, c)
increased glutamate to glutamine ratio. Indeed, the correlation between Gls1 expression
and the glutamate to glutamine ratio was positive. Combined, these data indicate that
increased ratio of glutamate to glutamine observed in recurrent tumors might reflect
increased glutamine to glutamate conversion due to upregulation of Gls1 expression.
In addition to changes in glutamate to glutamine ratio, recurrent tumors also
exhibited lower phosphocholine levels compared to primary tumors. To investigate the
molecular determinants of this change, we assessed the expression of choline kinase α
(Chka) in primary and recurrent tumors. Choline kinase catalyzes the conversion of
choline to phosphocholine (Figure 4A). qRT-PCR analysis revealed nearly 3-fold lower
Chka expression in recurrent tumors compared to primary tumors (p<0.05) (Figure 4B).
Univariate linear regression demonstrates a statistically significant correlation between
phosphocholine metabolite levels and Chka expression (r=0.503, p=0.034) (Figure 4C).
As anticipated based on the fact that Chka catalyzes the conversion of choline into
phosphocholine, the correlation between phosphocholine levels and Chka expression
was positive. Overall, our data suggest that decrease in phosphocholine level observed
in recurrent tumors may be due to Chka downregulation.
Spectroscopic profiling also revealed lower succinate levels in recurrent tumors
compared to primary tumors. The conversion of succinate to fumarate in the TCA cycle
is catalyzed by succinate dehydrogenase. To investigate whether changes in the
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expression of this enzyme might underlie observed changes in succinate levels in
recurrent tumors, qRT-PCR quantification of succinate dehydrogenase B (Sdhb) levels
was performed.

Recurrent tumors exhibited 2-fold higher Sdhb levels compared to

primary tumors (p<0.05) (Figure 4B).

Univariate linear regression also showed a

significant correlation between succinate levels and Sdhb expression levels among the
tumors analyzed (r=0.486, p=0.041) (Figure 4C). As expected based on the fact that
Sdhb catalyzes the conversion of succinate to fumarate, the correlation between
succinate levels and Sdhb expression was negative. Together, the data suggest that the
decreased succinate levels observed in recurrent tumors might be a consequence of
increased succinate consumption due to Sdhb upregulation.

Changes in metabolism during mammary tumor recurrence in mice are associated
with decreased relapse-free survival in women with HER2-positive human breast
cancer
We generate a metabolic gene expression signature based on changes in expression
levels of the six profiled metabolic genes whose expression differed between primary
and recurrent MTB/TAN tumors examined in this study (Figure 5A). This signature was
used to assign a score to individual tumors based on the expression levels of those six
genes. As expected, the scores generated using this signature were higher in recurrent
MTB/TAN mouse tumors compared to primary tumors, in an independent cohort of mice
(Figure 5B). We then assessed the potential prognostic value of this metabolic gene
expression signature assessing scores in a group of 947 human breast cancer patients
with node-negative breast cancer.

Since the signature had been generated and

validated in a HER2/neu-positive breast cancer mouse model, we preformed a human
association analysis in patients whose breast cancers were HER2-positive.

This

analysis revealed that patients whose breast cancers expressed levels of these
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metabolic enzymes that most closely resembled those found in recurrent mouse
mammary tumors were more likely to relapse over a 5-year period (HR=2.42, p=0.004
and pcorrected=0.007) (Figure 5C).

3.4 Discussion
In this study, we show that primary and recurrent mammary tumors display different 1H
MRS metabolic profiles and we correlate these metabolic changes with corresponding
changes in expression levels of enzymes associated with the production or consumption
of those metabolites.

Specifically, recurrent tumors exhibit higher levels of lactate,

glutamate, taurine and glycine, and lower levels of succinate, glutamine, phosphocholine
and myo-inositol. Tumor expression levels of Ldhb, Gldc, Gls, Sdhb and Chka were
significantly correlated with the levels of lactate, glycine, glutamate/glutamine, succinate
and phosphocholine, respectively. Furthermore, a metabolic gene expression signature
generated based on alterations in gene expression that occur during tumor recurrence in
mice was associated with decreased relapse-free survival in HER2-positive breast
cancer patients. Combined, these results suggest that tumor metabolism evolves during
breast cancer progression and raise the possibility that changes in the expression of
certain key metabolic genes may be useful for predicting clinical outcomes in breast
cancer patients.
While a role for MRS in evaluating metabolism in breast cancers has previously
been established through spectroscopic studies133,

142-144

, few studies have examined

differences in metabolism between primary and recurrent tumors. In a study evaluating
the role of 1H MRS and GC-MS metabolic profiling in the early detection of breast cancer
recurrence, eleven serum metabolites were identified that were able to predict breast
cancer recurrence in a cohort of 56 patients130. Similarly, studies of human brain tumors
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using 1H MRS and

31

P MRS identified a number of metabolic changes, including those

in glycine, alanine, glutamate and total choline in recurrent astrocytomas and
glioblastomas128,

129

.

In agreement with those studies, our results further confirm a

changing metabolic landscape during cancer progression.
In this study, we report increased lactate levels in recurrent mammary tumors in
mice. Increased lactate concentrations have been correlated with metastatic spread and
recurrence in cervical cancer145 and have been shown to predict prognosis in several
cancers, including brain and breast cancers146,

147

. Spectroscopic studies examining

tumor recurrence in breast cancer and brain cancer patients also reported increased
lactate levels in recurrent tumors128-130. Our results suggest that Ldhb dowregulation
may be one underlying molecular determinant of the observed increase in lactate levels
during tumor progression. Previous studies have implicated Ldha and Pkm2 as key
players in modulating lactate concentrations in tumors83,

148

.

tumorigenesis, however, has received relatively little attention.

The role of Ldhb in
Some have reported

Ldhb downregulation and increased lactate levels in highly metastatic prostate cancer
cell lines87 and metastatic hepatocellular carcinoma149.

We speculate that Ldhb

downregulation might play a role in breast cancer recurrence. However, further studies
will be needed to investigate this possibility.
Similar to our observation showing increased glycine levels in recurrent tumors in
mice, higher glycine levels have been reported in recurrent astrocytomas and recurrent
glioblastomas compared to their corresponding primary tumors128. Increased glycine
production occurs when higher amounts of carbon from glycolysis are diverted into
serine biosynthesis, the pathway implicated in glycine and serine production. Genetic
profiling of enzymes involved in this pathway in mice revealed increased Phgdh levels
and lower Gldc levels in recurrent tumors. Recent studies have identified Phgdh as a
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central player in tumorigenesis and have implicated it in modulating glycine levels in a
number of human cancers150,

151

.

In our study however, Gldc, but not Phgdh, was

significantly correlated with glycine levels in tumor samples. Gldc is a key component of
the glycine cleavage system. We speculate that lower Gldc levels might result in glycine
accumulation due to reduced glycine breakdown. Recent studies suggest a role for
glycine decarboxylase in tumor initiatiting cells in non-small cell lung cancer152. Further
studies will be needed to evaluate the role of Gldc in cancer progression.
Recurrent mouse mammary tumors also exhibited increased levels of glutamate
and decreased levels of glutamine, reflected in an increased glutamate to glutamine ratio
(glu/gln). An increased glu/gln rato has also been reported in recurrent astroctyomas in
humans128. Interestingly, examination of sera from patients with recurrent breast cancer
showed decreased, rather than increased, glutamate levels compared to patients without
recurrence130. We speculate that the differences in our findings might stem from the fact
that our measurements were made in tumor tissue whereas decreased glutamate levels
were reported in patients’ sera. While tumor tissue might exhibit increased glutamate
production, glutamate might not be readily secreted into the blood.
The observed increase in glu/gln ratio observed in this study could be explained
by the increase in Gls1 levels that are found in recurrent tumors. The production of
glutamate from glutamine is catalyzed by glutaminase (Gls1). Here, we report increased
Gls1 levels in recurrent tumor recurrence that correlated with increases in the ratio of
glu/gln. Gls1 has been identified as a key component in Myc-driven tumorigenesis97, 98
and its expression is required for tumor growth in xerograft models100, 153, 154. Gls1 has
not been previously implicated in the process of tumor recurrence.

Indeed, to our

knowledge, few studies have examined the association between changes in
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glutaminolytic activity and tumor progression.

Our data suggest that increased

glutamine metabolism may play a role in breast cancer progression.
Another metabolic feature of tumor recurrence observed in our model was
decreased phosphocholine production. Choline metabolism in tumorigenesis has been
subject of intense study since the 1980s155. In particular, phosphocholine has been
shown to be a second messenger essential for mitogenic acitivity156. Multiple studies
have reported an association between increased choline uptake and phosphocholine
production and malignant transformation157-160, as well as progressive increases in total
choline during tumor progression125,

127

.

Fewer studies, however, have reported

decreased total choline or phosphocholine levels in tumors.

Examination of tissue

samples from recurrent brain tumors found increased total choline levels in recurrent
astrocytoma, but decreased total choline in recurrent glioblastomas, compared to
corresponding primary tumors128.

Similarly, decreases in phosphocholine/glyceryl-

phosphocholine ratio have been reported during mammary tumors progression from
estrogen-dependent growth to estrogen-independent growth161.
We speculate that the decrease in phosphocholine levels that we observe in
recurrent mouse mammary tumors could be due to the HER2/neu-independent growth of
recurrent tumors. Activation of the PI3K pathway has been demonstrated to upregulate
Chka levels in tumors162,

163

.

In this regard, the PI3K pathway is active in primary

HER2/neu-driven tumors, but not in recurrent tumors in our model. As predicted from
this, we found decreased levels of Chka in recurrent mammary tumors. Chka catalyzes
the conversion of choline into phosphocholine and expression levels of Chka correlated
with the observed phosphocholine levels in the samples analyzed. While increased
Chka levels and increased choline metabolism have been previously correlated with
worse prognosis in human cancer127, 164, our results suggest that decreased Chka levels
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and decreased phosphocholine levels might be a feature of tumor progression in certain
cancers.
Recurrent tumors exhibited lower succinate levels compared to primary tumors.
Dysregulated succinate metabolism has been linked to tumorigenesis.

Specifically,

several studies have identified mutations in succinate dehydrogenase that result in
succinate accumulation, a phenomenon that promotes tumorignenesis through the
stabilization of hypoxia inducible factor (Hif)165. The conversion of succinate to fumarate
is catalyzed by succinate dehydrogenase (Sdh).

In this study, we report increased

levels of Sdhb expression in recurrent tumors that were correlated with succinate levels.
In theory, higher Sdhb levels will be expected to induce higher consumption of
succinate, resulting in lower levels of succinate in recurrent tumors. Sdhb dysregulation
has been previously reported in familial phaeochromocytomas and paragangliomas166.
While we have not yet determined whether succinate dehydrogenase is mutated in
recurrent tumors, we speculate that increased Sdhb expression may contribute to breast
cancer progression.
Spectroscopic profiling of recurrent tumors also revealed decreased myo-Inositol
and increased taurine levels compared to primary tumors.

Previous studies have

reported both increases and decreases in myo-inositol and taurine levels with malignant
transformation in breast and brain tumors128, 143, 167 as well as a decrease in myo-inositol
levels as astrocytomas progress to higher grades126. Both taurine and myo-inositol play
a role in cellullar osmoregulation168. Myo-inositol has also been shown to contribute to
the cellullar messenger inositol polyphosphates pool169.

However, the precise

contribution of myo-inositol and taurine levels to tumorigenesis remains undefined.
Based on our findings in this study, we speculate that changes in myo-inositol and
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taurine metabolism might be involved in tumor recurrence either through their effect on
osmoregulation and/or through the role of myo-inositol in cellullar signaling.
To begin to assess the potential clinical applicability of our findings, we
generated a gene expression signature based on the expression of key metabolic
enzymes identified in our study and assessed its prognostic potential in a cohort of
breast cancer patients.

Expression of metabolic enzymes associated with tumor

recurrence in mice was associated with decreased recurrence-free survival in patients
with HER2-positive breast cancers.

Previous studies have suggested a role for

metabolic profiling of sera samples in the prognosis assessment of patients with breast
cancer130 as well as colorectal cancer131. Our study further confirms that evaluation of
the expression of specific metabolic enzymes could potentially aid in predicting risk of
relapse in patients diagnosed with HER2-positive breast cancer.
While our study identifies a number of metabolic differences between primary
and recurrent mammary tumors, our analysis was limited to fourteen metabolites
detectable by 1H MRS. A more comprehensive metabolic profiling study remains to be
conducted using mass spectrometry for a broader view of the metabolic changes that
occur during tumor progression. Furthermore, the genetic profiling component of this
study was limited to assessing gene expression levels by qRT-PCR. Clearly, changes in
the expression levels of metabolic enzymes are only one contributing factor to the level
of enzymatic activity that can alter metabolite levels. More comprehensive future studies
will be needed to directly assess changes in enzyme activity at the protein level. An
additional limitation of this study is that the human association analysis focused on
patients with HER2-positive breast cancers without stratification by tumor subtype or
classical prognostic characteristics. Stratification of larger human datasets by tumor
grade and subtype, while accounting for known clinical prognostic factors, could unveil
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additional associations between changes in metabolites and breast cancer progression.
Finally, this study was limited to examining steady-state metabolite levels in tumor
extracts. Given that metabolism is a dynamic process, future studies using isotopic
labeling experiments in vivo will be needed to gain a better understanding of the
changes in metabolic pathway fluxes that might accompany tumor recurrence.
Taken together, our results suggest that tumor metabolism evolves during breast
cancer progression. Specifically, recurrent tumors exhibit increased lactate levels as
well as increased glutamate to glutamine ratio that may be indicative of a more active
glutaminolytic phenotype. We also found increases in glycine levels that may reflect the
diversion of glycolytic intermediates into serine biosynthesis. Finally, recurrent tumors
also exhibited decreased phosphocholine and Chka levels. Overall, our results indicate
that metabolic profiling could improve our understanding of the molecular pathways
involved in breast cancer recurrence. Further assessment of these pathways might
enable the identification of novel therapeutic targets as well as diagnostic or prognostic
markers useful in the management of breast cancer patients.
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3.5 Tables
Table 1. 1H Metabolites assessed in this study. Chemical shifts are measured in
reference to 3-trimethylsilylpropionate (TSP) at 0 ppm. (m:multiplet; db:doublet; GPC:
glycerophosphocholine; PC: phosphocholine).

Chemical
Metabolite

Abbreviation

Spin-Spin

Proton(s)

Shift (ppm)
Lactate

Lac

1.33

Doublet

CH3

Alanine

Ala

1.47

Doublet

CH3

Acetate

Acet

1.91

Singlet

CH3

Glutamate

Glu

2.06

Multiplet

CH2

Succinate

Succ

2.40

Singlet

CH2

Glutamine

Gln

2.46

db of triplet

CH2

Creatine

Cr

3.03

Singlet

CH3

Choline

Cho

3.20

Singlet

(CH3)3-N+

PC

PC

3.59

Singlet

(CH3)3-N+

GPC

GPC

3.67

Singlet

(CH3)3-N+

Taurine

Tau

3.25,3.41

Triplet, triplet

CH2-N, CH2-S

Glycine

Gly

3.97

Singlet

CH2

myo-Inositol

Ino

3.29,3.55,4.07

Triplet, m, triplet

H5;H1,H3;H2

Formate

For

8.46

Singlet

CH-O
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Table 2. Metabolite quantification in primary and recurrent mammary tumors. Results
are normalized to grams of wet weight of the extracted tumor. g ww: grams of wet
weight; gly: glycine; gln: glutamine; glu: glutamate; tCho: total choline; ala: alanine; cr:
creatine, pc: phosphocholine, gpc: glycerophophocholine .

Primary Tumor

Recurrent Tumor

(µmol/g ww)

(µmol/g ww)

Lactate

7.85 ± 1.66

11.38 ± 1.40

<0.001

Alanine

2.14 ± 0.41

2.08 ± 0.34

0.372

Acetate

1.26 ± 0.92

0.83 ± 0.44

0.122

Glutamate

3.48 ± 0.37

4.45 ± 1.43

0.042

Succinate

0.61 ± 0.10

0.44 ± 0.05

<0.001

Glutamine

0.59 ± 0.19

0.32 ± 0.07

0.002

Creatine

1.82 ± 0.59

1.90 ± 0.70

0.397

Choline

0.35 ± 0.11

0.31 ± 0.06

0.172

PC

1.03 ± 0.39

0.52 ± 0.16

0.002

GPC

1.40 ± 0.40

1.26 ± 0.29

0.216

Taurine

5.20 ± 0.87

7.31 ± 2.14

0.016

Glycine

1.18 ± 0.09

2.18 ± 0.56

<0.001

myo-Inositol

4.42 ± 2.1

2.65 ± 0.66

0.020

Formate

0.99 ± 0.79

0.71 ± 0.31

0.178

Gly/Cr

0.69 ± 0.18

1.22 ± 0.45

0.002

tCho/Cr

1.61 ± 0.46

1.98 ± 2.59

0.342

Ala/Cr

1.27 ± 0.42

1.21 ± 0.47

0.385

Glu/Gln

6.74 ± 2.38

12.67 ± 1.53

<0.001

Metabolite

p-value
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3.6 Figure Legends

Figure 1. Primary and recurrent mammary tumors exhibit different metabolic
phenotypes.

(A) The HER2/neu doxycycline-inducible bitransgenic mouse model

(MTB/TAN) used in this study reproduces key features of human breast cancer
progression: primary tumor development, tumor dormancy and tumor recurrence. (B)
Sample spectra from an un-induced mammary gland, a primary tumor and a recurrent
tumor displaying different metabolic profiles. TSP is used as an external. Spectra are
shown for tissue of similar weights. TSP: 3-trimethylsilylpropionate; Lac: Lactate CH3;
Ala: Alanine CH3; Acet: Acetate CH3; Glu: Glutamate CH2-4; Succ: Succinate CH2; Gln:
Glutamine CH2-4; Cr: Creatine CH3; Cho: Choline; Phosphocholine (PC) and
Glycerophosphocholine (GPC); Ino: Inositol; Tau: Taurine CH2-N-; Gly: Glycine; For:
Formate; tCho is total choline and is the combination of choline, PC and GPC. (C)
Principal component analysis conducted on the metabolites analyzed in this study
confirms distinct metabolic signatures for primary and recurrent tumors. Un-induced
display metabolic profiles distinct from tumors.

Figure 2. Lactate metabolism is upregulated in mammary tumor recurrence. (A)
Reactions leading to lactate production in glycolysis. Only enzymes previously shown to
affect lactate levels are shown. (B) Expression levels of enzymes implicated in lactate
production in primary and recurrent tumors in the MTB/TAN model. (C) Correlation
between lactate levels measured by proton MRS and expression levels of associated
metabolic enzymes assessed by qRT-PCR. Pkm2: pyruvate kinase isoform M2; Ldha:
lactate dehydrogenase A; Ldhb: lactate dehydrogenase B.
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Figure 3. Glycine metabolism is upregulated in mammary tumor recurrence. (A)
Reactions leading to glycine production.

3-PG is a metabolic intermediate in the

glycolytic pathway. (B) Expression levels of enzymes in the pathways implicated in
glycine production in primary and recurrent tumors in the MTB/TAN model.

(C)

Correlation between glycine levels measured by proton MRS and expression levels of
associated metabolic enzymes assessed by qRT-PCR. 3-PG: 3-Phophoglycerate; 3PHP: 3-Phosphohyroxypyruvate; Phgdh: phosphoglycerate dehydrogenase; Gldc:
glycine decarboxylase.

Figure 4. Glutamine, choline and succinate metabolism exhibit marked changes
during mammary tumor recurrence.

(A) Reactions leading to consumption of

glutamine, choline and succinate respectively.

(B) Expression levels of enzymes

implicated in each of the metabolic pathways in primary and recurrent tumors in the
MTB/TAN model. (C) Correlation between metabolite levels or ratio measured by proton
MRS and expression levels of associated metabolic enzymes assessed by qRT-PCR.
Gls: glutaminase, Chka: choline kinase α; Sdhb: succinate dehydrogenase b; Gln:
glutamine; Glu: glutamate.

Figure 5. High expression in human breast cancers of metabolic enzymes
characteristic of recurrent mouse mammary tumors is associated with decreased
relapse-free survival in HER2-positive human breast cancer.

(A) A heatmap

showing expression levels of 6 profiled metabolic genes whose expression differed
between primary and recurrent MTB/TAN tumors. qRT-PCR expression levels of these
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genes were used to generate a metabolic gene expression signature. (B) Validation of
the generated metabolic expression signature in an independent set of 10 primary and
recurrent tumors showing that recurrent MTB/TAN tumors exhibit higher metabolic gene
expression activity score.

(C) Expression of metabolic enzymes characteristic of

recurrent mouse mammary tumors is associated with decreased 5-year relapse-free
survival in HER2-positive breast cancer patients. Ldhb: lactate dehyrdrogenase B; Gldc:
glycine decarboxylase; Gls: glutaminase; Chka: choline kinase α; Sdhb: succinate
dehydrogenase b; H.R.: hazard ratio.
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CHAPTER 4

Metabolic Reprogramming in Cancer: Unraveling the Role of Glutamine in
Tumorigenesis

ABSTRACT
Increased glutaminolysis is now recognized as a key feature of the metabolic profile of
cancer cells, along with increased aerobic glycolysis (the Warburg effect).

In this

chapter, we discuss the roles of glutamine in contributing to the core metabolism of
proliferating cells by supporting energy production and biosynthesis. We address how
oncogenes and tumor suppressors regulate glutamine metabolism and how cells
coordinate glucose and glutamine as nutrient sources. Finally, we highlight the novel
therapeutic and imaging applications that are emerging as a result of our improved
understanding of the role of glutamine metabolism in cancer.

4.1 Introduction
Glutamine has long been recognized to play a unique role in the metabolism of
proliferating cells, as compared to other amino acids88, 89. It is the most abundant amino
acid in plasma, and most tumors consume and utilize glutamine at much higher rates
than other amino acids88. Although glutamine is a non-essential amino acid in normal,
non-dividing tissue, it is essential for the proliferation of most cells and the viability of
some cancer cells that have become addicted to glutamine170. Glutamine metabolism
contributes to the ability of cancer cells to continuously grow and proliferate by
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supporting ATP production and biosynthesis of proteins, lipids, and nucleic acids.
Glutamine also modulates redox homeostasis and can impact the activity of signal
transduction pathways90, 92.
Glutamine’s involvement in oxidative mitochondrial metabolism in cancer cells
was reported as early as the 1970s171, and recent investigation has greatly expanded
our understanding of the role and regulation of glutamine metabolism in cancer. In this
article, we discuss the role of glutamine in supporting cellular proliferation and review
current knowledge of how oncogenes and tumor suppressors regulate glutamine
metabolism. We also discuss mechanisms through which metabolism of glutamine and
glucose may be coordinated.

Finally, we address the therapeutic and imaging

applications that are emerging as a result of increasing recognition of the importance of
glutamine metabolism in cancer.

4.2 Glutamine Metabolism Supports Cell Proliferation
Glutamine plays several important metabolic roles in the cell. It serves as a carbon
source for energy production, contributes carbon and nitrogen to biosynthetic reactions,
and regulates redox homeostasis (Figure 1). Glutamine availability and metabolism can
also modulate activity of signal transduction pathways. As we discuss below, each of
these functions of glutamine contributes to its ability to support cell growth and
proliferation.
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Glutamine: a Primary Carbon Source for Energy Production and Biosynthesis
Each of glutamine’s fates in the cell serve important functions, although it is glutamine’s
role in supporting mitochondrial metabolism that is the primary reason that it is required
in such large quantities. While non-proliferating cells can completely oxidize glucosederived carbon in the TCA cycle to support their energy needs, proliferating cells use
nutrients to support biosynthesis in addition to ATP production74. In proliferating cells,
the TCA cycle metabolite citrate is exported out of the mitochondria to be used for
generation of acetyl-CoA in the cytoplasm, which serves as a precursor for lipid
biosynthesis. Because of the continual loss of citrate from the TCA cycle, replenishment
of TCA intermediates (anaplerosis) is necessary, and glutamine serves as an important
anaplerotic substrate in most proliferating cells.

Citrate is generated from the

condensation of acetyl-CoA and oxaloacetate, and 13C labeling of glucose and glutamine
in proliferating glioblastoma cells demonstrated that in these cells glutamine is a major
source of oxaloacetate, whereas glucose carbon is the predominant source of acetylCoA91. Glutamine’s role as a carbon source supporting TCA cycle function is critical for
glutamine-addicted cancer cells. Cells expressing oncogenic levels of c-Myc die upon
glutamine withdrawal, and viability can be restored by supplementing cells with TCA
cycle intermediates, such as pyruvate, oxaloacetate, or alpha-ketoglutarate97, 98, 172.
By contributing to citrate production, glutamine also supports de novo
lipogenesis91,

173

. While glutamine frequently plays a supporting role in lipogenesis by

allowing transfer of glucose-derived acetyl-CoA from the mitochondria to the cytoplasm
through citrate, glutamine carbon can also directly supply acetyl-CoA for lipogenesis.
This can occur through two mechanisms. First, glutamine can contribute to lipogenesis
through conversion of malate into pyruvate by malic enzyme, providing pyruvate that can
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then re-enter the TCA cycle as acetyl-CoA174, 175. Second, glutamine, after conversion to
alpha-ketoglutarate, can undergo reductive carboxylation to generate isocitrate, which is
then converted into citrate176-181.

The direct contribution of glutamine to de novo

lipogenesis is particularly apparent under conditions of hypoxia or mitochondrial
dysfunction, in which a number of cancer cell lines were shown to depend almost
exclusively on the reductive metabolism of alpha-ketoglutarate to synthesize acetylCoA177-179,

181

. Remarkably, HIF-alpha expression is sufficient to drive reductive

carboxylation of alpha-ketoglutarate, even under normoxic conditions, indicating that
“reversal” of the TCA cycle can be actively programmed177, 178. In lymphoma cells, on
the other hand, Myc was shown to promote increased oxidation of glutamine, even
under hypoxia174. Glutamine could in fact fully sustain the oxidative TCA cycle, even in
the absence of glucose, in Myc-driven cells174. Recent estimates indicate that 10-25% of
acetyl-CoA used for de novo lipogenesis comes from glutamine under normoxic
conditions, and that up to 80% of acetyl-CoA for lipogenesis may come from glutamine
in hypoxia178.

Thus, the mechanism by which glutamine fuels lipid synthesis and

proliferation is highly dependent on the oxygen and nutrient availability in the tumor
environment, as well as oncogene expression, underlining the metabolic flexibility of
cancer cells.

Glutamine: a Nitrogen Donor
In addition to the major function of glutamine in supplying carbon to mitochondria,
glutamine serves as a nitrogen source. As depicted in Figure 1, the amido and amino
groups of glutamine contribute to multiple biosynthetic pathways, including synthesis of
non-essential amino acids, nucleotides, and hexosamines.
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Glutamine deprivation

causes growth arrest in most cell lines, and recent studies have highlighted glutamine’s
role as a nitrogen donor during proliferation. Supplementation of glutamine-starved Mycdriven cells with TCA intermediates was shown to rescue viability but not proliferation,
suggesting that during proliferation, glutamine serves critical functions in addition to
supporting the TCA cycle172. Indeed, rescue of proliferation during glutamine deprivation
in Hep3B cells was more potent when cells were supplemented with alternate nitrogen
sources such as alanine or asparagine than with alpha-ketoglutarate. Supplementation
of alanine and alpha-ketoglutarate together produced a synergistic rescue182.
In particular, glutamine’s role in nucleotide biosynthesis, in which it is an obligate
nitrogen donor for both purine and pyrimidine synthesis, has been implicated in ongoing
support of proliferation. K-ras transformed fibroblasts cultured in glutamine-depleted
media exhibit decreased cellular proliferation and abortive S phase entrance, which
could be restored by addition of the four deoxyribonucleotides183. This result suggests
that DNA synthesis may be particularly constrained by availability of glutamine and thus
may inhibit proliferation when glutamine availability is limited.

Interestingly, the

expression of glutaminase (Gls1), an enzyme that catalyzes the conversion of glutamine
to glutamate, is regulated during the cell cycle, with high expression during S phase that
decreases as cells progress into G2/M. Glutamine consumption correlates with Gls1
expression, and following entry into S Phase, glutamine-deprived cells fail to progress to
G2/M phases184. Thus, glutamine’s function during DNA synthesis contributes to its role
in supporting cell proliferation.
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Role of Glutamine in Cell Signaling
In addition to its direct metabolic roles, glutamine has also been implicated in modulating
cell signaling pathways to promote growth. Slc1a5 (ASCT2), a high-affinity L-glutamine
transporter, is upregulated in multiple types of cancer and has been implicated in
mediating net glutamine uptake in cancer cells185.

Entry of glutamine into the cell

through Slc1a5 plays a role in regulating mammalian target of rapamycin complex 1
(mTORC1) activity185-187. The mechanism for this was recently elucidated; glutamine
uptake and subsequent rapid efflux through Slc7a5 (LAT1) in exchange for essential
amino acids (EAA) allows EAA-dependent mTORC1 activation186.
In addition to its role in promoting mTORC1 activation to support cell growth,
some evidence suggests a possible role for glutamine in regulation of other signaling
pathways. As a substrate for oxidative mitochondrial metabolism, glutamine may also
influence signaling through regulation of mitochondrial ROS production188. For example,
in IL-3-dependent hematopoietic progenitors, inhibition of glutamine metabolism with 6diazo-5-oxo-L-norleucine (DON) blocks the sustained IL-3-dependent phosphorylation of
Stat5175.

Stat5 phosphorylation in DON-treated cells could be rescued by alpha-

ketoglutarate, suggesting that mitochondrial metabolism of glutamine could modulate
Stat5 phosphorylation.

Antioxidant treatment inhibited glutamine-dependent Stat5

phosphorylation in this context, consistent with previous studies showing that Stat5
phosphorylation can be promoted under conditions in which reactive oxygen species
(ROS) levels are elevated189,

190

.

In the context of oncogenic Kras, glutamine

metabolism and mitochondrial ROS production was shown to contribute to cells’ capacity
to proliferate by promoting ERK signaling191. Through modulation of physiological ROS
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production from the mitochondria, glutamine metabolism may participate in modulating
multiple cell signaling pathways.

Glutamine in Regulation of Redox Homeostasis
In addition to glutamine metabolism contributing to mitochondrial ROS production
through its oxidation in the TCA cycle, much recent evidence indicates that glutamine
metabolism plays a key role in the maintenance of cellular redox homeostasis98, 174, 192,
193

. This is due in large part to the role of glutamine in synthesis of glutathione, an

endogenous antioxidant comprised of glutamate, cysteine, and glycine194,

195

.

As

described above, glutamate derives in large part from glutamine taken up by the cell.
Furthermore, glutamate can contribute to the uptake of cystine through the
countertransporter Slc7a11196.

In its antioxidant role, glutathione (GSH) donates

electrons, becoming oxidized (GSSG). In order to restore glutathione to its reduced
form, NADPH is required. Glutamine metabolism can also lead to increased production
of NADPH, through its metabolism through malic enzyme92.

Accordingly, glutamine

metabolism was shown to promote an increased GSH/GSSG ratio in p53+/+ cells
(discussed further below)192, 193.

4.3 Oncogenes Regulate Glutamine Metabolism
As outlined above, glutamine plays an important role in supporting cancer cell
proliferation. Perhaps not surprisingly, data has emerged in recent years demonstrating
that glutamine metabolism is directly regulated by oncogenes and tumor suppressors.
Increased glutaminase activity was reported to correlate with tumor growth rate as early
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as the 1960s

197, 198

, and Myc has recently emerged as a critical regulator of glutamine

metabolism and glutamine addiction in cancer cells97, 98, 172. A growing number of other
tumor suppressors and oncogenes have also been implicated in regulating glutamine
metabolism100, 192, 193, 199.

Myc: Master Regulator of Glutamine Metabolism
Myc, a proto-oncogene and major regulator of cell proliferation, stimulates expression of
multiple metabolic genes and is well known to promote glycolytic metabolism

200

. More

recently, it has become clear that Myc also stimulates glutamine uptake and metabolism
97, 98

. Oncogenic levels of Myc cause glutamine addiction, and cells undergo apoptosis

when deprived of glutamine97,

172

. Myc stimulates glutamine metabolism both directly

and indirectly. As a transcription factor, Myc directly binds the promoters and stimulates
expression of glutamine metabolism genes, such as the transporter Slc1a597. Myc also
promotes glutaminase activity indirectly by repressing expression of miR-23a/b, which
targets Gls198.
What functions of glutamine are critical for mediating cell survival in the context
of oncogenic Myc?

Viability in the absence of glutamine was rescued by

supplementation with TCA cycle substrates97,

98,

172

, indicating that glutamine’s

anaplerotic role is critical for supporting cell survival in Myc-transformed cells.
Furthermore, RNAi-mediated suppression of Gls1 also led to an increase in ROS levels
and cell death, associated with diminished glutathione levels98.

In Myc-driven cells,

carbon derived from glutamine was shown to be preferentially used for glutathione
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synthesis, in contrast to carbon originating from glycolysis174. These results suggest that
glutamine’s antioxidant roles are important for survival in Myc-driven cells.

Role of Rho GTPases in Glutamine Metabolism
Rho GTPases have also recently been reported to regulate glutamine metabolism

100

.

Cancer cells dependent on Rho GTPase signaling display higher glutaminase activity,
regulated in an NF-kB-dependent manner, and glutaminase activity is required for the
transforming capability of at least three different Rho GTPases (Cdc42, Rac1 and
RhoC)100. A small molecule inhibitor that impaired the growth and invasive potential of
RhoGTPase-transformed fibroblasts and human cancer cells was found to target
glutaminase, suggesting that glutamine metabolism could potentially be targeted in the
context of Rho GTPase-driven tumorigenesis100.

Ras Transformation and Glutamine
While Kras-mediated transformation has been reported to stimulate greater dependence
on metabolism of glucose than glutamine, Kras-transformed cells nevertheless exhibit
sensitivity to reduced glutamine conditions and fail to proliferate at levels of glutamine
that can support growth of non-transformed cells183. Metabolic flux analysis provided
evidence for both increased utilization of glutamine carbon to support the TCA cycle and
contribution of glutamine’s nitrogen to biosynthetic processes in Kras transformed
cells201. Interestingly, mitochondrial metabolism was shown to promote proliferation in
the context of oncogenic Kras through generation of ROS intermediates by the Qo site of
mitochondrial complex III.

Glutamine-dependent ROS production promoted growth
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through regulation of ERK signaling, and disruption of mitochondrial respiration led to
decreased tumor formation in an in vivo mouse model of Kras-driven lung cancer199.
Depending on ROS levels and cellular state, ROS can either have proproliferative effects in stimulating signal transduction or can cause damage and death 188,
202

.

The role of glutamine in the regulation of ROS levels appears to be different

depending on context98, 174, 192, 193, 199. Moreover, the complementing effects of glutamine
in increasing oxidative mitochondrial metabolism and hence ROS production versus
promotion of antioxidant defenses may balance differently and regulate different cell
fates depending on cell type and/or oncogenic context.

p53: A tumor suppressor’s role in glutamine metabolism
p53 is the first tumor suppressor to be shown to regulate glutamine metabolism. p53
induces the expression of Gls2, leading to increased mitochondrial oxidative
phosphorylation and energy production from glutaminolysis.

Gls2 induction also

increased glutathione levels and reduced ROS levels, conveying protection against
oxidative stress-induced apoptosis. Induction of Gls2 was suggested to contribute to
p53-dependent tumor suppression, since Gls2 expression was reduced in liver tumors
and overexpression of Gls2 reduced tumor cell growth and colony formation 192, 193.
It is noteworthy that Gls1 and Gls2 seem to have contrasting effects in
tumorigenesis. Myc induces the expression of Gls1, while p53 induces the expression of
Gls2.

Gls1 downregulation inhibits oncogenic transformation and cancer cell

proliferation100, 153, 154, 174 while overexpression of Gls2 is tumor suppressive192, 193. The
two isoenzymes of glutaminase are known to have different structural and kinetic
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properties, are subject to different regulation mechanisms, and exhibit different tissuespecific expression203.

Notably, both enzymes have been implicated in regulating

glutathione production and redox homeostasis, which is important for mediating cell
survival in Myc-driven cells, as well as for protecting against p53-dependent apoptosis98,
192, 193

. Hence, cellular context may be important for determining whether these enzymes

act to promote or suppress tumorigenesis. It is also possible that alternate activities of
these enzymes could also play a role in their divergent effects; for example, Gls2 was
reported to interact with other proteins and to alter gene expression patterns in glioma
cells204,

205

. Further investigation is needed to understand the mechanisms underlying

the different roles of Gls1 and Gls2 in tumorigenesis.

4.4 Mutations in Metabolic Enzymes and Glutamine Metabolism
As described above, a growing number of mutations in cancer have been reported to
impact glutamine metabolism. Metabolic enzymes are also mutated in some cancers,
including mutations in succinate dehydrogenase (SDHA, SDHB, SDHC, SDHAF2),
fumarate hydratase (FH), and isocitrate dehydrogenase (IDH1/2). While the metabolic
profiles of tumors bearing mutations in metabolic enzymes are unique based on the
mutation, glutamine metabolism is also impacted in each of these circumstances.

IDH Mutations and Glutamine Metabolism
Mutations within IDH1 and IDH2 have been reported in low-grade gliomas, acute
myeloid leukemias, and a number of other malignancies206-212. While wild type IDH1 and
2 interconvert alpha-ketoglutarate and isocitrate, these mutations result in a neomorphic
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activity that catalyzes the conversion of alpha-ketoglutarate into 2-hydroxyglutarate (2HG), a molecule described as an oncometabolite for its ability to independently induce
metabolic changes similar to those associated with IDH mutations213,

214

.

2-HG is

thought to act by inhibiting certain alpha-ketoglutarate-dependent enzymes, including
histone demethylases and Tet proteins, which can convert 5-methylcytosine into 5hydroymethylcytosine and may participate in DNA demethylation215-219.
Glutamine is the main source of alpha-ketoglutarate used by mutant IDH to
produce 2-HG.

Hence, the possibility that targeting glutamine metabolism could

influence the activity of the mutant IDH enzyme was investigated154.

Glutaminase

inhibition indeed led to slowed proliferation of glioblastoma cells expressing mutant as
compared to wild-type IDH1, and the growth suppression was rescued by alphaketoglutarate. However, despite reducing glutamate and alpha-ketoglutarate levels and
suppressing growth in IDH1 mutant cells, 2-HG levels remained unaltered upon Gls
inhibition154.

The mechanism through which Gls inhibition selectively acts on cells

expressing mutant IDH is not clear. Of note, metabolic profiling of IDH mutant cell lines
indicates that broad metabolic changes occur in the presence of mutant IDH, including
altered levels of TCA intermediates220; it is plausible that such alterations could play a
role in sensitizing IDH mutant cells to suppression of glutaminase.

SDH and FH Mutations and Glutamine Metabolism
Mutations in the genes encoding the TCA cycle enzymes succinate dehydrogenase
(SDH) and fumarate hydratase (FH) cause familial and sporadic paraganglioma and
phaeochromocytoma (SDH mutations) or hereditary leiomyomatosis and renal cell
carcinoma (FH mutations)221, 222. These mutations render the enzymes inactive, leading
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to the accumulation of succinate and fumarate in the mitochondria. High levels of these
metabolites can inhibit members of the prolyl hydroxylase family (PHDs), which are
alpha-ketoglutarate dependent223, 224. This prevents the degradation of hypoxia inducible
factor-1 (HIF-1α) and leads to a pseudohypoxic response and enhanced glycolysis. The
pseudohypoxic response mediates the increased tumorigenicity induced by the loss of
these mitochondrial tumor suppressors223-225.
Two recent studies have investigated the metabolic changes that result from FH
mutations that allow these cells to survive and proliferate. Metabolic modeling to assess
pathways that allow cells to survive in the absence of FH, identified the heme
biosynthesis pathway as synthetically lethal with FH mutations226. Glutamine carbon is
diverted into heme biosynthesis from succinyl-CoA. This mechanism simultaneously
allows generation of NADH by alpha-ketoglutarate dehydrogenase in order to fuel some
ATP production by oxidative phosphorylation, as well as providing an outlet for glutamine
carbon, from the impasse in the TCA cycle created by FH deficiency226. To generate
acetyl-CoA to synthesize lipids, FH-deficient cells were shown to rely on reductive
carboxylation of glutamine-derived alpha-ketoglutarate to provide citrate181.

4.5 Coordinating Glutamine and Glucose Utilization in Cancer
As we have discussed, glutamine metabolism supports proliferation at several levels and
its metabolism is directly regulated in many cancers. Together, glucose and glutamine
serve as the primary nutrients to fuel cancer cell proliferation. Recent data indicate that
the metabolism of these two nutrients is linked and that proliferating cells actively
coordinate their metabolism (Figure 2). In cancer cells, oncogenic Myc puts into place
gene expression programs to simultaneously increase the uptake and metabolism of
79

both glucose and glutamine, as has been discussed in recent reviews200, 227, 228. Cells
presumably must also be able to detect and adapt to changing nutrient availability. Two
distinct mechanisms, described in section 5.1, have recently been reported through
which glucose or glutamine availability is sensed and used to regulate the metabolism of
the other nutrient. On the other hand, recent data, discussed in section 5.2, indicates
that some cancer cells also have the capacity to switch carbon source or compensate for
reduced availability or metabolism of one nutrient by utilizing more of the other.

Metabolism of glucose and glutamine is coordinated
Recent data suggest that cells actively employ mechanisms to regulate metabolism of
glucose or glutamine, dependent on the availability of the other (Figure 2). Glucose
availability was recently shown in an IL-3-dependent hematopoietic cell line to modulate
cellular uptake of glutamine through the hexosamine biosynthetic pathway175, a branch
of glucose metabolism that generates UDP-N-acetyl-D-glucosamine (UDP-GlcNAc), a
donor substrate for glycosylation reactions229, 230. Glucose deprivation inhibited growthfactor-stimulated glutamine uptake, as a result of suppression of IL-3R surface
expression and downstream signaling. IL-3R is N-glycosylated and supplementing cells
with the GlcNAc, a hexosamine pathway metabolite, at least partially rescued IL-3R
surface expression and IL-3-dependent glutamine uptake. Hence, glucose flux into the
hexosamine biosynthetic pathway to support surface receptor glycosylation may serve
as a metabolic checkpoint, though which cells can regulate growth-factor-dependent
uptake of glutamine, in a glucose-dependent manner175.
Reciprocally, a mechanism has been described through which glutamine
availability can modulate glucose uptake, through the transcription factor MondoA.
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MondoA is a member of the basic helix-loop-heliz zipper (bHLHZip) transcription factor
family. Similar to Myc, MondoA interacts with Mlx, a Max-like bHLHZip protein, and
binds to E-box sites on target genes227. The MondoA:Mlx complex is a glucose sensor
present in the cytoplasm231.

Upon glucose uptake, the MondoA complex detects

elevations in glucose-6-phosphate levels and transits into the nucleus232.

There, it

stimulates expression of thioredoxin interacting protein (TXNIP), which constrains
glucose uptake232.

A recent study showed that glutamine availability inhibited

transcriptional activation of TXNIP expression by recruiting a histone deacetylasedependent co-repressor to the N-terminus of MondoA233. Reduced TXNIP expression
led to enhanced glucose uptake, as well as cell growth and proliferation.
Supplementation of cells with alpha-ketoglutarate could also promote transcriptional
repression of TXNIP and the induction of glucose uptake, suggesting that glutaminedependent anaplerosis modulates glucose uptake and cell growth through regulation of
MondoA transcriptional activity233.

Carbon source flexibility in cancer cells
Glucose and glutamine metabolism are regulated in a coordinated manner, and nutrient
addiction can cause cancer cells to die in the absence of either glucose or glutamine.
Cancer cells are notoriously resourceful, however, and two recent studies suggest that
some cancer cells may be able to switch carbon sources. Using SF188 glioblastoma
cells, which overexpress Myc, the effects of impairments in glucose availability on
glutamine uptake and metabolism were assessed93. Glucose deprivation caused a large
increase in the activity of glutamate dehydrogenase (GDH), and GDH was shown to be
required for cells to survive impairments in glycolysis93. Reciprocally, impairment of
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glutamine metabolism led cells to adapt to become fully reliant on glucose for
mitochondrial metabolism234.

Silencing of glutaminase suppressed growth, but cells

were able to partially compensate by utilizing pyruvate carboxylase (PC) to allow use of
glucose-derived carbon for anaplerosis234.

Thus, glutamine and glucose metabolic

pathways might be able to compensate for one another in some circumstances, a
possibility that should be considered when developing cancer therapeutics targeting
metabolism.

4.6 Glutamine Metabolism: Therapeutic and Imaging Implications
Therapeutic Targeting of Glutamine Metabolism
With the recognition that metabolic reprogramming is a key feature of transformed cells
has come significant interest in targeting metabolism, including glutamine metabolism,
as a cancer therapy. With glutamine participating in several key processes necessary
for proliferation, as described in this article, there may be opportunities to interfere with
glutamine metabolism at multiple points. Gls inhibition has shown promise in several
models100, 101, 153, 154, 174, 235. Given the adaptability of cancer cells, inhibition of glutamine
metabolism may potentially work best when combined with other therapies. Specific
strategies for targeting glutamine metabolism in cancer cells have been recently
reviewed in detail, to which the reader is referred for more information92, 99, 236. Targeting
glutamine metabolism is an area of intense interest with much potential for future
investigation and therapeutic benefit.

82

Glutamine Imaging: New Diagnostic Potential
Interest in imaging glutamine metabolism is also rising, in recognition of its potential to
elucidate biologic characteristics of tumors exhibiting increased glutamine metabolism
and to assess response to glutamine-targeted therapy237.

Novel glutamine-based

imaging techniques have emerged over the last few years, including positron emission
tomography (PET) imaging and hyperpolarized magnetic resonance (MR).
Fluorinated glutamines have been synthesized for PET imaging, analogous to
the commonly used fluorodeoxyglucose-(FDG)-PET used for imaging tumors that
consume high levels of glucose. In particular,

18

F-(2S,4R)4-fluoroglutamine was shown

to be taken up both by glutamine-dependent cancer cell lines and by tumors in mice,
indicating the promise of this technology for imaging glutaminolytic tumors238, 239. Very
recently, another glutamine PET tracer, l-[5-11C]-glutamine, was described and has
shown promise for the imaging of glutaminolytic cells and tumors, both in vitro and in
vivo240.
Magnetic resonance imaging has long been used as a technique allowing direct
assessment of glutaminolytic intermediates.

1

H magnetic resonance spectroscopy

(MRS) allows the quantification of both glutamine and glutamate and can be used to
measure the steady-state concentrations of both of these metabolites in vitro and in
vivo169,

237, 241

. However, metabolism is a dynamic process and increased information

can be gained from examining metabolic fluxes. Probing metabolic fluxes has been
typically achieved by administering isotopically-labeled compounds (such as

13

C-labeled

metabolites) to cells or animals and following the incorporation of the labeled nuclei (e.g.
carbon) into downstream metabolites91, 242, 243. Yet, the biggest challenge with
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13

C MRS

has long been the low signal-to-noise ratio (SNR) due to the low gyromagnetic ratio of
the NMR-active carbon. Advances in MR imaging recently led to the introduction of a
novel method, hyperpolarized MR, for real-time monitoring of single enzyme-catalyzed
reactions of glutamine and glutamate metabolism. In hyperpolarized MR, a molecule is
labeled with an NMR-active nucleus (typically

13

C) and that molecule is hyperpolarized

using dynamic nuclear polarization (DNP). By dramatically increasing the fraction of
targeted nuclei that are polarized (by as much of a factor of 105), DNP allows a large
increase in the SNR for detection of the labeled metabolite compared to

13

C MR

conducted at thermal equilibrium. This allows the user to observe the carbon transfer
from substrate to product, as well as to compute the in vivo reaction rate of the
conversion being observed.

In the case of glutamine metabolism, this includes the

ability to monitor and quantify the progressive conversion of glutamine into glutamate
and glutamate into alpha-ketoglutarate. To date, successful hyperpolarization has been
reported for [5-13C]-glutamine, [1-13C]-glutamate, and [5-13C-4-2H2]-glutamine

244-246

.

While these agents have been successfully used in cells, their implementation in animal
models remains limited.

The polarization tends to decay relatively rapidly following

injection into living tissues minimizing the time frame during which the signal can be
detected. For instance, the spin-lattice relaxation (T1) of the labeled carbon in [5-13C]glutamine is on the order of 16 seconds245.

Strategies allowing improvements in

polarization levels and T1 prolongation of these agents might pave the way for wider in
vivo implementation.
Overall, these techniques show significant promise for the monitoring of
glutamine metabolism in vivo allowing improved diagnosis and monitoring of glutaminedependent tumors.
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4.7 Conclusion
Glutamine is one of the most versatile nutrients, contributing to many aspects of
metabolism in cancer and proliferating cells. It is required in large quantities to support
mitochondrial metabolism during proliferation, and its roles as a nitrogen donor and a
regulator of cellular redox status and signal transduction also contribute to proper cell
function, growth, and proliferation.
The uptake and metabolism of the other major carbon source supporting
proliferation, glucose, has been a major research focus in several fields for years, and
new details continue to emerge. Glucose uptake is highly complex and is regulated both
through transcriptional control of the expression of glycolytic enzymes and signalingdependent control of the trafficking of the glucose transporters themselves.

By

comparison, the regulation of glutamine metabolism is relatively poorly understood,
though intense research into this topic is rapidly increasing our understanding of the role
of glutamine in cancer. It is likely that additional complexities and levels of regulation will
continue to emerge with further investigation.

Better understanding of the signal

transduction pathways that regulate glutamine metabolism, both in response to normal
growth factor cues and oncogene activation, will be important. Understanding how cells
adapt to inhibition of metabolic pathways will also be critical as more therapeutics
targeting cancer cell metabolism are developed. Future investigation should also focus
on in vivo study of glutamine metabolism, particularly as better imaging technologies
emerge, with the ultimate goal of identifying strategies to most effectively target
glutamine metabolism in cancer, likely in combination with other therapies.
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4.8 Figure Legends
Figure 1. Glutamine metabolism in cancer cells.

Glutamine contributes to

bioenergetics and biosynthesis through reactions that use its α-nitrogen (green), γnitrogen (yellow) or carbon skeleton (pink).

The γ-nitrogen from glutamine’s amide

group is a required nitrogen source for synthesis of nucleotides, hexosamines, and
asparagine.

During nucleotide synthesis, the alpha nitrogen is contributed in three

independent enzymatic steps in purine synthesis and two reactions in pyrimidine
synthesis. The alpha nitrogen can also be removed by glutaminase, which generates
glutamate and ammonia. Ammonia has been previously shown to play a role in inducing
autophagy. Glutamate carries most of glutamine’s α-nitrogen and is a major nitrogen
source for nonessential amino acid production in cells. Alanine aminotransferase (also
known as glutamate: pyruvate transaminase; Gpt) and aspartate aminotransferase (also
known as glutamate: oxaloacetate transaminase; Got) catalyze the transfer of
glutamate’s amino group directly into pyruvate and oxaloacetate to produce alanine and
aspartate, respectively. Synthesis of other non-essential amino acids, including serine
and the amino acids synthesized from serine, glycine and cysteine, requires the
contribution of the amino group from glutamate.
synthesis of arginine and proline.

Glutamate is also a precursor for

In addition to its role in amino acid synthesis,

glutamate is an important component of the synthesis of glutathione, an endogenous
antioxidant that protects cells against various forms of oxidative stress. The final major
fate of glutamine, following its conversion to glutamate and then glutamate’s conversion
to alpha-ketoglutarate, is the oxidation of its carbon backbone in the mitochondria
leading to energy production. Glutaminolysis contributes to production of mitochondrial
NADH, which is used to support ATP production by oxidative phosphorylation.
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Glutamine metabolism also contributes to production of NADPH and lipid and amino acid
biosynthesis. The TCA cycle metabolite citrate can also exit the mitochondria to be used
for generation of cytoplasmic acetyl-CoA, a precursor for fatty acid biosynthesis.
Similarly, malate produced in the TCA cycle can exit the mitochondria and contribute to
pyruvate and lactate production. gln: glutamine; glu: glutamate; gls: glutaminase; GSH:
glutathione; OAA: oxaloacetate; Asp: aspartate; Pyr: pyruvate; Ala: alanine; Gpt:
glutamate: pyruvate transaminase ; Got: glutamate: oxaloacetate transaminase; α-KG:
α-ketoglutarate; glc: glucose.

Figure 2. Coordination of glutamine and glucose utilization during proliferation.
Glucose and glutamine metabolism are linked and actively coordinated in cancer cells.
Myc simultaneously increases the uptake and metabolism of both glucose and glutamine
by regulating key transporters and enzymes involved in both pathways (shown in blue).
Those targets highlighted in blue are transcriptionally activated by Myc, while those
boxed in blue are regulated by Myc through other mechanisms. PKM2 expression is
promoted by Myc through regulation of splicing factors and Gls1 is a target of miR23a/b,
which is transcriptionally repressed by Myc. Two other mechanisms have been recently
described that can contribute to cellular adaptation to nutrient availability.

Glucose

availability can control cellular uptake of glutamine through utilization of glucose in the
hexosamine biosynthetic pathway (pathway shown in green). Glucose deprivation leads
to a suppression of growth-factor-stimulated glutamine uptake, as a result of
suppression of growth factor surface expression and downstream signaling in the
absence of glucose. On the other hand, glutamine availability can be sensed by the cell
to control uptake of glucose through the transcription factor MondoA (pathway shown in
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pink).

The MondoA complex is a glucose sensor present in the cytoplasm.

Upon

increase in glucose levels, MondoA detects elevation in glucose-6-phosphate levels and
is translocated into the nucleus. There, it interacts with a MondoA transcriptional target,
TXNIP, that induces a potent feedback circuit that restricts glucose uptake and cell
growth. Glutamine availability inhibits activation of TXNIP and induces an increase in
glucose uptake. Glut1: glucose transporter 1; HK2: Hexokinase 2; G6P: glucose-6phosphate; F6P: fructose-6-phosophate; F-1,6-BP: fructose-1,6-biphosphate; PEP:
phosphoenolpyruvate; PFK: phosphofructokinase; PKM2: pyruvate kinase isoform M2;
Ldha: lactate dehydrogenase A; GF: growth factor; GlcNAc: N-acetyl-D-glucosamine;
gls: glutaminase; Slc1a5 (ASCT2): a high-affinity L-glutamine transporter.
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CHAPTER 5

Glutamine Addiction: A Targetable Hallmark of Breast Cancer Recurrence

ABSTRACT
Increased glutaminolysis has been increasingly recognized as a key feature of
tumorigenesis.

To date, no association has been established between glutamine

metabolism and breast cancer progression.

In this study, we investigate the

glutaminolytic differences between primary and recurrent mammary tumors and assess
their role as a potential therapeutic target.

We use an MMTV-rtTa;TetO-HER2/neu

doxycycline-inducible bitransgenic mouse model which accurately reproduces key
features of the natural history of human breast cancer progression: primary tumor
development, tumor dormancy and recurrence. We find that recurrent tumors exhibit
higher glutamine uptake and glutamate production, when compared to primary tumors.
13

C-labeling experiments suggest increased glutaminolytic activity and increased

reductive carboxylation in tumor recurrence.

The observed increase in glutamine

metabolism also seems to contribute to the tumorigenicity of recurrent mammary tumor
cells. Recurrent, but not primary tumor cells are glutamine-addicted. The observed
changes in the glutaminolytic profile are accompanied by increased expression of the
glutamine transporter, Slc1a5, as well as increased expression of glutaminase (Gls1) in
recurrent tumors. Both Slc1a5 and Gls1 expression are required for recurrent, but not
primary tumor growth in vivo.

Recurrent tumors also exhibit increased endogenous

expression of the Myc oncogene. Myc was found to be required for Slc1a5 and Gls1
expression as well as increased glutamine uptake and glutamate production in recurrent
tumor cells. Human association analysis reveals a statistically significant association
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between SLC1A5, but not GLS1 expression and increased recurrence risk in 11 human
breast cancer datasets.

Combined, our results suggest that recurrent HER2/neu

mammary tumors are glutamine-addicted. Targeting glutamine metabolism might be a
promising therapeutic strategy for the treatment of breast cancer recurrence.

5.1 Introduction
Breast cancer is the leading cause of cancer-related death and the most commonly
diagnosed malignancy among women worldwide247. While advances in detection and
therapy have led to improvements in the overall survival of women diagnosed with
primary breast cancer, a substantial fraction of breast cancer survivors will ultimately
relapse with recurrent breast cancer. Indeed, since recurrent breast cancer can be
treated, but not cured, tumor recurrence remains the principal cause of mortality in this
disease66.

Nevertheless, despite its clinical importance, the molecular mechanisms

underlying tumor recurrence remain poorly understood.
Dysregulated metabolism has long been known as a hallmark of human cancer,
particularly aerobic glycolysis or the Warburg effect

74, 75

.

More recently, increased

utilization of glutamine has emerged as an important component of the altered metabolic
profile of cancer cells90-92, 99. Since the 1950s, glutamine has been recognized as key
nutrient for proliferating cancer cells88, 89. For example, glutamine is an obligate nitrogen
donor for nucleotide and amino acid synthesis, contributes to bioenergetics, supports
cell defenses against oxidative stress, and complements glucose metabolism73, 75, 90-93.
Glutamine also influences a number of signaling pathways that contribute to tumor
growth, most notably through maintaining activity of the mTOR kinase186.
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To date,

however, no association between changes in glutamine metabolism and cancer
progression has been established.
In this study, we have investigated the changes in glutamine metabolism within
the context of a genetically engineered mouse model for mammary tumorigenesis
induced by the oncogene HER2/neu that accurately recapitulates key features of the
natural history of human breast cancer progression, including minimal residual disease,
tumor dormancy and recurrence63, 66. A member of the epidermal growth factor receptor
family of tyrosine kinases, HER2/neu is amplified and overexpressed in ~20% of primary
human breast cancers and its overexpression is associated with aggressive tumor
behavior, high rates of recurrence and poor prognosis51, 55, 57, 123. Supporting the critical
role of HER2/neu signaling in human breast cancer, therapies such as trastuzumab and
lapatinib that target this molecule are effective in treating both early stage and advanced
breast cancers248-251. In addition, HER2/neu activation results in downstream activation
of the PI3K-AKT signaling pathway, an important regulator of cellular metabolism67, 68, 71.
Our in vivo and in vitro studies reveal increased glutaminolysis in mammary
tumor recurrence.

13

C labeling experiments in vivo also reveal higher rates of reductive

carboxylation in recurrent tumors. These metabolic observations are accompanied by
Myc-driven increased expression levels of both Slc1a5 and Gls1. Slc1a5 is a glutamine
transporter and Gls1 expresses the glutaminase enzyme, the enzyme that catalyzes the
conversion of glutamine to glutamate at the beginning of the glutaminolytic pathway.
Slc1a5 and Gls1 are found to be required for recurrent, but not primary tumor growth.
SLC1A5 expression levels are also positively correlated with reduced 10-year
recurrence-free risk in human breast cancer patients.
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5.2 Methods
Animals, cell culture and recurrence assays
The MMTV-rtTa;TetO-HER2/neu (MTB/TAN) doxycycline-inducible bitransgenic mouse
model has previously been described63,

132

.

All mice were housed and treated in

accordance with protocols approved by the Institutional Animal Care and Use Committee
at the University of Pennsylvania. MTB/TAN mice were bred, housed, induced with 2
mg/ml doxycycline, monitored for tumor development and recurrence, and sacrificed as
previously described66.
Tumor cells from primary mammary tumors arising in MTB/TAN mice maintained
on doxycycline were isolated and cultured in the presence of doxycycline as described66,
as were tumor cells from recurrent mammary tumors arising in MTB/TAN mice bearing
tumors that had fully regressed following doxycycline withdrawal and HER2/neu
downregulation, and had then subsequently recurred spontaneously in the absence of
doxycycline or HER2/neu transgene expression. Primary and recurrent tumor cells were
transduced with retroviruses expressing either shRNAs targeting genes of interest and
puromycin was used to select stably-transduced polyclonal cells.

Glutamine addiction assay
To assess the glutamine addiction phenotype of tumor cells, 300,000 primary or
recurrent tumor cells were plated in triplicate in complete tumor media and incubated for
24 hr. Culture media was then removed and replaced with fresh tumor media, fresh
tumor media lacking glutamine (Invitrogen), or fresh tumor media lacking glutamine but
supplemented with 7 mM alpha-ketoglutarate (Sigma-Aldrich). Following incubation for
96 hr, cell viability was quantified by trypan blue exclusion using a Vi-CELL Cell Viability
Analyzer (Beckman Coulter).
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Slc1a5, Gls1 and Myc knockdown
For in vivo experiments, Slc1a5 and Gls1 expression were knocked down using
retroviruses expressing commercially available shRNA constructs targeting these genes
(Applied Biosystems). Five shRNA-expressing constructs were tested for each gene.
The two shRNA's yielding the greatest knockdown for each gene were used for
subsequent experiments. An shRNA targeting renilla luciferase was used as a negative
control. Slc1a5 and Gls1 expression knockdown was confirmed by qRT-PCR.
For in vitro experiments, knockdown of c-Myc expression in recurrent tumor cells
was performed using commercially available siRNAs (Ambion). Two different siRNAs
exhibiting c-Myc knockdown were employed.
negative control (Ambion).

A scrambled siRNA was used as a

siRNA transduction was performed according to

manufacturer's instructions and cells were incubated with siRNAs for 48 hr.

Myc

knockdown was confirmed by qRT-PCR.

Orthotopic tumor assays
Orthotopic tumor growth assays were performed in athymic nude mice (nu/nu)
purchased from Taconic (Germantown, NY).

Cells were injected into the inguinal

mammary fat pads of 10-12 nu/nu mice for each experimental group. Experiments were
performed in parallel with five experimental arms, including one experimental arm for
each of the Slc1a5 or Gls1 shRNA contructs, as well as a control arm for the renilla
luciferase shRNA. Each of the number four mammary fat pads of each mouse was
injected with 500,000 tumor cells.
For primary orthotopic tumor growth assays, HER2/neu expression in
transplanted cells was induced by administering 2 mg/mL doxycycline in drinking water.
Mice injected with recurrent tumor cells were maintained on water without doxycycline.
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Tumor size was measured 2-3 times per week and tumor volume was determined by
caliper measurements for each injected site using the following formula: Tumor volume =
(smallest diameter2 * largest diameter)/2. Tumors were followed until they reached a
size of approximately 15x15 mm. Mean tumor growth rate (MGR) was calculated for
each tumor as described252.

RNA Isolation and qRT-PCR
RNA extraction was performed on snap-frozen primary and recurrent mammary tumor
tissue and cell samples as described253. Samples were homogenized and RNA isolation
was carried out using the RNeasy RNA isolation kit (Qiagen) according to
manufacturer’s instructions. Reverse transcription was performed from 2 µg of RNA
using the cDNA High Capacity Reverse Transcriptase Kit (Applied Biosystems)
according to the manufacturer's instructions. qRT-PCR analysis for Slc1a5 and Gls1
mRNA levels was performed on the Applied Biosystems 7900 HT Fast Real-Time PCR
system using 6-carboxyfluorescein–labeled Taqman probes (Applied Biosystems).
Expression levels of each gene were normalized to TBP.

Western blotting
Mammary tumors and cultured cell were homogenized in T-PER protein lysis buffer
(Thermo Scientific). Primary antibodies were obtained from Abcam (anti-Slc1a5 and
anti-Gls1), or Santa Cruz (anti-c-Myc). Horse radish peroxidase-conjugated secondary
antibodies (Jackson Laboratories) were used to probe membranes incubated with the
anti-c-Myc antibody. The enhanced chemiluminescent system (ECL; Amersham) was
used to detect the bound secondary antibodies. Anti-Slc1a5 and Gls primary antibodies
were detected using Alexa-Fluor-conjugated secondary antibodies (Molecular Probes).
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The Odyssey V3.0 system (Li-COR Biosciences) was used to visualize and quantify
proteins of interest.

Glutamine and glutamate level determination in culture
Ex vivo tumor culture experiments were performed following a procedure similar to that
described by Banerjee et al.254. Briefly, a total of 4 primary and 4 recurrent mammary
tumors that had reached a size of 12x12 mm were dissected using sterile technique,
diced to yield fragments approximately 2x2 mm in diameter, weighed and equally
distributed between 3 wells containing tumor culture media. Samples were maintained
in a tissue culture incubator in 5% CO2 at 37oC for 96 hr, after which tumor tissue was
collected, re-weighed, and the culture media harvested for determination of metabolite
levels. Concentrations of glutamine and glutamate in culture media were determined
using a 7100 Multiparameter Bioanalytical System (YSI life Sciences). The amount of
each metabolite consumed or produced by tumor tissue samples was computed as the
difference between the level of that metabolite in conditioned media from cultured tumor
fragments compared to its level in control media incubated without tissue, and then
normalized to the average weight of cultured tumor in that well. Positive values denote
metabolite production, whereas negative values denote metabolite consumption.
Samples from each tested condition were run in triplicate and statistical significance was
determined using a Student's t-test.
A similar procedure for metabolite level determination was used for cell culture
studies. 300,000 cells were plated and incubated in cell culture media for 96 hours.
Glutamine consumption and glutamate production levels were determined using a 7100
Multiparameter Bioanalytical System (YSI life Sciences). Measured metabolite levels
were normalized to the number of cultured cells in each well.
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PET imaging
A total of 6 mice, 3 bearing primary mammary tumors and 3 bearing recurrent tumors,
were each injected with 508±13 µCi of L-[5-11C]-Glutamine prepared as described255.
Dynamic PET imaging was performed on a small-animal Mosaic PET scanner (Philips,
Inc.).

For each mouse, 12 frames were acquired at 5-min intervals.

Tumor

segmentation and uptake quantification were performed at each frame for each mouse
using the AMIDE software256. Uptake values were normalized according to the injected
dose and the weight of each mouse and the area under each uptake curve (AUC) was
computed.

Differences in AUC values between primary and recurrent tumors were

assessed using a Student's t-test.

13

C-labeling experiments

A total of 8 mice, 4 bearing primary tumors and 4 bearing recurrent mammary tumors,
were infused through a tail vein catheter with an 8 mM solution of L-[3-13C]-glutamine
(Isotec) over a period of 45 minutes. At the end of the infusion period, tumors were
dissected and clamp-frozen in liquid nitrogen. Perchloric acid extraction was performed
as described128. NMR spectroscopy was performed at 9.4T on an Avance III 400 widebore spectrometer (Bruker). Carbon spectra were acquired overnight with a 5 mm BBO
probe under the following conditions: pulse width of 45 degrees, TR 1.4s, 24 kHz
spectral width, 64K data points and 35,000 – 40,000 scans. Spectral analysis was
performed using the NMR NUTS software (Acorn, Inc.). Statistical significance was
determined using a Student's t-test.
Measurement of

13

C isotopomers was performed on a Triple Quad 6410 mass

spectrometer combined with an LC 1290 Infinity mass selective detector (Agilent), as
described257. Briefly, samples were first purified by passage through either AG-1 or AG98

50 cation exchange columns (Biorad) and then converted into t-butyldimethylsilyl
derivatives. Isotopic enrichment of glutamine was monitored using ions at 431, 432,
433, 434, 435, 436 and 437 m/z for M0, M+1, M+2, M+3, M+4, M+5 and M+6,
13

C-glutamate was monitored using ions at 432,

respectively. Isotopic enrichment of

433, 434, 435, 436 and 437 m/z for M0, M+1, M+2, M+3, M+4 or M+5, respectively.
Isotopic enrichment of 13C-aspartate was monitored using ions at 418, 419, 420, 421 and
422 m/z for M0, M+1, M+2, M+3 and M+4, respectively. Isotopic enrichment of

13

C-

succinate was monitored using ions at 289, 290, 291, 293 and 294 m/z for M0, M+1,
M+2, M+3 and M+4, respectively. Isotopic enrichment of

13

C-lactate was monitored

using ions at 261, 262, 263 and 264 m/z for M0, M+1, M+2 and M+3, respectively.
Isotopic enrichment of

13

C-malate was monitored using ions at 419, 420, 421, 422 and

423 m/z for M0, M+1, M+2, M+3 and M+4, respectively. Isotopic enrichment of

13

C-

citrate was monitored using ions at 459, 460, 461, 462, 463, 464 and 465 m/z for M0,
M+1, M+2, M+3, M+4, M+5 and M+6, respectively.
13

C-enrichment is reported in molar percent enrichment (MPE), reflecting the mol

fraction (%) of analytes containing

13

C atoms in excess of natural abundance, where

MPE (M+i) = % AM+i/[AM + Σ AM+i], and AM and AM+i represent the peak area from MS ions
corrected for natural abundance and corresponding to the unlabeled (M0) and

13

C-

labeled (M+i) mass isotopomers, respectively.

Human breast cancer microarray data analysis
Meta-analysis of the association between relapse-free survival and the expression of
SLC1A5 and GLS was performed using microarray and clinical data from 11 human
breast cancer data sets. Data were obtained from NCBI GEO or authors' websites258-261.
Microarray data were converted to base 2 log scale if the original data were on a
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different scale. Affymetrix microarray data were normalized using Robust Multi-array
Average (RMA) when .CEL files were available.

For situations in which multiple

microarray features mapped to the same gene on a single platform, the feature with the
highest median absolute deviation (for two-color arrays), or the probe set with "_at" suffix
and highest median expression (for Affymetrix arrays) was chosen to represent the
target gene.
Within each data set, the effect size of the association between mRNA
expression for a given gene and 10-year relapse-free survival was estimated using two
different methods: 1) hazard ratio from Cox proportional hazards regression in which
gene expression was modeled as a continuous variable; and 2) the concordance index
(c-index). Each type of effect size estimate was combined across data sets by metaanalysis using the inverse-variance weighting method. For data sets in which relapsefree survival information was not available, but distant metastasis-free survival
information was available, metastasis-free survival was used for survival analysis.
Between-study homogeneity of survival association was tested using chi-squared
test on Cochran’s Q statistic, for which a p-value of less than 0.1 was interpreted as
evidence of significant heterogeneity. In the presence of significant heterogeneity, the
random-effect model was used for meta-analysis.

In the absence of significant

heterogeneity, the fixed-effect model was used. Cox proportional hazards regression,
concordance index analysis, and meta-analysis were performed using the “coxph”
function in the “survival” package, the “survConcordance” function in the “survival”
package and the “metagen” function in the “meta” packages in R 2.15.0. The precision
of the meta-analysis p-values was verified using Monte Carlo permutation tests by
randomly permuting sample labels and repeating the above meta-analyses 10,000
times.
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5.3 Results
Recurrent mammary tumors exhibit increased glutamine consumption and
glutamate production
To better define the molecular and cellular events that contribute to breast cancer
recurrence, we have developed a doxycycline-inducible transgenic mouse model that
displays key features of human breast cancer progression, including minimal residual
disease, tumor dormancy and recurrence.

In this model, the reverse tetracycline-

inducible transactivator (rtTA) is specifically expressed within the epithelial compartment
of the mammary gland under the control of the mouse mammary tumor virus (MMTV)
promoter132 in mice bearing the MMTV-rtTA transgene (MTB), and expression of the
HER2/neu oncogene is driven by the tet operator63 in mice bearing the TetO-HER2/neu
transgene (TAN).

Following the administration of doxycycline to MMTV-rtTA;TetO-

HER2/neu (MTB/TAN) bitransgenic mice in drinking water, doxycycline-bound rtTA in
mammary epithelial cells binds to the tet operator and induces expression of the
HER2/neu oncogene132.

Doxycycline induction of HER2/neu in bitransgenic animals

results in the development of epithelial hyperplasias, focal atypical hyperplasias and,
ultimately, invasive mammary adenocarcinomas in a manner that is highly penetrant,
mammary-specific, and absolutely dependent on transgene induction by doxycycline.
Importantly, the inducible nature of these transgenic models permits the
complete downregulation of the HER2/neu oncogenic stimulus following tumor
formation. Surprisingly, we have found that virtually all HER2/neu-induced mammary
tumors regress to a non-palpable state following oncogene downregulation, suggesting
that tumors become “addicted” to the oncogenic signaling pathways that led to their
formation63, 66. However, analogous to the phenomena of tumor recurrence in women
with breast cancer, many fully regressed tumors in MTB/TAN mice spontaneously recur
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over periods of up to a year, ultimately resulting in the death of the animal66. As such,
this model parallels the natural history of human breast cancer and enables mechanistic
approaches to elucidating the mechanisms that underlie tumor recurrence.
To begin to investigate whether changes in glutamine metabolism occur during
the process of mammary tumor recurrence in vivo, we used the L-[5-11C]-glutamine
tracer to perform dynamic positron emission tomography (PET) on MTB/TAN
bitransgenic mice bearing either primary or recurrent mammary tumors. Both primary
and recurrent mammary tumors exhibited L-[5-11C]-glutamine uptake higher than that of
non-tumor tissues, however L-[5-11C]-glutamine uptake in recurrent tumors appeared to
be higher than that of primary tumors (Fig. 1A). Quantification of normalized L-[5-11C]glutamine tumor uptake over time revealed higher uptake over time for recurrent tumors
compared to primary mammary tumors (AUCmean= 313.4±34.4 vs. 242.5 ±8.92; p=0.007)
(Fig. 1B). This suggested the possibility that glutaminolysis is up-regulated during the
process of mammary tumor recurrence in vivo.
To further explore this potential difference in glutamine metabolism, we
conducted tumor culture experiments in which explanted primary and recurrent
mammary tumors from MTB/TAN mice were dissected, minced and cultured for 96
hours.

Differences in glutamine uptake and glutamate production were determined.

Concentrations of glutamine and glutamate in culture media were determined using a
7100 Multiparameter Bioanalytical System and the amount of each metabolite consumed
or produced by each tumor sample was computed as the difference between the level of
that metabolite in conditioned media from cultured tumor fragments compared to its level
in control media incubated in the absence of tumor tissue. Results were normalized by
weight of cultured tumor tissue.
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In accordance with our in vivo PET studies using L-[5-11C]-glutamine, this
analysis revealed that recurrent mammary tumors exhibited a 3.4-fold higher level of
glutamine uptake compared to primary tumors (Fig. 1C; p=0.001). Consistent with this,
recurrent tumors also displayed a 1.7-fold increase in glutamate production compared to
primary tumors (Fig. 1D; p=0.004). Together with our findings using L-[5-11C]-glutamine
PET, these results suggest that recurrent mammary tumors in MTB/TAN mice exhibit
higher glutamine uptake and metabolism than primary mammary tumors in this same
model.

Recurrent tumors display higher glutaminolytic flux and increased reductive
carboxylation
To investigate the differences in glutaminolytic activity between primary and recurrent
mammary tumors, we next performed 13C-glutamine labeling experiments. Mice bearing
primary and recurrent tumors were infused with a solution containing L-[3-13C]glutamine.

Metabolism of the

13

C- labeled tracer was followed using magnetic

resonance spectroscopy (MRS) and mass spectrometry.
Using MRS, we found that primary and recurrent mammary tumors displayed
clear differences in the concentrations of 3-13C-glutamine (Gln-3) and3-13C-glutamate
(Glu-3) (Fig. 2A). Specifically, the integral ratio of labeled Glu-3 to labeled Gln-3 was
2.8-fold higher in recurrent tumors compared to primary tumors (Fig. 2B; p<0.001). This
suggests that recurrent tumors exhibit greater conversion of glutamine to glutamate than
primary tumors.
Assessment of metabolite isotopomers from this experiment using mass
spectrometry revealed higher mole percent excess (MPE) in recurrent tumors compared
to primary tumors for all tested intermediates of the glutaminolytic pathway downstream
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of glutamine (Fig. 2C). Specifically, glutamate, aspartate, succinate, malate, citrate and
lactate each exhibited higher

13

C-labeling amounts in recurrent tumors than in primary

tumors. Conversely, glutamine displayed lower labeling in recurrent tumors compared to
primary tumors, which would be consistent with higher consumption of the 13C-glutamine
label in recurrent tumors.
Interestingly, assessment of metabolite isotopomers from this experiment also
revealed higher overall labeling of citrate compared to succinate in both primary and
recurrent mammary tumors.

This suggests the possibility that active reductive

carboxylation may occur in each of these tumor types in vivo. This effect, however, was
more pronounced in recurrent tumors, as evidenced by higher MPE that were observed
for each if the metabolites considered. In aggregate, these results are compatible with a
model in which recurrent tumors exhibit increased glutaminolytic flux as well as reductive
carboxylation.

Recurrent, but not primary, tumor cells are glutamine-addicted
To begin to assess the functional significance of the increase in glutaminolysis that we
observed in recurrent mammary tumors, we next sought to determine the effect of
glutamine deprivation on the viability and growth of primary and recurrent mammary
tumor cells in vitro. Primary and recurrent mammary tumor cell lines derived from tumorbearing MTB/TAN mice were plated in control media containing glutamine, growth
factors and serum and then shifted to control media, to media lacking glutamine, or to
media lacking glutamine but supplemented with alpha-ketoglutarate.
When grown in control media containing glutamine, both primary and recurrent
tumor cells became fully confluent 96 hours post plating (Fig. 3A). In contrast, culturing
cells in glutamine-deprived media led to marked cell death in recurrent, but not primary,
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tumor cells.

This effect on recurrent tumor cells was rescued by supplementing

glutamine-deprived media with alpha-ketoglutarate.
Consistent with these observations, quantification of cell viability by trypan blue
exclusion revealed an 47% reduction in cell viability, when recurrent tumor cells were
cultured in media lacking glutamine, compared to recurrent tumor cells cultured in
control media containing glutamine (Fig. 3B; p=0.002). In contrast, no difference was
observed in the viability of primary tumors cells cultured in media containing or lacking
glutamine.

The loss of cell viability observed in recurrent tumor cells subjected to

glutamine deprivation was fully and efficiently rescued by the addition of alphaketoglutarate to the medium, indicating that the carbon backbone of glutamine is
required for recurrent tumor cell growth. Together, these observations are consistent
with a model in with recurrent, but not primary, mammary tumors cells are glutamineaddicted.

Slc1a5, Gls1 and glutamine metabolism are up-regulated in recurrent tumors in a
c-Myc-dependent manner
During glutaminolysis, glutamine can first be taken up by cancer cells through the
sodium-dependent neutral amino acid transporter, Slc1a5. Glutamine is subsequently
converted to glutamate by glutaminase, a reaction reported to be the rate-limiting step in
glutamine metabolism262,

263

.

In an effort to identify the underlying molecular

determinants for the increase in glutamine uptake observed in recurrent tumors, we first
measured expression of the glutamine transporter Slc1a5 by qRT-PCR and
immunoblotting, since we had observed increased uptake of glutamine by PET in vivo as
well as increased uptake of glutamine from culture medium in vitro. Slc1a5 is known to
be a key neutral amino acid transporter in cells and its inhibition reduces glutamine
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uptake in vitro186. This analysis revealed that recurrent mammary tumors exhibit 2.8-fold
higher steady-state levels of Slc1a5 than primary tumors, at the mRNA level (Fig. 4A;
p=0.002). Immunoblotting also revealed higher Slc1a5 at the protein level (Fig. 4B).
Analogous to our findings with Slc1a5, our observation that recurrent tumors
exhibit higher levels of glutamate production compared to primary tumors, led us to
investigate whether glutaminase (Gls1) is upregulated in recurrent tumors, since Gls1
expresses the glutaminase enzyme which is known to catalyze the conversion of
glutamine into gltuamate. We found that recurrent tumors express a 1.8-fold higher level
of Gls1 expression than primary tumors at the mRNA level (p=0.024) (Fig. 5A).
Immunoblotting also revealed higher Gls1 at the protein level (Fig. 5B).
In light of the upregulation of glutamine metabolism that we observed in recurrent
tumors, as well as the known regulatory role of the proto-oncogene c-Myc and glutamine
metabolism, we considered the possibility that c-Myc was responsible for the observed
upregulation of Slc1a5 and Gls1 in recurrent mammary tumors.

Myc has been

previously shown to regulate Slc1a5 level by binding to its promoter, as well as modulate
Gls1 levels through mir23a/b97,
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.

Consistent with this prediction, immunoblotting

revealed Myc upregulation in recurrent mammary tumors (Fig. 7A). Myc upregulation
was accompanied by increased expression of the downstream Myc targets Odc1,
Ccnb1, Mthfd2, Nap1l1, Col1a1, and Pmp22 (Fig. 7B).
Consistent with the supposition that c-Myc upregulation contributes to the
observed upregulation of Slc1a5 and Gls1 in recurrent tumors, downregulation of c-Myc
expression in recurrent tumor cell lines using siRNA approaches resulted in
downregulation of Slc1a5 and Gls1 (Fig. 7C). In addition, c-Myc downregulation by
either of two siRNAs also led to a decrease in glutamine consumption as well as a
decrease in glutamate production in recurrent tumor cells (Fig. 7D). Together, these
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findings suggest that c-Myc upregulation in recurrent mammary tumors is responsible for
the observed increases in Slc1a5 and Gls1 expression, as well as for increased
glutamine metabolism.

Slc1a5 is required for recurrent, but not primary, tumor growth
Our observations to this point suggested the possibility that the growth of recurrent, but
not primary mammary tumors is dependent upon the c-Myc-induced upregulation of
glutamine transport and metabolism. To begin to test this hypothesis, we asked whether
upregulation of Slc1a5 contributed to the higher levels of glutamine uptake observed in
recurrent tumors, as well as recurrent tumor growth. To this end, we knocked down
expression of Slc1a5 in primary and recurrent tumor cells using retrovirally transduced
shRNAs (Fig. 4C, E).

As anticipated, Slc1a5 downregulation was accompanied by

decreased glutamine uptake in both primary and recurrent tumor cells.
Primary and recurrent tumor cells with and without Slc1a5 knockdown were then
implanted orthotopically into the mammary glands of nu/nu mice in order to assess the
effect of Slc1a5 knockdown on the rate of orthotopic tumor growth.

Slc1a5

downregulation did not alter the growth rate of primary orthotopic tumors as tumors
formed by primary tumor cells expressing either of two Slc1a5 shRNAs grew at the same
rate as tumors formed by primary tumor cells expressing a control hairpin (Fig. 4D). In
contrast, orthotopic tumors formed by recurrent tumor cells expressing shRNAs directed
against Slc1a5 grew 3.5 to 4.6-fold more slowly than tumors formed by recurrent tumor
cells

expressing

a

control

hairpin

(Fig.

4F;

23.36±12.82

MGRcontrol

MGRshRNA1=6.71±2.35, MGRshRNA2=5.03±1.34; pshRNA1<0.001, pshRNA2<0.001).

vs.

These

findings indicate that while Slc1a5 is required for efficient glutamine uptake in both
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primary and recurrent mammary tumor cells, Slc1a5 is required for the growth of
recurrent, but not primary, mammary tumors.

Gls1 is required for recurrent, but not primary, tumor growth
To investigate the functional consequences of Gls1 upregulation on tumor growth, we
knocked down expression of Gls1 in primary as well as recurrent tumor cells using two
different shRNAs (Fig. 5C, E). As anticipated, Gls1 downregulation was accompanied
by reduced glutamate production in both primary and recurrent tumor cells.
Primary and recurrent tumor cells with and without Gls1 knockdown were next
implanted orthotopically into the mammary glands of nu/nu mice in order to assess the
effect of Gls1 knockdown on the rate of orthotopic tumor growth.

As observed for

Slc1a5, Gls1 downregulation did not alter the growth rate of primary orthotopic tumors as
tumors formed by primary tumor cells expressing either of two Gls1 shRNAs grew at the
same rate as tumors formed by primary tumor cells expressing a control hairpin (Fig.
5D). In contrast, orthotopic tumors formed by recurrent tumor cells expressing shRNAs
directed against Gls1 grew 3.9 to 4.2 fold more slowly than tumors formed by recurrent
tumor cells expressing a control hairpin (Fig. 5F; 23.36±12.82 MGRcontrol vs.
MGRshRNA1=6.30±1.98, MGRshRNA2=5.23±0.99; pshRNA1<0.001, pshRNA2<0.001).

These

findings indicate that while Gls1 is required for efficient glutamate production in both
primary and recurrent mammary tumor cells, Gls1 is required for the growth of recurrent,
but not primary mammary tumors.
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Elevated Slc1a5 expression is associated with an increased risk of recurrence in
women with breast cancer
Our observations in mice that glutaminolysis is up-regulated in recurrent mammary
tumors, that recurrent mammary tumor cells are glutamine-addicted, and the both
Slc1a5 and Gls1 are differentially required for recurrent tumor growth, we considered the
possibility that expression Slc1a5 or Gls1 in primary tumors might be associated with
recurrence-free survival in women with breast cancer. Based on the above data, we
hypothesized that if upregulation of glutaminolysis functionally contributes to tumor
recurrence in humans, that women with primary breast cancers expressing higher levels
of Slc1a5 or Gls1 might relapse at a faster rate than women whose breast cancers
express lower levels of Slc1a5 or Gls1.
To test this hypothesis, we collected unique patient profiles from 11 published
human primary breast cancer microarray data sets, each of which contained at least 50
patients in addition to information on relapse-free survival. For each data set, the effect
size of the association between Slc1a5 or Gls1 mRNA expression and relapse-free
survival was estimated using Cox proportional hazard regression in which Slc1a5 or
Gls1expression were modeled as continuous variables; and 2) the concordance index
(c-index). To derive an overall estimate and statistical significance of the association
between mRNA expression and relapse-free survival while accounting for the
heterogeneity among data sets, effect size estimates were combined across data sets
by meta-analysis using the inverse-variance weighting method.

In the presence of

significant heterogeneity (p-value for Cochran’s Q statistic < 0.1), a random-effect mode
was used for meta-analysis. Otherwise, a fixed-effect model was used.
When considering all patients encompassed by the 11 data sets, a significant
positive association was observed between elevated SLC1A5 expression and risk of
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relapse in breast cancer patients within 10 years of diagnosis (H.R. = 1.41 [1.18-1.67],
p=0.00012; Fig. 6A).

In contrast, no significant association was observed between

GLS1 expression and relapse-free survival (Fig. 6B). These results suggest an overall
association between SLC1A5 expression and the risk of tumor recurrence and breast
cancer patients.

5.4 Discussion
Since the 1950s, glutamine has been recognized as an important nutrient for
proliferating cancer cells88. Glutamine acts as a carbon and nitrogen source supporting
energy production as well as contributing to biosynthesis reactions and redox
homeostasis74,

91, 173, 182, 191

.

In this study, we have shown that recurrent mammary

tumors that spontaneously arise in genetically engineered mice following HER2/neu
downregulation and primary tumor regression exhibit increased glutaminolysis and are
glutamine-addicted.

While several studies have demonstrated significantly reduced

viability of a number of human cancer cell lines following glutamine withdrawal97, 98, 172,
199

, to our knowledge no study has demonstrated a shift from glutamine independence to

glutamine addiction during the course of cancer progression in vivo in an autochthonous
tumor model. Our results highlight the potential importance of glutaminolysis beyond its
previously reported role in primary tumor growth.
In this study we have demonstrated that recurrent mammary tumors that arise in
a HER2/neu-induced mammary tumor model exhibit increased glutamine uptake and
glutamate production, as well as increased reductive carboxylation, compared to primary
tumors.

This observed increase in glutaminolysis was accompanied by increased
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expression of the glutamine transporter, Slc1a5, as well as the glutaminase enzyme,
Gls1. Moreover, we found that upregulation of Slc1a5 and Gls1 was driven by c-Myc,
which was itself upregulated in recurrent tumors and shown to be required for their
observed glutaminolytic phenotype.

Finally, consistent with the glutamine-addicted

nature of recurrent mammary tumor cells, we found that Slc1a5 and Gls1 are each
preferentially required for the growth of recurrent, but not primary, mammary tumors.
Combined, these results suggest an important role of glutamine metabolism in the
recurrence of HER2/neu-induced mammary tumors.
In this study, we report the spontaneous upregulation of both Slc1a5 and Gls1
during the process of recurrence of HER2/neu-induced primary mammary tumors
induced to regress by HER2/neu pathway downregulation. We also find that Slc1a5 and
Gls1 are each required in vivo for the growth of recurrent, but not primary, tumors. Gls1
has previously been reported to be required for tumor growth in some primary tumors in
the context of xenografted tumors from cell lines100,

101, 153, 262, 263

. To our knowledge,

however, a requirement for Slc1a5 in tumor growth has not been previously
demonstrated. Indeed, while the conversion of glutamine to glutamate catalyzed by
glutaminases is a known rate-limiting step in glutamine metabolism, transport of
glutamine by Slc1a5 is not. As such, our results provide some of the first evidence to
support an important functional role for Slc1a5 in tumor growth, as well as functional role
for Slc1a5 and Gls1 in tumor progression.
While many studies have established a key role for Slc1a5 in glutamine transport
in cancer cells185, 186, Slc1a5 can transport a number of small neutral amino acids other
than glutamine. As such, it is possible that the functional effect of Slc1a5 knockdown on
tumor growth could be due to differential transport of a neutral amino acid other than
glutamine.

Nevertheless, given the tight association that we observe in our model
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between spontaneous Slc1a5 upregulation and increased glutamine metabolism, as well
as shRNA-mediated Slc1a5 knockdown and downregulation of glutamine uptake, we
favor the possibility that the effects of Slc1a5 in recurrent tumor cells are indeed
mediated by its transport of glutamine.
To date, a number of oncogenes have been reported to regulate glutamine
metabolism97,

98, 191, 192

.

Among those, Myc is known to be a key regulater of

glutaminolysis in cancer cells264. Oncogenic levels of Myc have been shown to directly
induce glutamine addiction as well as apoptosis following glutamine withdrawal97, 172. In
our model, we observe the spontaneous upregulation of Myc expression, as well as the
expression of Myc transcriptional targets, during the spontaneous recurrence of
HER2/neu-induced mammary tumors.

Moreover, we find that Myc upregulation is

responsible for the observed glutaminolytic phenotype of recurrent tumors by virtue of its
ability to positively regulate the expression of Slc1a5 and Gls1.

Myc has been

previously shown to transcriptionally regulate a number of genes involved in metabolism,
including Slc1a597, and is known to regulate glutaminase activity indirectly by repressing
the expression of miR23a/b98.

Our findings that glutamine metabolism in recurrent

tumors is regulated by Myc expression provides further in vivo confirmation of these
reports and highlight an important role of Myc in cancer recurrence.

This, in turn,

suggests the potential utility of blocking downstream metabolic effectors of the Myc
pathway, particularly those involved in glutamine metabolism, in human cancers.
Glutamine carbon is known to support de novo lipogenesis, which can occur
through the conversion of glutamine-derived α-ketoglutarate to citrate through reductive
carboxylation followed by acetyl-coA production176-181. Previous studies have reported
this finding in vitro. Our findings provide evidence for increased reductive carboxylation
in vivo in recurrent mammary tumors, compared to primary tumors, manifested as high
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citrate labeling from glutamine. It has been suggested that the “reverse” TCA cycle
accompanying active reductive carboxylation is most pronounced under hypoxic
conditions and within the context of mitochondrial dysfunction177-179,

181

. We speculate

that the increase in reductive carboxylation that we observe in recurrent tumors may
result from increased hypoxic conditions within these tumors.

However, direct

demonstration that this is the case will require further investigation.
Finally, our analysis of relapse-free survival in breast cancer patients revealed a
significant positive association of SLC1A5, but not GLS1, expression levels with an
increased risk of recurrence.

Consistent with our findings in genetically engineered

mouse models for breast cancer recurrence, patients with primary tumors expressing
elevated levels of SLC1A5 exhibited higher 10-year relapse rates when compared to
women whose cancers expressed lower levels of SLC1A5.

These results are in

agreement with reports in the literature indicating that of high SLC1A5 levels are
associated with reduced survival in some human cancers, including colorectal265 and
prostate adenocarcinomas266. To our knowledge, however, no studies have established
an association between GLS1 expression levels and survival in human cancer patients.
Additional work will be needed to determine, by multivariate analysis, whether either of
these genes is associated with patient outcome independent of currently used
clinicoprognostic factors.
In conclusion, our findings provide direct evidence for an evolving metabolic
phenotype of breast cancers during the course of tumor progression, as well as support
for a role for glutamine metabolism as a potentially targetable feature in recurrent breast
cancers. While additional studies will be required to assess the translational potential of
our findings. Glutamine addiction, a newly identified hallmark of breast cancer
recurrence, can be further exploited to establish potential early tumor recurrence
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diagnotic markers of increased glutamine uptake; targeted anti-recurrence therapies
against Slc1a5 and Gls1; and finally breast cancer prognostic markers through SLC1A5
expression profiling in individual tumors.
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5.5 Figure Legends
Figure 1. Recurrent tumors exhibit increased glutamine metabolism (A) L-[5-11C]Glutamine PET imaging reveals higher tracer uptake in recurrent tumors relative to
primary tumors.

(B) Quantification of the L-[5-11C]-Glutamine dynamic PET

measurements shows higher mean area under the curve (AUC) in recurrent tumors,
when compared to primary tumors. Uptake values at each timeframe were normalized
to the injected dose and the weight of each mouse. (C) Tumor culture experiments
reveal higher glutamine uptake in recurrent tumors.

(D) Tumor culture experiments

show increased glutamate production in recurrent tumors. The measured metabolite
levels in the tumor culture experiments were normalized to the wet weight of the cultured
tumors.

Figure 2. Recurrent tumors exhibit higher glutaminolytic flux and increased
reductive carboxylation (A) Assessment of L-[3-13C]-glutamine metabolism using

13

C-

magnetic resonance spectroscopy (MRS) reveals increased labeled glutamate
production

from

glutamine

in

recurrent

tumors

relative

to

primary

Representative spectra from 2 of the tumors examined are shown.

tumors.

Glu-3: 3-13C-

glutamate; Gln-3: 3-13C-glutamine. (B) Quantification of the integral ratio of the Glu-3
peak to the Gln-3 peak in all the primary and recurrent tumors examined reveals
statistically significant higher ratios in recurrent tumors. (C) Assessment of metabolite
isotopomers using mass spectrometry reveals higher mole percent excess levels of
glutamate, aspartate, succinate, malate, citrate and lactate in recurrent tumors when
compared to primary tumors.

Glutamine labeling was lower in recurrent tumors
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indicating higher label consumption. Gln: glutamine; Glu: glutamate; Asp: aspartate;
Succ: sucinate; Mal: malate; Citric: citrate; Lac: lactate.

Figure 3. Recurrent tumor cells are glutamine-addicted (A) Primary tumors cells
cultured in control media and media lacking glutamine exhibit similar growth
characteristics.

Recurrent tumor cells cultured in media lacking glutamine exhibit

decreased growth and increased cell death compared to those cultured in control media.
The observed glutamine-addiction phenotype displayed by recurrent tumor cells can be
rescued by media supplementation with α-ketoglutarate.

(B) Quantification of cell

viability by trypan blue reveals decreased viability of recurrent tumor cells cultured in
media lacking glutamine.

All other conditions exhibited similar viability levels.

Gln:

glutamine; α-kg: α-ketoglutarate.

Figure 4. Slc1a5 is upregulated in recurrence and is required for tumor growth (A)
qRT-PCR profiling of primary and recurrent tumors reveals higher expression levels of
Slc1a5 at the mRNA level.

(B) Recurrent tumors exhibit higher protein levels in

recurrent tumors. (C) Confirmation of Slca15 knockdown in primary tumor cells was
assessed by qRT-PCR. 2 shRNA constructs were used. Ctrl: Control. (D) Slc1a5
knockdown does not affect the mean growth rate of primary tumors in vivo.

(E)

Confirmation of Slc1a5 knockdown in recurrent tumor cells was performed by qRT-PCR.
2 shRNA constructs were used. (F) Slc1a5 downregulation in recurrent tumors leads to
statistically significant lower mean growth rate of recurrent tumors in vivo. Mean tumor
growth rate was calculated from bi-weekly caliper measurement of tumor dimensions.
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Figure 5. Gls1 is upregulated in recurrence and is required for tumor growth (A)
Recurrent tumors exhibit higher expression of Gls1 levels relative to primary tumors at
the mRNA level. Gene expression levels were assessed using qRT-PCR. (B) Gls1 has
higher expression at the protein level in recurrent tumors. (C) Confirmation of Gls1
knockdown in primary tumor cells by qRT-PCR. 2 shRNA constructs were used. (D)
Gls1 downregulation does not affect primary tumor mean growth rate in vivo.

(E)

Confirmation of Gls1 knockdown in recurrent tumor cells. 2 shRNA constructs were
used. (F) Gls1 knockdown results in a marked decrease in mean tumor growth rate in
recurrent tumors in vivo. Mean tumor growth rate was calculated from bi-weekly caliper
measurement of tumor dimensions.

Figure 6. SLC1A5, but not GLS1 expression is associated with recurrence risk in
human breast cancer (A) Cox proportional hazard regression of 11 human datasets
reveals a statistically significant association between high SLC1A5 expression and 10year cancer relapse risk. When all datasets are considered, the random effect model
yields a hazard ratio of 1.58 (p=0.0067). HR: hazard ratio; CI: confidence interval. (B)
Examination of the same human datasets does not reveal a statistically significant
association between GLS1 expression and 10-year relapse risk. The combined hazard
ratio was 0.96 (p=0.56). This analysis was conducted using a meta-analysis-based
algorithm.

Figure 7. Myc is upregulated in recurrence and drives Slc1a5 and Gls1
upregulation (A) Myc exhibits increased expression in recurrent tumors on the protein
level. (B) Myc upregulation is accompanied by increased expression of a number of
known downstream Myc targets. Target expression level was assessed using qRT117

PCR. (C) Downregulation of Myc expression in recurrent tumor cells is accompanied by
decreased expression of Slc1a5 and Gls1. Myc downregulation was achieved with Myctargeted siRNAs. Gene expression levels were assessed using qRT-PCR. (D) Myc
downregulation was also accompanied by decreased glutamine consumption and
decreased glutamate production.

Negative values correspond to metabolite

consumption and positive values correspond to metabolite production.
measurements were normalized to the average number of cells in each well.
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CHAPTER 6

Ldhb Downregulation by Sirt3 Contributes to the Warburg Effect and
Promotes Breast Cancer Recurrence

ABSTRACT
Tumor recurrence is the principal cause of mortality in women with breast cancer.
Despite its clinical importance, little is known about the mechanisms underlying breast
cancer recurrence. Increased lactate levels have been shown to be a poor prognostic
marker in cancer patients and have been proposed to be a characteristic feature of
metastatic and recurrent tumors. In this study, we assess changes in lactate metabolism
during breast cancer progression in a genetically-engineered mouse model of
HER2/neu-induced breast cancer that recapitulates key features of the natural history of
breast cancer progression including primary tumor development, tumor dormancy and
recurrence. We find that recurrent mammary tumors exhibit increased lactate levels,
compared to primary tumors, and that downregulation of Ldhb in recurrent tumors was
responsible for this change. Ldhb, a subunit of the LDH enzyme, favors the conversion
of lactate to pyruvate. Consequently, decreased Ldhb expression in recurrent tumors
favors the accumulation of lactate due to a reduced ability to oxidize this metabolite. We
further determined that Ldhb downregulation plays a functional role in tumor recurrence
as Ldhb knockdown in primary tumor cells was sufficient to promote tumor recurrence in
orthotopic mouse experiments. Consistent with a role for Ldhb downregulation in human
breast cancer progression, low Ldhb was associated with reduced recurrence-free
survival in breast cancer patients, particularly those whose tumors exhibited HER2/neu
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amplification. Ldhb downregulation in recurrent tumors was due to downregulation of
the NAD-dependent mitochondrial deacetylase, Sirt3, an effect that was mediated by
Hif1-α. Taken together, our results suggest a functional role for Ldhb downregulation in
promoting breast cancer recurrence and suggest potential clinical applications of Ldhb
expression as a prognostic factor in human breast cancer.

6.1 Introduction
Breast cancer is the most commonly diagnosed malignancy in women and is the second
leading cause of cancer-related death in women in the U.S.2, 5. Among women with
breast cancer, tumor recurrence represents the principal cause of mortality17.
Nevertheless, little is known about the molecular mechanisms by which breast cancer
cells survive therapy and recur. In particular, while dysregulated metabolism has long
been recognized as a key feature of cancer development, the metabolic changes
accompanying cancer recurrence are largely unexplored.

Progress in this area has

been greatly hindered by the lack of models for breast cancer recurrence. To address
this gap, our laboratory has developed a series of inducible bitransgenic mouse models
that accurately recapitulate human breast cancer progression, including primary tumor
development, minimal residual disease, tumor dormancy and recurrence63-65. In this
study, we explore the changes in lactate metabolism that accompany breast cancer
progression and identify their underlying causes and potential functional role in tumor
recurrence.
Increased lactate production in tumors has generally been associated with
advanced disease in cancer patients.

For example, high lactate levels have been
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reported in metastatic recurrent tumors in human cervical cancers, head and neck
cancers, lung cancers and colorectal cancers145, 267-271. In addition, lactate accumulation
in the plasma of cancer patients has also been found to be positively correlated with
tumor burden82. These results provide evidence for a potential role of increased lactate
metabolism in cancer progression.
The tendency of cancer cells to produce large amounts of lactate, despite the
presence of oxygen, was first observed by Otto Warburg in the 1930s76. Today, aerobic
glycolysis, or the Warburg effect, is recognized as one of the most characteristic features
of the metabolic profile of cancer cells.

In the presence of oxygen, cancer cells

metabolize most of the glucose they uptake and convert it to lactate. At the end of the
glycolytic pathway, lactate dehydrogenase catalyzes the interconversion of pyruvate to
lactate. Lactate dehydrogenases consist of homo- and hetero- tetramers of M and H
proteins encoded by the Ldha and Ldhb genes respectively85. Five iso-enzymes, with
different activity levels, have been described: LDH1 (4H), LDH2 (3H1M), LDH3 (2H2M),
LDH4 (1H3M) and LDH5 (4M)85. LDH5, which consists of 4 Ldha subunits, is known to
favor the conversion of pyruvate to lactate85. To date, differential lactate production in
cancer cells has mainly been ascribed to changes in Ldha84, 272. More recently, cancer
cells were found to preferentially express the embryonic isoform of pyruvate kinase,
Pkm2273, which increases lactate levels in tumors273. In addition, both Ldha and Pkm2
appear to be required for tumor growth83, 274. In contrast, at present, little is known about
the role of Ldhb in tumorigenesis.
In this study, we investigate changes in lactate metabolism during breast cancer
progression and characterize the functional role of these changes on tumorigenesis. In
doing so, we establish a novel role for Ldhb downregulation in promoting cancer
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recurrence in genetically engineerd mice and identify the mechanism behind the
observed changes in mammary tumorigenesis and tumor recurrence. Consistent with a
role in human breast cancer progression, Ldhb downregulation was associated with
reduced recurrence-free survival in breast cancer patients.

6.2 Methods
Animals, cell culture and recurrence assay
The MMTV-rtTa;TetO-HER2/neu (MTB/TAN) doxycycline-inducible bitransgenic mouse
model has been described63, 132. All mice were housed and treated in accordance with
protocols approved by the Institutional Animal Care and Use Committee at the University
of Pennsylvania. MTB/TAN mice were bred, housed, induced with 2 mg/ml doxycycline,
monitored for tumor development and recurrence, and sacrificed as described66.
Tumor cells from primary mammary tumors arising in MTB/TAN mice maintained
on doxycycline were isolated and cultured in the presence of doxycycline as described66.
Primary tumor cells were transduced with retroviruses expressing shRNAs targeting
genes of interest and were selected in puromycin for stably-transduced polyclonal
populations.

Magnetic resonance spectroscopy
PCA extraction was performed on 4 primary and 4 recurrent flash-frozen tumor samples
using 12% perchloric acid. Extracted samples were lyophilized and dissolved in 0.6 ml
D2O. 1H NMR spectroscopy was performed at 400MHz on a Bruker Avance DMX 400
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wide-bore spectrometer.

Fully relaxed proton spectra were acquired with a 5 mm

inverse probe using the following conditions: PW 45º, TR 8s, water saturation during the
relaxation delay, 6775 Hz SW, TD 64k and 64 scans. An external standard made of
trimethylsilylpropionic acid (TSP) was introduced in the NMR tube and used as a
chemical shift reference and as a quantification standard.

Metabolite resonance

assignments were made based on previously published spectra in breast cancer
tissue133. Analysis of collected NMR spectra was performed using NUTS (Acorn NMR
Inc).

13

C-labeling experiments and mass spectrometry

Three primary tumor-bearing mice and three recurrent mammary tumor-bearing mice,
were infused through a tail vein catheter with a 200 mM solution of D-[1,2-13C]-glucose
(Isotec) over a period of 45 minutes. Six additional mice, 3 bearing primary tumors and
3 bearing recurrent tumors were infused through a tail vein catheter with a 40 mM
solution of L-[U-13C]-lactate for 45 minutes. At the end of the infusion period, tumors
were dissected and clamp-frozen in liquid nitrogen.

Perchloric acid extraction was

performed as described128.
Measurement of

13

C isotopomers was performed on a Triple Quad 6410 mass

spectrometer combined with an LC 1290 Infinity mass selective detector (Agilent), as
described257. Briefly, samples were first purified by passage through either AG-1 or AG50 cation exchange columns (Biorad) and then converted into t-butyldimethylsilyl
derivatives.

Isotopic enrichment of lactate, alanine, citrate, glutamate, malate and

aspartate were monitored.

13

C-enrichment was computed as molar percent enrichment
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(MPE), reflecting the mol fraction (%) of analytes containing

13

C atoms in excess of

natural abundance, where MPE (M+i) = % AM+i/[AM + Σ AM+i], and AM and AM+i represent
the peak area from LC-MS ions corrected for natural abundance and corresponding to
the unlabeled (M0) and 13C-labeled (M+i) mass isotopomers, respectively. To reflect the
amount of each labeled metabolite pool relative to the total available metabolite amount
in the tissue, results are presented as the Σ

13

C- labeled Metabolite: Σ(13C- labeled

Metabolite) = [Metabolite Concentration] x Σ(MPE).

In vitro metabolite level quantification
300,000 cells were plated and incubated in cell culture media for 96 hours. Lactate and
glucose levels present in the media at 96 hours were determined using a 7100
Multiparameter Bioanalytical System (YSI life Sciences). The amount of each metabolite
consumed or produced by cells in each well was computed as the difference between
the level of that metabolite in conditioned media from cultured cells compared to its level
in control media incubated without cells, and then normalized to the average number of
cultured cells in that well. Positive values denote metabolite level increase, whereas
negative values denote metabolite level decrease. Samples from each tested condition
were run in triplicate and statistical significance was determined using a student's t-test.

RNA isolation and qRT-PCR
RNA extraction was performed on snap-frozen primary and recurrent mammary tumor
tissue and cell samples as described253. Samples were homogenized and RNA isolation
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was carried out using the RNeasy RNA isolation kit (Qiagen) according to
manufacturer’s instructions. Reverse transcription was performed from 2 µg of RNA
using the cDNA High Capacity Reverse Transcriptase Kit (Applied Biosystems). qRTPCR analysis for mRNA levels was carried out on an Applied Biosystems 7900 HT Fast
Real-Time PCR system using 6-carboxyfluorescein–labeled Taqman probes (Applied
Biosystems). Expression levels were normalized to TBP.

Western blotting
Mammary tumors were homogenized with a sonicator in TPER protein lysis buffer
(Thermo Scientific). Primary antibodies were obtained from Abcam (anti-Ldhb and antiLdha), or Cell Signaling (anti-Pkm2, anti-Sirt3 and anti-Hif1). Horse radish peroxidaseconjugated secondary antibodies (Jackson Laboratories) were used to probe
membranes incubated with the anti-Pkm2, anti-Hif1 and anti-Sirt3 antibodies.

The

enhanced chemiluminescent system (ECL; Amersham) was used to detect the bound
secondary antibodies.

Anti-Ldha and Ldhb primary antibodies were detected using

Alexa-Fluor-conjugated secondary antibodies (Molecular Probes). The Odyssey V3.0
system (Li-COR Biosciences) was used to visualize and quantify proteins of interest.

Hif1 gene pathway activity
A hypoxia gene expression signature was generated from a dataset obtained from the
NCBI GEO website (GSE3188).

Cyber-T analysis was performed

to identify

differentially regulated genes in breast cancer cells under hypoxic conditions. A p-value
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cutoff of 0.01 and a fold change cutoff of 2 generated a 288-gene hypoxia gene
signature. The generated signature was used to assess hypoxic pathway activity in
microarray data of mouse tumors using a scoring system described previously134.

Pkm1 and Pkm2 isoform quantification
We designed 5’ and 3’ oligonucleotide primers (ACACGAAGGTCGACATCCTC and
CAAGGGGACTACCCTCTGG) for the Pkm gene. Using RNA extracted from primary
and recurrent tumor samples, Pkm1 and Pkm2 were amplified using PCR. Equivalent
amounts of amplified Pkm1 and Pkm2 fragments were digested with Pst1, Econ1
restriction enzyme, both enzymes or neither enzymes. EcoN1 is specific for Pkm1 and
Pst1 is specific for the Pkm2. Following digestion, products were electrophoresed on a
non-denaturing polyacrylamide gel. The gel was stained with ethidium bromide prior to
UV imaging.

LDH activity determination
LDH was extracted from primary and recurrent tumor samples using the Biovision LDH
Activity Quantification kit (Biovision, Inc.) according to manufacturer's instructions.
Protein amounts were quantified in each of the extracted samples and the same amount
of protein was loaded in each well prior to activity measurements. Enzyme activity is
presented as amount of lactate converted into pyruvate in nmol/min/ml.
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Zymography
To separate the different LDH isoenzymes, aliquots from the same samples extracted for
LDH activity assays were subjected to a non-denaturing polyacrylamide gel for
electrophoresis.

Following electrophoresis, gels were placed in a staining solution

containing NAD+, lactate and Syber Gold. NADH produced during the conversion of
lactate to pyruvate reacts with Syber Gold thereby reflecting the activity of each of the
LDH isoenzymes.

Ldhb shRNA constructs
Oligonucleotides

targeted

against

Ldhb

were

designed

using

RNAi

Central

(http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA). The following sequences were
used: Ldhb shRNA-1: TGCTGTTGACAGTGAGCGCCCTCATCGAGTCCATGCTGAATAGTGAAGCCACAGATGTATTCAGCATGGACTCGATGAGGTGCCTACTGCCTCGG;
and Ldhb shRNA-2: TGCTGTTGACAGTGAGCGAACAGACAATGACAGTGAGAACTAGTGAAGCCACAGATGTAGTTCTCACTGTCATTGTCTGTCTGCCTACTGCCTCGGA.
Oligonucleotides were cloned into the MLP vector and retroviral vectors and
supernatants were generated as described253.
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siRNA experiments
Knockdown of Sirt3 and Hif1 expression in primary tumor cells was performed using
commercially available siRNAs (Ambion). A scrambled siRNA was used as a negative
control (Ambion).

siRNA transduction was performed according to manufacturer's

instructions and cells were incubated with siRNAs for 48 hrs. Sirt3 and Hif1 knockdown
were confirmed by qRT-PCR.

Orthotopic tumor assay
Orthotopic tumor assays were performed in athymic nude mice (nu/nu) (Taconic,
Germantown, NY). Cells were injected into the inguinal mammary fat pads of 10-12
nu/nu mice for each experimental group. Experiments were performed in parallel with
three experimental arms, including one experimental arm for each of the Ldhb shRNA
contructs, as well as an arm for a control shRNA. Cells expressing an empty MLP
vector were used in the control group.

1 million tumor cells were injected into the

number four mammary fat pads of each mouse.
For primary orthotopic tumor growth assays, HER2/neu expression in
transplanted cells was induced by administering 2 mg/mL doxycycline in drinking water.
Tumor size was measured 2-3 times per week and tumor volume was determined by
caliper measurements for each injected site using the following formula: Tumor volume =
(smallest diameter2 * largest diameter)/2. Tumors were followed until they reached a
size of approximately 15x15 mm. Mean tumor growth rate (MGR) was calculated for
each tumor as described252.
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For orthotopic recurrence assays, mice were maintained on doxycycline until
primary tumors reached a size of 3x3 mm. Doxycycline was then withdrawn and tumors
were followed for regression.

The incidence and latency of tumor recurrence was

assessed from biweekly measurements.

Kaplan-Meier curves were generated for

recurrence-free survival following doxycycline withdrawal and compared between the
two cohorts using a logrank test.

Human association analysis
Microarray data sets135,

137, 138

profiled using the Affymetrix HG-U133A platform were

downloaded from Gene Expression Omnibus and individually RMA-normalized.

943

lymph node-negative patients who did not receive any systemic adjuvant therapy were
identified according to available clinical information.

Microarray data were mean-

centered by gene within each data set and combined into one data set. HER2-positive
status was approximated by inspection of the rank plot of HER2 mRNA levels, and
defined as samples having mean-centered log2 expression greater than 1. Patients
were assigned to high- or low-scoring classes based on their metabolic gene expression
signature scores. The cutoff between high- and low-scoring classes was determined by
an outcome-oriented approach140. Differences in 5-year relapse-free survival between
the two classes were assessed by p-value from the log-rank test and hazard ratio from
Cox proportional hazards regression. To guard against high false-positive rates resulted
from multiple testing, a corrected p-value was also calculated as part of the cut-point
determination step140.

Analyses were performed specifically for the HER2-positive

subset of patients. All data analyses were performed in the R environment141.
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6.3 Results
To assess the differences in lactate metabolism between primary and recurrent tumors,
we made use of a previously described doxycycline-dependent genetically engineered
mouse model for HER2/neu-induced mammary tumorigenesis63,

66

.

In this model,

activation of HER2/neu results in mammary epithelial hyperplasia and the eventual
development of primary mammary tumors that are addicted to HER2/neu expression63.
When doxycycline is withdrawn, the resulting acute downregulation of HER2/neu
pathway activity results in the regression of mammary tumors to a non-palpable state.
This mimics the effect of therapy in women with HER2/neu-amplified breast cancers who
are treated with a targeted agent that blocks HER2/neu activity63. Akin to human breast
cancer patients, primary mammary tumors that regress to a non-palpable state following
doxycycline withdrawal subsequently recur with stochastic kinetics following a variable
latent period that mimics human tumor dormancy66. Recurrent mammary tumors in this
system do not re-activate the HER2/neu transgene, but rather escape their dependence
on HER2/neu signaling by activating alternate growth and survival pathways66.

Recurrent tumors exhibit higher lactate levels than primary tumors
We used 1H magnetic resonance spectroscopy (MRS) to evaluate lactate levels in
primary and recurrent mammary tumors. Metabolic profiling of primary and recurrent
mammary tumors revealed several metabolites whose concentrations differed between
primary and recurrent tumors, including lactate whose levels were 30% higher levels in
recurrent tumors (p=0.002) (Figure 1A).

These results were confirmed with mass

spectrometry where in metabolite quantification in primary and recurrent tumors also
revealed 40% higher lactate levels in recurrent tumors (p=0.014) (Figure 1B).
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To further characterize the source of the higher lactate levels observed in
recurrent tumors, we used 13C-labeled compounds and determined their isotopic labeling
at specific metabolic steps. Since increased lactate levels in cancer cells have primarily
been attributed to the Warburg effect, we tested the hypothesis that increased lactate
levels in recurrent tumors result from increased glycolytic flux. To achieve this end, we
infused [1,2-13C]-glucose into primary as well as recurrent tumor-bearing mice. The total
amount of

13

C-labeled metabolite was used as a readout of glucose carbon contribution

to each of the assessed metabolites. Surprisingly, this analysis revealed that glucose
exhibited a lower

13

C-labled carbon contribution to lactate in recurrent tumors compared

to primary tumors (p=0.004) (Figure 1C). This suggested that the increased lactate
levels observed in recurrent tumors might not simply be the product of increased glucose
metabolism.
We next sought to determine whether increased lactate concentrations in
recurrent tumors might result from lactate accumulation in the tumors driven by reduced
lactate metabolism.

To test this hypothesis, we infused [3-13C]-lactate into primary

tumor-bearing mice and recurrent tumor-bearing mice. Assessment of isotopic labeling
and quantification of the total amount of available metabolite revealed a higher total
amount of labeled lactate in recurrent tumors compared to primary tumors (p=0.01)
(Figure 1D). Consistent with our hypothesis, recurrent tumors displayed lower levels of
total labeled alanine from lactate, potentially reflecting reduced lactate uptake and
metabolism in recurrent tumors (Figure 1D).
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Recurrent tumors exhibit similar Ldha and Pkm2 but lower Ldhb levels
To identify the underlying molecular determinants responsible for the observed
differences in lactate levels, we used qRT-PCR to quantify the mRNA expression levels
of Ldha and Ldhb. Expression profiling in primary and recurrent tumors revealed similar
Ldha expression levels (p=0.151), but a 5-fold decrease in Ldhb expression levels as
tumors progressed from the primary to recurrent stage (p=0.016) (Figure 2A). These
results were confirmed at the protein level where Ldha levels were similar in primary and
recurrent tumors and Ldhb levels were decreased in recurrent tumors (Figure 2B).
Another enzyme implicated in contributing to increased lactate levels in cancer is
the embryonic isoform of pyruvate kinase, Pkm2. To assess whether differences in
Pkm2 levels, or differences in the Pkm2/Pkm1 ratio, might be responsible for the
observed change in lactate level, we examined Pkm2 expression at the mRNA and
protein levels and compared them to those of Pkm1, the adult isoform of pyruvate
kinase.

Since Pkm1 and Pkm2 result from alternative splicing of the Pkm gene

transcript (Figure 2C), we designed primers to amplify both Pkm1 and Pkm2 and sought
to quantify each isoform using restriction enzymes specific to each amplified fragment.
Our results revealed that primary and recurrent tumors exhibited similar levels of Pkm1
and Pkm2 (Figure 2C). This was further confirmed by western blotting which revealed
similar levels of Pkm2 protein in primary and recurrent tumors (Figure 2D).
In summary, our results indicate that primary and recurrent mammary tumors
exhibit similar Ldha and Pkm2 levels, but lower levels of Ldhb, suggesting that reduced
Ldhb levels might contribute to the elevated levels of lactate observed in recurrent
tumors.
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Ldhb downregulation levels result in lower LDH activity and reduced lactate
metabolism in recurrent tumors
To further characterize the metabolic effects of Ldhb downregulation, we evaluated the
distribution of LDH isoforms in primary and recurrent tumors. The LDH enzyme is a
tetramer consisting of different numbers of Ldha and Ldhb subunits, which manifests as
five different enzyme isoforms.

The LDH5 isoform consists of four Ldha subunits

whereas the LDH1 isoform consists of four Ldhb subunits. Zymography performed on
protein lystes prepared from primary and recurrent tumors revealed a shift in the
distribution of the LDH isoforms as tumors recur. While primary tumors expressed all
five isoforms of LDH, recurrent tumors only expressed LDH4 and LDH5, and lacked LDH
isoforms containing two or more subunits of Ldhb (isoforms 1, 2 and 3) (Figure 3A).
As Ldhb is known to favor the conversion of lactate into pyruvate, we sought to
quantify any differences in the rate of this reaction between primary and recurrent
tumors. Profiling of LDH enzymatic activity in primary and recurrent tumors revealed
40% lower LDH activity converting lactate to pyruvate in recurrent tumors compared to
primary tumors (p=0.014) (Figure 3B).
To directly address whether reduced Ldhb levels contributed to the high lactate
levels observed in recurrent tumors, we downregulated expression of Ldhb in a recurrent
tumor cell line (Figure 3C), incubated these Ldhb knockdown cells in media containing
lactate and quantified the amount of lactate present in the media at 96 hours. These
studies revealed that shRNA-mediated Ldhb downregulation resulted in signficant
increase in the amount of lactate present in the media at 96 hours compared to the cells
expressing a control shRNA (p<0.05) (Figure 3D). Similar results were obtained with
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two different shRNA constructs.

These findings suggest Ldhb downregulation in

recurrent tumor cells could contribute to higher lactate levels that we observed in the
recurrent tumors in vivo.

Lower Ldhb levels promote tumor recurrence in mice and are correlated with
lower recurrence-free survival in human breast cancer
To assess the functional effect of Ldhb downregulation on breast cancer progression, we
employed an orthotopic tumor assay in which we genetically manipulated the expression
of Ldhb in primary tumor cells derived from MMTV-rtTa;TetO-HER2/neu mice in which a
HER2/neu transgene was expressed in a doxycycline-inducible manner (Figure 3C) prior
to injecting them in the mammary fat pad of nu/nu mice. In this assay, primary tumor
growth was induced by doxycycline administration to nu/nu mice whose mammary fat
pads had been injected with primary tumor cells that had been transduced with an Ldhb
shRNA or control shRNA. When those tumors reached a size of 3x3 mm, doxycycline
was withdrawn to induce tumor regression then monitored for the appearance of
recurrent tumors (Figure 4A). Our results revealed that primary tumors derived from
cells in which Ldhb had been knocked down recurred at a significantly faster rate
compared to primary tumors derived from cells transduced with a control shRNA
(Figures 4B and 4C).

These results were reproduced with two different shRNA

constructs (HR1=0.2755, p1=0.001 and HR2=0.21, p2<0.001). This indicates that Ldhb
downregulation in primary tumor cells is sufficient to promotoe tumor recurrence.
To further assess the effect of Ldhb knockdown on tumorigenesis, we
investigated the effect of Ldhb knockdown on primary tumor growth. Primary tumor cells
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expressing either a control shRNA or an shRNA directed against Ldhb were injected into
the mammary fat pads of nu/nu mice. Tumor growth was induced by the administration
of doxycycline to induce HER2/neu transgene expression and was followed biweekly
until tumors reached a size of 15x15 mm. Quantification of mean tumor growth rate did
not reveal any differences in primary tumor growth between control tumors and those
with Ldhb knockdown (p1=0.932, p2=0.743) (Figure 4D).
To investigate the potential clinical relevance of our findings, we assessed the
association between Ldhb gene expression levels and the risk of tumor recurrence in a
cohort of breast cancer patients with HER2-positive, node-negative tumors. Consistent
with our findings in mice, this analysis revealed that tumors with lower levels of LDHB
expression were associated with reduced 5-year metastasis-free survival (HR=-2.88 and
p=0.0158).
In aggregate, our results indicate that Ldhb downregulation is sufficient to
promote tumor recurrence, but has no effect on primary tumor growth.

Moreover,

reduced LDHB levels were associated with reduced recurrence-free survival in breast
cancer patients.

Ldhb downregulation is caused by Sirt3 downregulation
Sirt3 is an NAD-dependent mitochondrial deacetylase known to regulate glycolytic
activity through Hif1-α destabilization275. We hypothesized that the reduced levels of
Ldhb expression that we observed in recurrent tumors was due to a decrease in
expression of Sirt3. To begin to address this hypothesis, we assessed Sirt3 levels in
primary and recurrent tumors. qRT-PCR experiments revealed lower expression of Sirt3
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at the mRNA level in recurrent tumors (p=0.038) (Figure 5A). These results were further
confirmed by western blotting which revealed lower expression of Sirt3 at the protein
level in recurrent tumors (Figure 5B).
Next, we used siRNAs targeted against Sirt3 to directly address whether Sirt3
was capable of modulating Ldhb levels in recurrent tumor cells.

siRNA-mediated

downregulation of Sirt3 resulted in downregulation of Ldhb, but not Ldha (Figure 5C).
Similar results were obtained with two different siRNAs.
Consistent with this, assessment of changes in metabolite levels in the media 48
hours post-transfection revealed higher lactate levels in the media of cells with siRNAs
targeted against Sirt3 (Figure 5D). These findings suggest that Sirt3 downregulation in
recurrent tumors contributes to the observed decrease in Ldhb levels as well as the
accompanying increase in lactate levels observed in recurrent tumors.

Downregulation of Ldhb is mediated through Hif1
To further characterize the mechanism responsible for Ldhb downregulation, we
investigated whether the effect of Sirt3 was mediated through Hif1, a previouslydescribed downstream effector of Sirt3. First, we assessed whether recurrent tumors
exhibited higher levels of Hif1-α stabilization. Western blotting revealed higher levels of
Hif1 in recurrent tumors compared to primary tumors (Figure 6A). These results were
confirmed by assessing Hif1 pathway activity using a gene expression signature
incorporating known Hif1 targets.

Consistent with our immunoblotting results, Hif1

pathway activity was higher in recurrent tumors compared to primary tumors (p=0.022)
(Figure 6B).
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To address whether the effect of Sirt3 downregulation on Ldhb expression is
mediated through Hif1, we used siRNAs targeted against both Hif1 and Sirt3 in recurrent
tumor cells. Again, downregulation of Sirt3 expression led to a reduction in Ldhb levels
as previously (p=0.003). However, simultaneous downregulation of both Sirt3 and Hif1
abrogated the effect of Sirt3 dowregulation on Ldhb expression (Figure 6C). Ldha levels
were unaffected by Sirt3 or Hif1 downregulation.
Consistent with these findings, assessing changes in lactate levels in the media
in which the cells were incubated revealed that Sirt3 downregulation resulted in higher
lactate levels in the media, whereas simultaneous downregulation of both Sirt3 and Hif1
abrogated the effect of Sirt3 downregulation on lactate compared to control cells (Figure
6D). These results suggest that the effect of Sirt3 on Ldhb expression and lactate levels
is mediated through Hif1.

6.4 Discussion
In this work, we provide evidence for increased lactate levels as tumors progress from
primary to recurrent stage. Our findings further suggest that this increase in lactate
results from decrease in the expression of Ldhb, which encodes the LDH subunit that
favors the conversion of lactate to pyruvate.

Consistent with this, recurrent tumors

exhibited a shift in the LDH isoforms that they express towards homo- and heterodimers
containing fewer subunits of Ldhb which would be expected to result in a reduction in the
conversion of lactate to pyruvate. Notably, this reduction in Ldhb expression was also
associated with a functional effect on tumorigenesis, as Ldhb knockdown in primary
tumors accelerated the appearance of recurrent tumors indicating that Ldhb
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downregulation is sufficient for tumor recurrence. In contrast, Ldhb downregulation had
no effect on primary tumor growth.

Mechanistically, Ldhb downregulation could be

ascribed to downregulation of the NAD-dependent deacetylase, Sirt3, which was
observed in recurrent tumors. Finally, we find that the effect of Sirt3 on Ldhb and lactate
levels was mediated through Hif1.

Together, our findings suggest that Ldhb

downregulation plays a rate-limiting role in tumor recurrence.
High intratumoral lactate levels have previously been associated with poor
patient prognosis and increased risk for metastasis and recurrence in human cervical
cancers, head and neck cancers and lung cancers145, 267-270. Increased lactate levels are
also associated with increased tumor invasion, metastasis and tumor burden and have
been directly linked to tumor avoidance of immunosurveillance82, 276, 277. In this regard, it
has been postulated that high lactate levels in the extracellular space lead to an acidic
environment that results in more aggressive tumor behavior82. High lactate levels also
inhibit lactate export from T cells in the tumor microenvironment, significantly reducing
their function in tumor recognition276. Results from our study suggest that increased
lactate levels are associated with tumor progression and breast cancer recurrence.
While most metabolism models suggest that net increased lactate production in
cancer cells results from the Warburg effect, several studies suggest that exogenous
lactate can act as a carbon source for oxidative metabolism278-280. Specifically, evidence
exists suggesting a symbiosis between oxygenated and hypoxic cells within tumors,
wherein hypoxic cells use glucose as their major energy source while oxygenated cells
use lactate generated by hypoxic cells to maintain their metabolic activity280-282. Our
findings are compatible with this model in that we find that primary tumors, in our model,
do indeed uptake and metabolize lactate. In fact, in primary tumors, lactate was a
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significant precursor of alanine and glutamate carbon compared to glucose, consistent
with observations in rat C6 glioma cells278. Our findings also suggest differential lactate
metabolism by primary and recurrent tumors. In light of the increased lactate levels that
we observed in recurrent tumors, we had initially expected to find increased glycolytic
flux and increased lactate production in recurrent tumors. Surprisingly, we found that
recurrent tumors exhibited reduced glucose metabolism as well as reduced lactate
oxidation, despite the higher net amount of lactate found in those tumors.

These

findings suggest a potential metabolic shift away from lactate oxidation toward lactate
accumulation in recurrent tumors, which might underlie their aggressive behavior.
Previous reports have implicated Ldha levels in regulating lactate production and
in contributing to the ability of tumors to proliferate under hypoxic conditions272,

274

.

Similarly, cancer cells have recently been found to exhibit an isoform switch in pyruvate
kinase whereby tumors preferentially express high levels of the embryonic form Pkm2
compared to normal tissues, which primarily express Pkm1273.

This isoform switch

modulates lactate production and plays a functional role in tumorigenesis, in that Pkm2
is required for tumor growth273.

In our study, however, both Ldha and Pkm2 were

expressed at similar levels in primary and recurrent tumors, and were therefore unlikely
to be responsible for the increased levels of lactate observed in recurrent tumors.
Rather, we found that the ldhb subunit of LDH that preferentially converts lactate to
pyruvate, was markedly downregulated during the course of tumor recurrence. While
some reports have suggested a potential association between Ldhb downregulation and
increased metastasis in some human cancers87,

149, 283

, our findings provide the first

direct evidence for a functional role for Ldhb downregulation in tumor recurrence.
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Downregulation of Ldhb in recurrent tumors results in a reduction in LDH
isoforms 1-4 such that these tumors primarily express LDH5, an isoform that consists of
4 Ldha subunits. LDH5 has the highest efficiency of converting pyruvate to lactate. As
such, recurrent tumors exhibiting Ldhb dowregulation primarily produce and secrete
lactate while exhibiting a reduced ability to uptake and metabolize lactate. This would be
anticipated to result in lactate accumulation, as we observed in recurrent tumors.
A limited number of studies have suggested an association between decreased
Ldhb expression and increased metastasis and invasive tumor behavior.

A laser

microdissection study in colorectal tumors found a significant reduction in LDHB in the
infiltrative edges of the tumors, in the absence of changes in LDHA expression271.
Other studies have shown LDHB downregulation in metastatic human prostate cancer
samples when compared to benign prostate tissue87. These results are in agreement
with our findings that Ldhb is downregulated as tumors progress to the stage of
recurrence, and that LDHB downregulation is associated with reduced recurrence-free
survival in human breast cancer patients, primarily those exhibiting HER2-positive breast
cancer.
In this study, we have established a direct functional link between Ldhb
downregulation and reduced recurrence-free survival in an animal model that faithfully
recapitulates key features of breast cancer progression.

Using an orthotopic tumor

assay, we demonstrated that Ldhb downregulation is sufficient to promote tumor
recurrence. To our knowledge, this is the first evidence identifying a functional role for
Ldhb in tumor progression.

Reduced Ldhb expression contributes to lactic acid

accumulation by reducing lactate uptake and metabolism within tumors. This, in turn,
leads to decreased pH in the tumor microenvironment, thereby stimulating tumor
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invasion while impairing immunogenicity. A role for increased lactate levels in inducing
and selecting for a stem-like phenotype in cancer cells has also been suggested.
Moreover, Kennedy et al. have reported increased expression of the transcriptional
repressor Snail and epithelial-to-mesenchymal transition (EMT) in breast cancer cells
chronically subjected to high lactate levels284. As our laboratory has previously reported
increased Snail expression and EMT in recurrent tumors66, we speculate that tumor
recurrence driven by elevated lactate levels could facilitate induction of a stem-like
phenotype and EMT in a subset of tumor cells.

Such cells might persist following

regression of the primary tumor and could give rise to recurrent tumors at a later time.
Sirtuins have recently emerged as important regulators in cancer metabolism. In
particular, Sirt3, an NAD-dependent mitochondrial deacetylase has been reported to
repress glycolytic activity and proliferation in breast cancer cells and to modulate lactate
levels275. While Sirt3 has principally been found to affect Ldha expression275, we found
that Sirt3 was downregulated in recurrent tumors and demonstrated that Sirt3
downregulation in primary tumor cells led to a reduction in Ldhb expression. To our
knowledge, this is the first evidence that Sirt3 regulates Ldhb expression.
As lactate levels are also significantly influenced by hypoxia, we investigated the
link between Sirt3, hypoxia and Ldhb expression. Previous studies have established
that the ability of Sirt3 to regulate glycolytic activity is dependent upon Hif1-α
destabilization275. Consistent with this, we found higher Hif1-α protein levels in recurrent
tumors compared to primary tumors. Moreover, while Sirt3 downregulation led to a
reduction in Ldhb levels, siRNA-mediated Hif1 dowregulation abrogated the effect of
Sirt3 on Ldhb expression consistent with a model in which Sirt3 regulates Ldhb through
Hif1. Of note, Hif1 controls the expression of target genes by binding to the hypoxia
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response element (HRE) thereby inducing upregulation of target genes285.

To our

knowledge, few reports exist suggesting that Hif1-α stabilization induces downregulation
of gene expression. As such, the impact of Hif1 on Ldhb downregulation might be
mediated by a Hif1 target. In addition, some studies have suggested that the Ldhb
promoter is hypermethylated in human cancers87,

283

.

It is possible that promoter

hyperpmethylation might play an additional role in regulating the expression of Ldhb.
Interestingly, Ldha levels did not change during tumor recurrence despite Hif1-α
stabilization.
In summary, our findings provide direct evidence for a functional role for Ldhb
downregulation in tumor recurrence. Ldhb downregulation was sufficient to accelerate
tumor recurrence and was sufficient to induce lactate accumulation within tumors.
These changes were driven by Sirt3 downregulation and mediated by changes in Hif1
stabilization.

Our findings suggest that Ldhb expression may serve as a useful

prognostic marker for breast cancer patients and that modulating LDH activity may have
therapeutic utility.
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6.5 Figure Legends

Figure 1. Recurrent tumors exhibit higher lactate levels than primary tumors.
(A) 1H MRS reveals differences in selected metabolites between primary and recurrent
tumors. 30% higher steady-state lactate levels were observed in recurrent tumors.
Results are shown from a total of 4 primary and 4 recurrent tumors arising in MTB/TAN
mice. (B) Higher lactate levels in recurrent tumors confirmed by mass spectrometry
analysis in the same mice as in (A). Lactate levels are normalized to mg of total protein
(TP) in the analyzed tissue samples. (C)

13

C-labeled glucose infusion of tumor-bearing

mice reveals lower production of labeled lactate from glucose in recurrent tumors relative
to primary tumors. Results represent the amount of labeled metabolite from the total
available metabolite pool.

White bars represent primary tumors and black bars

represent recurrent tumors. (D) Labeled lactate infusion of tumor-bearing mice reveals
higher accumulation of labeled lactate and less lactate oxidation in recurrent tumors
compared to primary tumors. Results represent the total amount of labeled metabolite
pool. White bars represent primary tumors and black bars represent recurrent tumors.
(** indicates p<0.05).

Figure 2. Recurrent tumors exhibit lower Ldhb expression levels. (A) Recurrent
tumors exhibit lower Ldhb expression but similar Ldha expression at the mRNA level
compared to primary tumors.

Expression levels were assessed by qRT-PCR in 4

primary and 4 recurrent tumors. Expression was normalized to TBP. (B) Recurrent
tumors exhibit lower Ldhb, but similar Ldha protein levels compared to primary tumors.
Tubulin is shown as a loading control. (C, D) Recurrent tumors exhibit similar Pkm1 and
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Pkm2 expression levels. Pkm1 and Pkm2 are the product of differential splicing of the
Pkm gene.

Pkm1 and Pkm2 were amplified from RNA extracted from primary and

recurrent tumor samples.

Relative expression was assessed by electrophoresis of

digested or undigested amplification products on a non-denaturing polyacrylamide gel.
EcoN1 is a restriction enzyme specific for Pkm1 and Pst1 is specific for Pkm2. (E)
Recurrent tumors exhibit similar Pkm2 protein levels compared to primary tumors.
Tubulin is shown as a loading control.

Figure 3. Ldhb downregulation results in higher lactate levels (A) Zymography
reveals that recurrent tumors lack LDH isoenzymes LDH1, LDH2 and LDH3. Protein
was extracted from 3 primary and 3 recurrent tumors and electrophoresed on a nondenaturing polyacrylamide gel. (B) Assessment of the conversion of lactate to pyruvate
reveals reduced LDH activity in catalyzing that conversion compared to primary tumors.
Results are for LDH extracted from 3 primary and 3 recurrent tumors.

(C) shRNA

knockdown of Ldhb in primary tumor cells compared to controls. Expression levels were
assessed in primary tumor cells by qRT-PCR and normalized to TBP. (D) Conditioned
media from primary tumor cells with Ldhb knockdown exhibit higher lactate levels
compared to control cells. Results were normalized to the average number of cultured
cells in each well. (* indicates p<0.05).

Figure 4. Ldhb downregulation promotes tumor recurrence in mice and is
associated with reduced recurrence-free survival in human breast cancer.

(A)

Schematic of orthotopic tumor recurrence assay consisting of injecting genetically151

engineered primary-tumor derived cells into the mammary fat pad of nu/nu mice,
inducing tumor growth by doxycycline administration, withdrawing doxycycline treatment
to induce tumor regression to a non-palpable state followed by the stochastic
appearance of recurrent tumors following a latency period. (B,C) Ldhb knockdown in
primary tumors promotes recurrence in the MTB/TAN mouse model using two different
shRNA constructs. Results are from 24 injected sites in each experimental group. (D)
Primary tumors with Ldhb knockdown grow at a similar rate compared to control tumors.
Tumor growth was assessed by computing the mean growth rate (MGR) as tumors
increased in size from 5x5 mm to 15x15 mm. Results are from 20 injected sites in each
experimental group. (E) Ldhb knockdown is associated with reduced recurrence-free
survival in HER2-positive human breast cancer among patients with node-negative
disease who did not receive adjuvant therapy. (H.R.: Hazard Ratio; p: p-value).

Figure 5. Sirt3 downregulation reduces Ldhb levels in recurrence. (A) Recurrent
tumors exhibit low Sirt3 mRNA levels compared to primary tumors. Expression levels
were assessed by qRT-pCR and normalized to TBP. Results are from 4 primary and 4
recurrent tumors.

(B) Recurrent tumors exhibit lower Sirt3 protein levels relative to

primary tumors. Tubulin is shown as a loading control. (C) Downregulation of Sirt3 in
primary tumor cells leads to downregulation of Ldhb levels without affecting Ldha levels.
Sirt3 knockdown was achieved by siRNA transfection. Expression levels were assessed
by qRT-PCR and normalized to TBP. (D) Sirt3 knockdown results in increased lactate
levels in the culture media. Results were normalized to the average number of cultured
cells in each well.
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Figure 6. Sirt3 downregulation of Ldhb is mediated through Hif1. (A) Recurrent
tumors exhibit Hif1-α protein stabilization. Tubulin is used as a loading control. (B)
Recurrent tumors exhibit higher Hif1-α pathway activity. Pathway activity was assessed
by considering expression of known Hif1 targets. The EPS algorithm used outputs a
pathway activity score based on the combined expression of target genes present in the
signature. (C) Simultaneous downregulation of Sirt3 and Hif1 abrogates the effect of
Sirt3 on Ldhb expression levels. While Sirt3 downregulation leads to a decrease in Ldhb
levels, simultaneous downregulation of Sirt3 and Hif1 abrogates the effect of Sirt3 on
Ldhb expression.

Sirt3 and Hif1 were downregulated in primary tumor cells using

siRNAs targeted to those genes. Expression levels were assessed by qRT-PCR and
normalized to TBP. (D) Simultaneous downregulation of Sirt3 and Hif1 in primary tumor
cells does not change lactate levels in culture media. Results were normalized to the
average number of cultured cells in each well. (** indicates p<0.05).
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CHAPTER 7

Conclusions and Future Directions

7.1 Thesis Summary
In this work, we present evidence for an evolving metabolic phenotype within breast
cancers during the course of tumor recurrence.

We speculate that metabolic

reprogramming could be a mechanism by which tumors escape therapy and recur. A
better understanding of the basis for the metabolic changes that accompany tumor
recurrence might allow for the development of more effective approaches to preventing
and treating recurrent breast cancers.
Using a systems engineering approach, we have designed and implemented a
process-based system aimed at increasing our understanding of the metabolic and
genetic regulation of breast cancer recurrence. Magnetic resonance-based metabolic
profiling of primary and recurrent tumors allows for broad identification of potential
metabolic pathways that exhibit differential activity in recurrent tumors compared to
primary tumors in a mouse model of mammary tumor recurrence.
metabolic changes are further characterized with
vivo. Mass spectrometry analysis and

13

The identified

13

C-labeling infusion experiments in

C magnetic resonance spectroscopy are used

for pathway-focused assessment allowing the detection of changes in metabolic flux or
the identification of key dysregulated steps in a given pathway.

Once potential

dysregulated metabolic steps are identified, we proceed to identify the underlying
genetic determinant(s) of those changes and assess the functional role of those in
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tumorigenesis as well as their effect on tumor recurrence. If a gene is found to exhibit a
functional effect on tumor recurrence, the potential for clinical translation of our findings
is assessed using microarray and outcome data from human breast cancer patients.
The top-down process-based system of:
1. identifying potential dysregulated metabolic pathways using magnetic
resonance spectroscopy in a mouse model of mammary tumor
recurrence,
2. identifying the specific affected metabolic steps using

13

C-labeling

experiments,
3. connecting those to their underlying molecular determinants,
4. characterizing their functional effect in tumorigenesis,
5. assessing their translational potential using human microarray data
forms the basis of our magnetic resonance-based integrative metabolomics approach
that we propose and implement here as a mean to better understand the metabolic and
genetic regulation of breast cancer recurrence. This approach was implemented and
validated in two metabolic pathways, glutaminolysis and lactate metabolism, which
exhibited differences between primary and recurrent tumors in 1H magnetic resonance
studies.
1

H magnetic resonance profiling of primary and recurrent tumors led to the

identification of a number of metabolites whose levels exhibited statistically significant
differences between primary and recurrent tumors. Recurrent tumors displayed higher
lactate levels, lower succinate levels, higher glutamate to glutamine ratio, lower
phosphocholine levels and higher glycine levels than primary tumors. Higher levels of
Sdhb and Gls expression as well as lower levels of Chka, Gldc and Ldhb in recurrence
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can potentially explain the observed succinate, glu/gln, phosophocholine, glycine and
lactate metabolite level changes, respectively.

The identified changes might have

translational potential for human breast cancer prognosis prediction. A metabolic gene
expression signature based on the metabolic changes observed in recurrent tumors in
mice successfully predicted 5-year recurrence risk in human breast cancer patients with
HER2-positive disease. Two of the identified differences in this study, increased lactate
levels and increased glutamate to glutamine ratio, were further pursued using the
process-based system proposed above to further characterize their contribution to
breast cancer recurrence.
The first pathway we chose to assess was glutaminolysis with this pathway
known to be a key feature of tumorigenesis.

13

C-labeling experiments suggested

increased glutaminolytic activity and increased reductive carboxylation in tumor
recurrence. The observed changes in the glutaminolytic profile were accompanied by
increased expression of the glutamine transporter, Slc1a5, as well as increased
expression of glutaminase (Gls1) in recurrent tumors. Both Slc1a5 and Gls1 expression
were required for recurrent, but not primary tumor growth in vivo. Recurrent tumors also
exhibited increased endogenous expression of the Myc oncogene. Myc was found to be
required for Slc1a5 and Gls1 expression as well as increased glutamine uptake and
glutamate production in recurrent tumor cells.

Human association analysis further

revealed a positive correlation between Slc1a5 expression levels and recurrence-free
survival in human breast cancer patients.
The second pathway that we chose to further characterize was lactate
metabolism. The Warburg effect, consisting of increased aerobic glycolytic flux and
increased lactate production, is one of the most fundamental observations in cancer
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metabolism. Interestingly, 13C-labeling experiments showed that recurrent tumors do not
exhibit increased glycolytic flux but rather seem to accumulate lactate and display
reduced oxidation of this metabolite.

Molecular profiling experiments identified

downregulation of Ldhb in recurrent tumors as the potential underlying molecular
determinant of the differential lactate levels between the two tumor stages.

This

translated into recurrent tumors lacking LDH isozymes 1,2 and 3. Ldhb is found to be
regulated by the NAD-dependent mitochondrial deacetylase Sirt3; and this effect is
mediated through Hif1.

Functional experiments further suggested a role for Ldhb

downregulation in promoting tumor progression and recurrence. Furthermore, we found
that Ldhb downregulation in human breast cancer patients, particularly in those with
HER2-positive disease, is correlated with reduced recurrence-free survival.
Combined, our findings validate our proposed process-based system for
understanding the metabolic and genetic regulation of breast cancer recurrence. Our
findings further provide evidence for metabolic reprogramming in breast cancer
progression and suggest a role for increased glutaminolysis and lactate metabolism in
promoting recurrence. The identified molecular determinants, Slc1a5, Gls1 and Ldhb
might potentially serve as therapeutic targets as well as prognostic markers that could
aid in the clinical management of breast cancer patients.

7.2 Future Directions
From the Genome to the metabolome and back: how do metabolic changes drive
tumor recurrence?
In chapter 6, we provided evidence that Ldhb downregulation, which results in increased
lactate levels, promote tumor recurrence. The mechanism by which this process takes
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place remains to be investigated. Here, we propose a potential pathway that might be
underlying this phenomenon.
In this work, our findings suggest that Ldhb downregulation is induced by Sirt3
downregulation. In a separate experiment, we also found evidence that Sirt3 levels were
modulated by changes in Myc levels (Figure 1A). To our knowledge, this is the first
evidence of Myc regulating Sirt3 expression. With Sirt3 downregulation, tumors exhibit
increased lactate levels due to the associated Ldhb level changes. The accumulation of
lactate and the reduced conversion of lactate to pyruvate are accompanied by reduced
amounts of NADH, a key product of this reaction. High availability of NAD has been
found to correlate with increased expression and activation of another NAD-dependent
deacetylase, Sirt1286. Interestingly, increased Sirt1 levels and activity are correlated with
increased p53 deacetylation287. This, in turn, is associated with pro-survival signaling
and evasion of apoptosis. A schematic of this proposed pathway is shown in Figure 1B.
We speculate that increased Myc levels are the initiating genetic event that
triggers a number of downstream metabolic changes, one of which is increased lactate.
The increased lactate, in turn, might promote epigenetic changes by affecting p53
acetylation providing a survival advantage to some tumor cells and allowing them to
evade apoptosis.

The tumor cells where this phenomenon takes place might be

potentially persisting following HER2/neu downregulation and recurring at a later time.
In terms of the glutaminolytic changes that accompany breast cancer
progression, we speculate that a subset of cells in the primary tumors upregulate
glutamine metabolism and that those cells escape HER2/neu downregulation and persist
as a result of the ammonia generated from increased glutamine uptake and breakdown.
Ammonia is released as glutamine is converted into glutamate. Increased ammonia
levels in tumors have been associated with autophagy288, a mechanism that tumor cells
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might use to become dormant.

It is possible that during dormancy, most of the

increased glutamine uptake is diverted into ammonia to maintain autophagy. This can
be achieved by tumor cells maintaining low expression levels of enzymes that typically
allow the entry of glutamine carbon into the TCA cycle, such as Gls1 or Glud1. As
tumors escape from dormancy, cells might upregulate these genes allowing
glutaminolysis to support increased growth and energy production and leading to the
appearance of a recurrent tumor. We speculate that during dormancy, Myc upregulation
induces increased glutamine uptake and conversion into ammonia, potentially promoting
Atg1 levels to support autophagy.

As cells escape from dormancy, increased

glutaminolysis promotes tumor recurrence through the diversion of glutamine's carbon
into TCA cycle intermediates to support tumor growth.

Serine biosynthesis pathway: a potential therapeutic target for cancer recurrence
Recently, the serine biosynthesis pathway has emerged as a novel key pathway in
cancer metabolism289,
enzyme

responsible

290

. Particularly, phosphoglycerate dehydrogenase (Phgdh), the
for

the

conversion

of

3-phosphoglycerate

into

3-

phosphohydroxypyruvate, was found to play an important role in tumorigenesis.
Particularly, Phgdh was shown to be required for primary tumor growth in mammary
tumors in mice289,

290

. The association between increased serine biosynthesis, Phgdh

levels and cancer recurrence warrants further investigation.
In our model, D-[1,2-13C-]-glucose infusion revealed a more active serine
biosynthesis pathway in recurrent tumors compared to primary tumors.

13

C-MRS studies

show marked labeled glycine production from glucose in recurrent tumors relative to
primary tumors (Figures 2A and 2B).

In the serine biosynthesis pathway, serine is
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converted into glycine before glycine is broken down to contribute to nucleotide
synthesis. In our model, we assessed the levels of Phgdh expression. Indeed, recurrent
tumors exhibit increased expression levels of Phgdh compared to primary tumors
(Figure 2C).
Together, these results provide evidence for increased serine biosynthesis
pathway activity in recurrent tumors. The functional implication of these observations on
tumor recurrence should be further interrogated.

Myc: the master metabolic regulator of tumor recurrence
In this work, we presented evidence that Myc overexpression could be responsible for
the increase in glutaminolysis observed in recurrent tumors.

Similarly, figure 1A

suggests that Myc also regulates expression of the NAD-dependent mitochondrial
deacetylase, Sirt3. Sirt3, in turn, modulates Ldhb levels and lactate accumulation in
recurrent tumors.

While very little evidence is available connecting the serine

biosynthesis to Myc, available microarray data through the Myc oncogene database
(http://www.myc-cancer-gene.org/) suggests that Phgdh might be a Myc target.
Combined, these results lead us to speculate that Myc might act as a master
regulator of the metabolic reprogramming that accompanies tumor recurrence (Figure 3).
While primary tumors, in which HER2/neu is activated, are thought to be mainly
dependent on glycolysis for their energy needs, it is possible that Myc upregulation in a
subset of primary tumor cells might allow those to escape HER2/neu downregulation.
The metabolic pathways that are activated with Myc overexpression might confer a
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survival advantage to the transformed tumor cells and allows= them to undergo
dormancy and later recur.

Other potential regulators of metabolic reprogramming in recurrence: Does Akt
play a role?
While tumor recurrence in our model is HER2/neu-independent, unpublished data from
our lab suggests activation of the Akt pathway in recurrent tumors, as evidenced by the
detection of high p-Akt levels. With Akt known to play a role in metabolism, it remains to
be investigated how the activity of this pathway affects the metabolic reprogramming
observed in recurrent tumors.

Previous studies have suggested that Akt activity is

associated with decreased GSK-3 activity291. This, in turn, is known to lead to reduced
Myc phosphorylation and reduced Myc degradation291. Is it possible that Akt, acting
upstream of Myc, might be the ultimate metabolic regulator in tumor recurrence?
In an effort to address this question, we inhibited AKT in a human breast cancer
cell line, MCF-7, that we show to be glutamine addicted (Figure 4A and 4B). Within the
context of glutamine-addiction, AKT inhibition using 2 different siRNA constructs led to a
reduction in MYC levels as well as a decrease in both SLC1A5 and GLS1 levels (Figure
4C). These data provide preliminary evidence that AKT might act upstream of MYC and
regulate glutaminolysis and potentially other metabolic pathways through its effect on
MYC. The direct effect of Akt inhibition on the metabolism of recurrent tumor cells in our
mouse model remains to be further assessed. We speculate, however, that Akt might
be the ultimate regulator of metabolism in tumor recurrence (Figure 4D).
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Of note, Akt has been shown to have no effect on glutamine metabolism within
the context of Myc overexpression97. Our data suggest, however, a potential role of Akt
in glutamine metabolism, suggesting that this effect might be context-dependent.
Further human association analysis also shows that AKT activity is positively correlated
with SLC1A5 expression in human breast cancer samples, providing further evidence of
a potential link between AKT and glutamine metabolism (Table 1).

The exact

mechanism underlying this observation and the role of AKT in tumor recurrence is not
well understood.

Glutamate dehydrogenase: an alternative glutaminolytic target in breast cancer
recurrence
Glutamate dehydrogenase (Glud1), in addition to Got1 and Gpt1, is an enzyme
responsible for the conversion of glutamate into alpha-ketoglutarate.

This enzyme

catalyzes a critical step of glutaminolysis with this reaction being the entry point of the
glutamine carbon into the TCA cycle to support anaplerosis. Assessment of alphaketoglutarate levels in recurrent tumors revealed higher levels of this metabolite relative
to primary tumors (Figure 5A). These results were further confirmed with

13

C-labeling

experiments where we detected higher alpha-ketoglutarate enrichment in recurrent
tumors relative to primary tumors, following the infusion of [3-13C]- glutamine (Figure 5B).
Genetic profiling of primary and recurrent tumors in our model have shown similar levels
of Gpt1 and Got1 but higher levels of Glud1 at both the mRNA and protein level (Figure
5C and 5D). Glud1 has been shown to be an especially promising therapeutic target in
cancer. An in vivo study reported cytostatic effects resulting from Glud1 inhibition in
tumors, without the nonspecific toxicity usually observed with generalized inhibition of
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glutamine metabolism92. Another study reported decreased tumor growth in vivo upon
inhibition with aminooxyacetate (AOA), an agent that blocks the conversion of glutamate
to alpha-ketoglutarate292.

In light of this evidence and the known upregulation of

glutaminolysis in tumor recurrence, investigating the effect of Glud1 inhibition in tumor
recurrence is warranted.
Accordingly, we assessed the effect of Glud1 downregulation on tumor growth
using 1 shRNA targeted against this gene. Indeed, downregulation of Glud1 did lead to
a reduction in mean tumor growth rate of recurrent tumors relative to controls (Figure
5E). This provides preliminary evidence of the potential of Glud1 as a therapeutic target
of tumor recurrence.
Previous studies have suggested that Glud1 is regulated by Sirt4 in pancreatic
beta cells293. In our model, we have evidence that Sirt4 levels are higher in recurrent
tumors compared to primary tumors (Figure 5F). It remains to be investigated whether
Sirt4 level changes are behind the observed Glud1 expression level changes in tumor
recurrence.
Here, we show preliminary results for a role of Glud1 in tumor recurrence.
Further investigation is warranted to better understand the role of Glud1 and to further
characterize the mechanism responsible for the changes in its levels.

Hyperpolarized magnetic resonance: potential in breast cancer prognostication
NMR of hyperpolarized precursors has recently emerged as the technique of choice for
monitoring dynamic real-time changes in metabolism in vivo, with substantially high
resolution and sensitivity294-307. By creating an artificial non-equilibrium distribution of the
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spins, hyperpolarized imaging allows direct molecular imaging of the molecules
containing the hyperpolarized nucleus with a signal-to-noise ratio (SNR) up to 100,000
times greater than typical magnetic resonance techniques294-296. This new technique
offers many new possibilities for imaging tissue function in vivo308-313.
For the past few decades, the conventional magnetic resonance (MR) technique
used to monitor total metabolite concentrations in vivo has consisted of Nuclear
Magnetic Resonance (NMR) spectroscopy, a technique that exploits the magnetic
properties of NMR active nuclei119,

120

.

However, this approach can only measure

steady-state metabolite levels and is of limited utility in vivo, especially in the case of
lactate.

Lactate and lipid peaks usually overlap on 1H NMR spectra, such that

monitoring modulations in lactate can be difficult even when methods of lipid
suppression are used. This is especially a problem in the case of in vivo breast MRS
wherein a large percentage of the total composition of the tissue is fat. Similarly, the
glutamine and glutamate peaks typically overlap on 1D proton spectra, thereby
complicating the accurate quantification of the individual concentration of each of the two
metabolites in vivo.

13

C-MRS is another conventional MR technique to assess

metabolite levels but the low natural abundance of

13

C makes its use for in vivo studies

quite challenging due to SNR limitations.
Here, we propose using hyperpolarized [1-13C]-pyruvate and [5-13C]-glutamine for
the in vivo study of cellular metabolism.

We plan to investigate the role of their

conversion into lactate and glutamate, respectively, as potential biomarkers for cancer
progression.

Being able to reliably identify metabolic changes in tumor tissue and

showing that those changes could reflect Ldhb and Slc1a5 expression levels, might
provide evidence for a potential role of this technique in prognosis predication in cancer.
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Here, we conducted preliminary experiments in vivo where we injected primary
and recurrent tumor-bearing mice with [1-13C]-pyruvate and observed its conversion into
lactate in real time.

13

C-spectra were collected at 1s intervals and a representative stack

of those is presented for one mouse in Figure 6A. The area under each peak at each
time point was computed and normalized to the total carbon in the spectra. Normalized
peak amplitudes for both lactate and pyruvate were plotted with respect to time for each
of the mice assessed in this study (Figure 6B and 6C).

Preliminary results show

potential differences in dynamic lactate levels between primary and recurrent tumors.
Those differences were further quantified by fitting the lactate and pyruvate curves to a
modified Bloch equation model for two-site chemical exchange as previously described
by Day et al.310:

L and P denote lactate and pyruvate respectively. Lz and Pz are the z-magnetizations of
the 13C nucleus in lactate and pyruvate. ρL and ρP are the spin-lattice relaxation rates, L
and P at infinity are the equilibrium magnetizations which are equivalent to their steady
state concentrations. The data generated in our experiment were fit to this model using
the 5-parameter solution proposed by Ziehurt et al.314.

The fits obtained from the

generated model are presented in Figures 6D and 6E. Representative reaction rates
yielded by this model are presented in Table 2 for one primary and one recurrent tumor.
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Combined, these results show preliminary evidence that in vivo hyperpolarized
magnetic resonance spectroscopy is a viable technique for the assessment of in vivo
cancer metabolism.

It remains to be investigated how reproducible the detected

changes are and whether the observed differences correlate with gene expression
changes. If validated, this technique might have potential to play a role in breast cancer
prognostication,

Metabolic gene expression signature: how does it measure to current clinical
prognostic variables?
In Chapter 3, we presented a metabolic gene expression signature able to predict 5-year
recurrence status in a cohort of breast cancer patients diagnosed with HER2-positive
breast cancer. Current clinical practice assesses the recurrence risk of breast cancer
patients based on a number of clinicoprognostic variables, the most established of which
include tumor size, tumor grade, receptor status (ER and PR), and HER2 status. In
order to address the potential clinical contribution of our proposed metabolic gene
expression signature, we sought to assess whether this signature is an independent
predictor of recurrence and whether it adds to the information provided by the
traditionally used clinical prognostic variables.

Accordingly, we performed logistic

regression modeling with recurrence status as the response variable. Clinical variables
were only available for a small patient dataset consisting of 31 patients.

The first

implemented model included the currently used clinical variables that were available for
this dataset: tumor size, tumor grade and ER status (Table 3). Independent contribution
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of each partial regression coefficient was assessed using the Wald test. Tumor size was
an independent predictor of recurrence status.
Following the addition of the metabolic gene expression signature, both tumor
size and the metabolic gene expression score were independent contributors to the
prediction of recurrence status (Table 3). These results indicate that the metabolic gene
expression signature that we propose further adds to the currently used clinical variables
when it comes to patient prognosis assessment. These results were further validated by
receiver operator curve (ROC) analysis. The ROC curve of the clinical variables alone
had an AUC of 0.82. Addition of the metabolic gene expression score significantly
added to the performance of the model where the AUC of the new model was 0.91.
These results represent a proof-of-principle analysis and remain to be validated
in a larger dataset, with more clinical variables and potentially compared to clinicallyused recurrence assays such as Oncotype DX. If validated, the proposed metabolic
gene expression signature has significant potential to aid in prognosis prediction in
cancer patients.

7.3 Conclusions
In this work, we introduce magnetic resonance-based integrative metabolomics, a
process-based systems approach, to understand the metabolic and genetic regulation of
breast cancer recurrence. Using this approach, we 1) identified a number of potentially
dysregulated metabolic pathways using magnetic resonance spectroscopy in a disease
model system, 2) characterized the key affected steps using 13C-labeling experiments, 3)
identified the underlying molecular determinants of the observed metabolic changes, 4)
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investigated the functional effect of those changes on tumor recurrence, and 5)
assessed the translational potential of our findings. This approach was validated in two
metabolic pathways, glutaminolysis and lactate metabolism, which were shown to exhibit
differences between primary and recurrent tumors in our mouse model.

Recurrent

tumors exhibit increased glutamine uptake and metabolism. Those Myc-driven changes
are caused by increased expression of Gls1 and Slc1a5, two genes that seem to play a
role in recurrent tumor growth. Slc1a5 was also associated with human breast cancer
prognosis. Similarly, recurrent tumors exhibit increased lactate levels. Sirt3-mediated
downregulation of Ldhb is responsible for those changes.

Downregulation of Ldhb

seems to promote recurrence in mice and to be associated with decreased recurrencefree survival in human breast cancer patients.
The success of our proposed process-based system in elucidating some of the
metabolic regulation of breast cancer recurrence leads us to propose wider adoption of
this approach for the investigation of metabolism in tumorigenesis. This system provides
a top-down framework that allows multi-level assessment of the clinical and functional
relevance of a specific metabolic observation.

By combining molecular biology,

biochemistry, computational biology, imaging, statistical modeling, clinical science and
engineering principles, this interdisciplinary approach allows for rigorous assessment of
the diagnostic, prognostic and predictive potential of a given metabolic change. This
system might provide for better avenues for clinical translation of metabolic findings and
facilitate the adoption of basic science discoveries to aid in the management of cancer
patients.
In the era of personalized medicine, identifying tumors with specific metabolic
changes using imaging techniques shown to act as biomarkers for established functional
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genetic alterations (i.e. affecting tumor growth or progression), might serve as a
successful strategy to tailor treatments and prognosis assessment to individual patients.
Furthermore, with metabolic changes often occurring prior to morphologic changes in
cancer, such technique also has the potential to allow for early detection of tumors and
for the early and non-invasive assessment of the patients’ response to tailored therapies.
Lactate and glutamine imaging might be two such techniques and might aid in the early
detection of recurrent tumors and improve the management of breast cancer patients.
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7.4 Tables
Table 1. Correlation between AKT pathway activity and SLC1A5 expression in 12
human breast cancer datasets. Correlation was assessed using Pearson correlation
analysis.

Study

Pearson Correlation

P-value

Pawitan

0.386

5.06E-07

Chang

0.334

4.19E-09

Miller

0.321

2.00E-07

Hess

0.282

0.00101

Saal

0.256

0.00831

Chin

0.222

0.0156

VantVeer

0.219

0.0309

Bild

0.188

0.018

Oh

0.127

0.109

Sorlie

0.123

0.357

Wang

0.0926

0.118

Chanrion

-0.126

0.119
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Table 2. Representative reaction rate constants computed from hyperpolarized MRS
data from one primary and one recurrent tumors using a 5-parameter fit solution to
modified Bloch equation model for 2-site chemical exchange. Mice were injected with
hyperpolarized [1-13C]-pyruvate.

Primary Tumor

Recurrent Tumor

Kpyrlac (s-1)

0.037

0.093

Kpyrala (s-1)

0.011

0.0016
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Table 3. Logistic Regression Analysis to assess independent contribution of metabolic
gene expression signature in predicting recurrence risk after adjusting for a number of
clinicoprognostic variables in breast cancer patients. (p-value is result of Wald test; Reg.
Coef: regression coefficient; p-val: p-value).

Logistic Regression Model of Clinicoprognostic Variables
Reg. Coef.

p-val.

Model Constant

-3.18

0.371

ER Status

-0.29

0.780

Tumor Size

-1.78

0.046

Tumor Grade

1.69

0.1771

Logistic Regression Model of Clinicoprognostic Variables + Metabolic Signature
Reg. Coef.

p-val.

Model Constant

-6.80

0.227

ER Status

-0.80

0.562

Tumor Size

-3.69

0.041

Tumor Grade

3.71

0.081

Metabolic Signature

11.12

0.043
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7.5 Figure Legends

Figure 1. Model of increased lactate promoting breast cancer recurrence.
Downregulation of Myc is accompanied by upregulation of Sirt3 expression.

(A)
Myc

downregulation was achieved using 2 different siRNA constructs targeted against this
gene.

Expression levels were assessed by qRT-PCR and normalized to TBP.

(B)

Proposed model of how Myc Upregulation contributed to lactate level modulation
through its action on Sirt3. Increased lactate is thought to increase Sirt1 levels and
acitivty.

This affects p53 deacetylation and resulting in pro-survival signaling and

apoptosis resistance.

Figure 2. Recurrent tumors exhibit increased serine biosynthesis pathway activity.
(A,B) Infusion of D-[1,2-13C]-glucose in 3 primary and 3 recurrent tumor-bearing mice
results in markedly higher labeled glycine production in recurrent tumors when
compared to primary tumors.

Shown are representative

primary (A) and one recurrent mouse (B).

13

C-MRS spectra from one

Area where the glycine peak resides is

highlighted in red. Results were reproduced in all 3 primary and 3 recurrent tumors
considered. Glycine is produced from serine in the serine biosynthesis pathway. (C)
Recurrent tumors exhibit higher PHGDH levels when compared to primary tumors.
Expression levels were assessed using qRT-PCR and normalized to TBP. PHGDH is a
key enzyme in the serine biosynthesis pathway.
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Figure 3. Model of metabolic reprogramming in breast cancer recurrence.

In

primary tumors, neu activation activates the PI3k/AKT pathway, a known key regulator of
glycolysis.

With doxycycline withdrawal, neu and AKT activity are downregulated.

Recurring

tumors

exhibit

marked

metabolic

reprogramming

driven

by

Myc

overexpression. Recurrent tumors upregulate lactate metabolism, glutamine metabolism
and serine biosynthesis, all shown to be affected by Myc.

Figure 4. AKT might be another regulator of glutamine metabolism. (A) MCF-7
cells are glutamine- addicted and this effect is rescued by alpha-ketoglutarate. Cells
were cultured for 96 hours in 1) regular media, 2) glutamine-deprived media and 3)
glutamine-deprived media supplemented with alpha-ketoglutarate. (B) Quantification of
cell death in each well by trypan blue 96 hours post-incubation. Glutamine withdrawal
leads to death of a large proportion of the MCF-7 cells. Viability is restored by the
addition of alpha-ketoglutarate. Samples were run in triplicates. (C) AKT inhibition leads
to downregulation of MYC, SLC1A5 and GLS1 levels in MCF-7 cells. AKT inhibition was
achieved using 2 different siRNAs targeted against this gene. Expression levels were
assessed by qRT-PCR and normalized to TBP. (D) Proposed Model of AKT regulating
glutamine metabolism by acting through MYC.

Figure 5. Glud1 as an additional glutaminolytic target in breast cancer recurrence.
(A) Recurrent tumors exhibit higher alpha-ketoglutarate levels relative to primary tumors.
Results are from 4 primary and 4 recurrent tumors. (B) Recurrent tumors exhibit higher
alpha-ketoglutarate enrichment when compared to primary tumors following [3-13C]180

glutamine infusion. Enrichment was assessed using mass spectrometry. Results are
presented as mole percent excess (MPE). (C,D) Recurrent tumors exhibit higher levels
of Glud1 at both the mRNA and protein levels. mRNA levels were assessed using qRTPCR and normalized to TBP. In the western blot, tubulin was used as a loading control.
(E) Glud1 downregulation leads to reduced mean growth rate of recurrent tumors.
Glud1 downregulation was achieved by using an shRNA targeted again the gene. (F)
Sirt4 exhibits higher expression levels in recurrent tumors when compared to primary
tumors as assessed by qRT-PCR. Expression levels were normalized to TBP. Sirt4 has
been previously shown to modulate Glud1 levels.

Figure 6. Hyperpolarized magnetic resonance spectroscopy in primary and
recurrent tumor-bearing mice.

(A) Representative stacked spectra following the

injection of hyperpolarized 13C-pyruvate into the tail vein of a primary tumor-bearing
mouse. Spectra were collected at 1 second intervals. (B) Dynamic curves of pyruvate
level changes in the primary and recurrent tumors assessed in this study. Each point
corresponds to the area under the pyruvate curve at one time point.

Data were

normalized to total carbon. Muscle was used as a control. (C) Dynamic curves of
lactate level changes in the tumors considered. Each point corresponds to the area
under the curve at one time point. Data were also normalized to total carbon. Muscle
was used as a control. (D) Representative fit of a pyruvate curve from a primary tumor
using 5-parameter solution to the 2-site exchange chemical model. (E) Representative
fit of a lactate curve from a primary tumor using 5-parameter solution to the 2-site
chemical exchange model. The fits were used to estimate the LDH reaction rate.
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Figure 7. Performance of metabolic gene expression signature in predicting tumor
recurrence in breast cancer patients. Receiver Operator Curve (ROC) analysis was
performed on the results from 1) the logistic regression model that incorporates the
clinical prognostic variables and 2) the model that incorporates the metabolice gene
expression signature in addition to those variables.

Area under the curve (AUC)

computation revealed an improvement in the performance of the model when the
signature is added (AUC=0.91) compared to the model that incorporates the clinical
variables only (AUC=0.82).
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